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Abstract 
Aortic stenosis (AS) is a disease of not just the valve, but also of the myocardium. 
Patient symptoms and outcome are determined by the myocardial response; a 
crucial but poorly understood process. Diffuse and focal myocardial fibrosis play a 
key role. Until recently, both could only be assessed using invasive histology, but 
now cardiovascular magnetic resonance (CMR) offers late gadolinium enhancement 
(LGE) and extracellular volume fraction (ECV) techniques. In this thesis, I developed 
new methods to quantify ECV by synthetic ECV and cardiac CT. I then explored 
myocardial remodelling and fibrosis in patients with severe AS undergoing aortic 
valve replacement (AVR) using myocardial biopsy, CMR, biomarkers and a wide 
range of clinical parameters.  
Prior to AVR, CMR in patients with severe AS revealed important differences in 
myocardial remodelling between sexes, otherwise missed on echocardiography 
alone. Given apparently equal valve severity, the myocardial response to AS 
appeared unexpectedly maladaptive in men compared to women.   
Intra-operative myocardial biopsy revealed three pattern of fibrosis: endocardial 
fibrosis, microscars (mainly in the subendomyocardium), and diffuse interstitial 
fibrosis. Biopsy best captured the transmural gradient of fibrosis and microscars, 
while on CMR, LGE captured mainly microscars and ECV captured mid-myocardial 
related functional changes beyond LGE. Combining LGE and ECV allowed better 
stratification of AS patients. Incidentally, I found that 6% of AS patients older then 65 
years had wild-type transthyretin amyloid deposits on cardiac biopsy, which was 
associated with poor outcome. This is now the basis of a BHF research fellowship. 
Following AVR, I demonstrated for the first time non-invasively that diffuse fibrosis 
regresses (focal fibrosis did not), which is accompanied by structural and functional 
improvements suggesting that human diffuse fibrosis is plastic, measurable by CMR 
and a potential therapeutic target. 
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Figure 1: Aortic Stenosis – A Disease of the Myocardium. 
 
  
[In aortic Stenosis], dilatation of the ventricle is thus an unmixed evil, and 
hypertrophy of its walls is all that is necessary to compensate for obstructive lesion 
at the aortic orifice. 
Graham Steell, MD, FRCP, Professor of Medicine, Manchester Royal Infirmary. 
Text-Book on Diseases of the Heart, Manchester University Press, 1906.  
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Chapter 1 Introduction 
1.1 Aortic stenosis 
Aortic valve stenosis (AS) is defined as aortic valve thickening and calcification that 
causes a significant gradient across the aortic valve (usually with an aortic jet 
velocity of at least 2 m/sec). As is the most common valvular heart condition in the 
Western world. Its prevalence increases with age [1], with around 3% of people 
aged over 75 having severe AS [2]. In 2008/9, nearly 6000 patients underwent aortic 
valve replacement (AVR) for AS in England and this is predicted to double in the 
next decade [3]. The cost to the NHS for AVR surgery alone is over £200 million per 
year, not accounting for additional costs of medical management of AS.   
1.1.1 Natural history  
AS occurs when the aortic valve progressively fails to open fully. The most common 
aetiology in the elderly is calcific degeneration; congenital bicuspid or rheumatic 
(now rare) aortic valve disease present earlier. During a period of progressive valve 
narrowing, the LV adapts to the increased pressure with increasing concentric 
muscle hypertrophy. However, eventually this remodelling becomes maladaptive 
and the LV less compliant, leading to symptoms (breathlessness, chest pain, and 
syncope). This heralds a significant increase in morbidity and mortality. Untreated, 
most will die within five years [4] (Figure 1).  
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Figure 2: The natural history of aortic stenosis 
Onset of symptoms is preceded by a long latent period of increasing obstruction, leading to 
myocardial pressure overload. Adapted from Ross and Braunwald 1983.  
1.1.2 Indications for intervention  
AVR is the definitive therapy for severe AS and improves symptoms and survival [5]. 
For the majority of patients, this is performed by open surgery. Current guidelines for 
AS have evolved from clinical assessment to using transthoracic echocardiography 
as the primary diagnostic modality for evaluating aortic valve anatomy (leaflets, 
calcification, orifice area), AS severity (peak velocity, mean gradient and velocity 
ratio; Figure 3) as well as the LV response to chronic pressure overload [6, 7].  
When asymptomatic, surgery offers no obvious benefit in quality of life and the risk 
of sudden cardiac death is <1% per year [8, 9], however equally it is not zero, and 
once symptoms occur the death rate rises to 2% per month [10]. Uncovering latent 
symptoms and haemodynamic instability with exercise testing is a key new addition 
to current guidelines. For truly asymptomatic patients, current indicators poorly 
predict progression to symptoms – putting the 20% who develop symptoms within 1 
year at high risk, while waiting for their 6-monthly follow-up and eventual surgery 
(most patients will require an AVR within 2 years) [11].  
Review
www.thelancet.com   Vol 373   March 14, 2009 957
Pathophysiology and relation to symptoms
Onset of severe symptoms of aortic stenosis—angina, 
syncope, and heart failure—remains the major 
demarcation point in the disease’s course (fi gure 1).19 The 
asymptomatic patient has a good outlook even with severe 
obstruction, whereas an individual with symptoms has a 
mortality rate of about 25% per year. Thus, knowing how 
the pathophysiology of aortic stenosis causes symptoms 
and death is paramount to understanding the disease.
Pressure overload hypertrophy
As the table shows, narrowing of the aortic orifi ce to half 
its usual 3 cm² causes little obstruction to left-ventricular 
outfl ow and, thus, only a small pressure gradient exists 
across the valve. However, further decreases in valve area 
result in progressively greater left-ventricular pressure 
overload. Although still debated, many researchers view 
development of left-ventricular hypertrophy as a major 
compensatory mechanism,20–23 oﬀ setting the pressure 
overload. Pressure overload by itself increases left-
ventricular afterload, impairing ejection performance. 
Afterload is generally quantifi ed as wall stress ( ) with 
the Laplace equation, in which  =pr/2th and p is 
left-ventricular pressure, r is left-ventricular radius, and 
th is left-ventricular thickness. As pressure grows in the 
numerator of this equation it is oﬀ set by a rise in wall 
thickness (concentric left-ventricular hypertrophy) in the 
denominator, keeping afterload (wall stress) normal. 
Since afterload is a key determinant of ejection 
performance, its normalisation is important in 
maintaining normal ejection fraction and stroke volume.
Unfortunately, hypertrophy is a double-edged sword, 
benefi cial in some respects and deleterious in others. 
Although it helps to preserve ejection performance, 
hypertrophy also impairs coronary blood-fl ow reserve, 
reduces diastolic function, and is associated with 
increased mortality.24–30
In all other circulatory beds, oxygen delivery to tissues 
can be augmented by both a boost in blood fl ow to the 
region and an increase in oxygen extraction from 
haemoglobin. The heart is unique among all organs in 
that its blood fl ow is received mainly during diastole and 
oxygen extraction is always close to maximum. Thus, the 
only way in which the myocardium can match enhanced 
oxygen demand with increased supply is by boosting 
coronary blood fl ow. In healthy individuals, coronary 
blood fl ow reserve is 500–800% over resting fl ow; 
however, in the presence of concentric hypertrophy, 
reserve is diminished, usually to about 200–300%.26 This 
impairment could be secondary to reduced capillary 
ingrowth into the hypertrophied myocardium.27 
Additionally, the increased fi lling pressure needed to 
distend the thickened ventricular wall compresses the 
endocardium, further impairing blood fl ow to that layer 
of the myocardium. These abnormalities must contribute 
to the cause of angina in patients who develop it in the 
presence of normal epicardial coronary arteries. However, 
the explanation is not that simple because not all 
individuals with impaired fl ow reserve develop angina 
and angina does not correlate well with the extent of 
hypertrophy present. Angina does seem to accord with 
obstruction severity and diastolic fi lling time (the oxygen 
debt repayment period).28,29
Onset of dyspnoea and other symptoms of heart failure 
presage the worst outlook for the patient with aortic 
stenosis. Whereas concentric hypertrophy helps to 
maintain systolic performance, increased wall thickness 
impairs diastolic function. Diastole is typically divided 
into active relaxation and passive fi lling. During active 
relaxation, calcium is pumped back into the sarcoplasmic 
reticulum, causing the contractile interaction between 
actin and myosin to diminish. In concentric hypertrophy, 
this process is delayed, in turn holding up the onset of 
passive fi lling, shortening the time for blood to pass from 
the atria to the ventricles.30 Furthermore, increased wall 
thickness needs amplifi ed distending pressure to achieve 
the same diastolic volume as noted in a healthy 
individual.31 This augmented diastolic pressure leads to 
pulmonary congestion and dyspnoea. 
Concentric hypertrophy is not compensatory in all cases. 
In some patients, hypertrophy fails to normalise afterload,32 
allowing the abnormal afterload to reduce ventricular 
ejection performance, reducing cardiac output, adding to 
the heart failure syndrome. Eventually, contractile function 
also fails (fi gure 2),33 further restricting ejection 
Gradient (mm Hg) Aortic valve area (cm2) Cardiac output (L/min)
2 3·0 5·0
11 1·5 5·0
16 1·25 5·0
25 1·0 5·0
45 0·75 5·0
70 0·60 5·0
100 0·50 5·0
Table: Aortic valve ar a ve sus gradient 
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6
Figure 1: Survival of patients with aortic stenosis over time
After a long latent asymptomatic period, during which time survival is nearly normal, survival declines 
precipit usly once symptoms dev lop. Adapted with permission fr m Ross and collea ues.19 
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Figure 3: Grading of aortic stenosis 
Severely stenosed aortic valve with leaflet fusion (black arrow) at time of surgery (left). 
Grading of aortic stenosis by echocardiography (right) according to European and American 
Guidelines (Vahanian 2012, Nishimura 2014). Adapted from Walter et al 2012 [12]. 
There is no randomized controlled trial data to guide management in these particular 
patients [13]. There are indicators predicting adverse outcome in seemingly 
asymptomatic patients with severe AS, who should be considered for pre-emptive 
valve replacement: abnormal resting ECG with strain, critical AS (velocity >4.5-
5m/s), inappropriate LVH, reduced longitudinal strain, abnormal impedance, 
abnormal exercise test (serious arrhythmia, ischaemic response, abnormal blood 
pressure response), and elevated or rising brain natriuretic peptide [14-16]. The 
evidence base however is limited and derived from a small number of patients with a 
high likelihood of selection bias. Ultimately, better risk stratification is necessary to 
identify patients that would benefit from early surgery.  
1.1.3 Assessment of Aortic Stenosis beyond the Valve 
Unfortunately, these echocardiography parameters poorly predict symptom 
development and/or optimal timing of surgery [17]. The literature acknowledges this, 
and new concepts in the assessment of the severity of AS are appearing – highlighting 
the importance of the intricate interplay of the vasculature (aortic stiffness and 
hypertension), valve stenosis and responses of the ventricle to the global load 
(valvular-arterial impedance); see Figure 3.  
This concept was first highlighted by Professor Graham Steell in 1906 (Figure 1), who 
described LV decompensation an “unmixed evil”. Patients may tolerate severe AS for 
many years, but after the onset of symptoms and LV dysfunction, prognosis is poor 
[18, 19]. Consequently, AVR in symptomatic patients is a Class I indication [20]. In 
most asymptomatic patients however, prophylactic surgery is controversial [21, 22]. 
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Operative mortality is low at 1-3% (registry data), even <1.5% in Heart Valve 
Centres of Excellence [23].  
 
 
Figure 4: Complex physiology in aortic stenosis 
Aortic stenosis is not just a disease of the valve – the intricate interplay of valve, vasculature 
and ventricle eventually resulting in symptom development. 
1.1.4 The myocardium in Aortic Stenosis 
1.1.4.1 Left Ventricular Remodelling 
Left ventricular hypertrophy (LVH) occurs in response to increasing afterload and LV 
intra-cavity pressure in order to maintain normal wall stress. The adaptive changes 
result in alteration of the LV geometry (radius and wall thickness, or mass volume 
ratio) [24]. Four pattern of ventricular remodelling in AS have been described using 
imaging (based on wall thickness, LV volume and mass), which are (Figure 5): 
normal geometry, concentric remodelling, concentric hypertrophy and eccentric 
hypertrophy (LV decompensation) [25]. This response however is heterogeneous 
(10-20% of patients with severe AS display no LVH) and only weakly correlates with 
the degree of apparent AS. Importantly, other factors affecting the magnitude of 
hypertrophic response are age, sex, metabolic syndrome, obesity, angiotensin 
enzyme polymorphism and concomitant hypertension (see section 1.1.7).  
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Figure 5: Pattern of myocardial remodelling by CMR 
The four patterns of LVH and remodelling in AS demonstrated on CMR. 
Cioffe et al found that patients with inappropriately high LV mass index on 
echocardiography (LV mass exceeding 10% of the expected value predicted from 
height, sex and stroke work) had a 4.5-fold higher risk of adverse events compared 
to counterparts with appropriate LVH [26]. Electrocardiographic evidence of 
significant LVH with strain was also associated with cardiovascular events in the 
SEAS study [27]. Presence of severe LV hypertrophy has been shown to be a major 
determinant of late death [28], while conversely LV mass regression of more than 
150g is an independent predictor of improved long-term survival on multivariate 
analysis after AVR at 10 year [29]. Focus has recently turned on patients with 
preserved EF and paradoxical low-flow, low-gradient severe AS because they 
appear to have a worse prognosis [30].  As a population, they are characterized by 
severe concentric remodelling, high wall thickness, and small LV volumes and 
resulting low indexed stroke volume and mean gradients [30]. CMR as the reference 
standard for quantifying LV mass, volume and function allows a more accurate 
assessment of geometric changes, particularly in patients with challenging 
transthoracic echo windows (which are not uncommon in this population).  
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1.1.4.2 Impaired left ventricular function in AS 
Impaired systolic function (LVEF<50%) in severe AS is even in asymptomatic 
patients a class I indication for AVR (even in asymptomatic patients), but is a poor 
and late indicator of LV contractile deterioration. Prior to deterioration in systolic 
function, LVH and fibrosis result in impaired LV relaxation and diastolic dysfunction. 
Left atrial size, Doppler mitral inflow and myocardial tissue velocities assessed by 
echocardiography in AS are associated with worse patient symptoms and increased 
cardiovascular events [31]. Left atrial size is also associated with the development of 
atrial fibrillation, which in turn increases the risk of heart failure and cerebrovascular 
events [32]. Mitral annular plane systolic excursion (MAPSE) [33], and mid-wall 
fractional shorting [34] as well as myocardial deformation/strain [35] imaging by 
echocardiography allow detection of more subtle deterioration in myocardial 
contractility. In particular, strain imaging, which accounts for the different myofibril 
orientation within the myocardium, shows subendocardial dysfunction in mild AS 
(reduced longitudinal strain), mid-wall dysfunction in moderate AS (reduced 
circumferential strain), and transmural dysfunction in severe AS (reduced radial 
strain), and has been shown to be prognostic [36].  
1.1.4.3 Left ventricular remodelling after valve replacement 
Myocardial changes are also important for the recovery after surgery, and have 
been studied by echocardiography and CMR. Following valve replacement (surgical 
or transcatheter), LV mass (LVM) regresses fastest in the first 6 to 12 months with 
20% to 30% LVM reduction at 1 year, which is associated with significant 
improvement in LV systolic function [37-44]. Diastolic dysfunction (relaxation) only 
improves later with further regression of both LVH and diffuse fibrosis [45]. Patients 
with mild to moderate diffuse fibrosis at baseline show improvement in symptoms, 
LV function and a marked reduction in LVH after surgery [46, 47]. Patients, however, 
with severe fibrosis show only a slight clinical improvement, without a significant 
change in LV size or function [46]. As many patients develop diffuse fibrosis without 
symptoms or detectable reduced LV function [48], quantifying fibrosis directly has 
the potential to dramatically improve the management of these patients. 
1.1.4.4 Myocardial changes in AS 
Myocardial changes are thought to play a key role in functional deterioration, 
symptoms and outcome in AS [49].  
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Figure 6: Theoretical impetus for early aortic valve replacement. 
This is based on irreversible changes due to maladaptive ECM remodelling. AS, Aortic 
stenosis; AV, aortic valve; AVR, aortic valve replacement; ECM, extracellular matrix; LVH, 
left ventricular hypertrophy (Yarbrough 2011). 
The theoretical impetus for early AVR is therefore based on irreversible changes 
due to extracellular matrix (ECM) remodelling. Identification of a biomarker capable 
of heralding the transition from adaptive to maladaptive ECM remodelling would 
certainly have therapeutic value. Specifically, such a biomarker may be used to 
direct more timely elimination of the pressure overload state, thus optimizing the 
chances for normalisation within the ECM and improved postoperative outcomes 
[50] (Figure 6). 
1.1.5 The Myocardial Interstitium in AS 
The cardiac interstitium plays a key role in the myocardial remodelling processes, 
acting as the stage for an intricate interplay between fibroblasts, myocytes, the 
neuro-hormonal system and mechanical stresses. In health, the complex three-
dimensional extracellular matrix is composed of type I (80%) and type III (11%) 
collagen fibres (a ratio that changes in disease), which self-assemble into fibrils and 
large fibres after being secreted as procollagens and cleaved by proteinases. Fibrils 
are further strengthened by cross-links catalysed by lysyl oxidase (LOX)[51].  
CONCLUSIONS
Although forestalling AVR until the onset of symptoms
has proven to be a relatively successful strategy for patients
with severe AS for many years, it is apparent that interven-
tion delayed until this time point fails to achieve complete
regression of maladaptive changes that occur within the
myocardial ECM. Persistence of the products of myocardial
ECM elaboration secondary to ASmay translate into a post-
operative clinical condition characterized by a continued in-
crease in myocardial stiffness, that is, diastolic dysfunction.
The summation of remodeling events as they relate to mal-
adaptive phases of AS and LVH, and their temporal relation
to the development of heart failure and AVR, are shown in
Figure 3. As depicted by the hypothetic figure, cellular and
ECM remodeling occurs during the progression of AS. In
addition, clinical studies suggest that myocardial fibrosis
persists after AVR for AS and highlights potential inadequa-
cies of current treatment guidelines. Identification of a ma-
trix biomarker that reflects the transition to maladaptive
remodeling in the setting of LV pressure overload may
provide an opportunity to achievemore complete regression
of deleterious changes within the ECM at the time of AVR.
Targeting the ECM, and identification of just such
a biomarker, may ultimately provide clinicians with
a more precise means by which they are able to assess
and counsel their patients with severe, though perhaps
asymptomatic, AS.
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Figure 7: Myocardial fibrosis by scanning electron microscopy 
Scanning electron microscope image showing the extracellular skeleton made up of collagen 
microfibrils in a normal subject (A) and a patient with severe aortic stenosis, where there is 
significant expansion of the extracellular space by collagen fibrils (adapted from Kanzaki 
Circulation 2009), Bar=30 μm, magnification ×600 [52]. 
Collagen degradation is regulated by a family of proteolytic enzymes, the matrix 
metalloproteinases (MMPs), which are themselves regulated by their tissue 
inhibitors (TIMPs). The key intracellular components are actin and titin filaments, 
which during diastole serve as tensiometers and passive force generators [53]. In 
disease, this environment changes due to fibroblast metaplasia into myofibroblasts, 
an increase in larger diameter higher-tensile type I collagen relative to type III 
collagen and increased LOX activity leading to amplified fibre cross-linking. On an 
intracellular level, myofibroblast smooth muscle actin increases and titin filament 
phosphorylation occurs, causing passive stiffness.  
1.1.6 Interstitial versus Replacement fibrosis 
Myocardial fibrosis can be described by different, partly disease-specific patterns, 
described as compact or ‘focal,’ perimyseal, perivascular, plexiform or patchy [54]: in 
AS, interfibre and perivascular fibrosis increase disproportionally [54]. Alternatively, 
one can distinguish between replacement fibrosis and diffuse interstitial fibrosis (due 
to a change in quantity and quality of collagen I and III – phosphorylation and 
crosslinking). Replacement fibrosis can occur due to apoptosis (pathway leading to 
cell death that features the activation of caspases to cleave cellular substrates), 
autophagy (degradation of cellular components within the intact dying cell in 
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autophagic vacuoles) or oncosis (cell death accompanied by cellular and organelle 
swelling and membrane breakdown). 
 
Figure 8: Pathophysiology of myocardial fibrosis in Aortic Stenosis 
Chronic pressure overload of severe aortic stenosis results in compensatory concentric left 
ventricular hypertrophy, which is associated with not only increased myocyte volume but 
also coordinated remodelling and increased extracellular matrix, with development of both 
diffuse interstitial and focal replacement fibrosis. Adapted from Barone-Rochette 2014 [55]. 
Interestingly, replacement fibrosis in AS is predominantly due to ubiquitin mediated 
autophagy and oncosis rather than apoptosis, without any evidence of myocyte 
proliferation [56]. Furthermore, fibrosis in AS follows an endo- to epicardial gradient, 
with the increased fibrosis in the subendocardial portion (see section 1.4.5.2) likely 
due to a combination of increased cavity pressure, increased LVH-induced 
metabolic demand and reduced perfusion [57]. In histological practice, these 
subtypes of fibrosis are often captured together by staining procedures targeting the 
interstitium (picrosirus red/van Giessen/ Masson’s trichrome) and described as 
collagen volume fraction (CVF). Myocardial fibrosis quantified using CVF at the time 
of AVR is highly variable and only poorly correlates with haemodynamic markers of 
AS severity, nevertheless patients with severe fibrosis have a significantly worse 5-
year survival than those with only mild fibrosis (Figure 9 [58]). The current gold 
standard investigation for quantifiying fibrosis is endomyocardial biopsy, which is 
unfortunately prone to sampling error and is an invasive procedure associated with 
significant morbidity and mortality [59].  
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Figure 9: Myocardial fibrosis and outcome 
Myocardial fibrosis quantified by histology during valve replacement predicts outcome. 
Adapted from Azevedo et al 2010 [58]. 
 
1.1.7 Influences of myocardial remodelling in Aortic Stenosis 
The magnitude of the hypertrophic response to AS is also affected, among others, 
by age, sex, hypertension and occult disease (e.g. cardiac amyloid).  
1.1.7.1 Sex 
Sex appears to exert an important influence on LV remodelling [60-62]. Previous 
work has shown that men are more likely to have higher indexed LV mass, lower 
LVEF, and increased diastolic myocardial stiffness [42, 63], whereas women have 
more concentric remodelling with higher relative wall thickness and LVEF. To date 
however most studies have relied on echocardiography alone, with only limited 
combined echocardiography and CMR data available[42].  
1.1.7.2 Hypertension 
Hypertension is very common in calcific AS, depending on the age of the study 
population, e.g. affecting 72% of patients in the SEAS trial (Statin usE in Aortic 
Stenosis) [64]. The under-appreciation of hypertension and reluctance to treat it in 
this population results in increased vascular afterload and LV load (valvular-arterial 
impedance; Zva) leading to increased hypertrophic remodelling, interstitial fibrosis 
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and LV dysfunction [65], which in turn herald worse outcome. Uncontrolled 
hypertension may mask severity of AS, and should be treated aggressively, with re-
evaluation of AS severity after adequate control. In addition to the favourable effect 
on LV remodelling, the potential anti-fibrotic effect of ACE-inhibitors and angiotensin 
receptor blockers medications may be beneficial [66-68].  
1.1.7.3 Cardiac Amyloidosis 
Amyloidosis is a rare multisystem disease characterised by the extracellular 
deposition of abnormally folded protein [69, 70]. Cardiac involvement is the leading 
cause of morbidity and mortality in these patients, and is characterised by a 
progressive infiltrative cardiomyopathy. Deposits of amyloid accumulate in the 
ventricular myocardium, almost always of either immunoglobulin light-chain (AL) or 
transthyretin (ATTR) type [69, 70]. ATTR cardiac amyloid deposition is present in up 
to a 25% of individuals aged over 85 at autopsy [71]. To date, this has been no more 
than an academic observation, but technology is changing this: cardiac imaging, 
particularly CMR and 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid (DPD) 
scintigraphy can now detect the disease antemortem, often without the need for 
invasive endomyocardial biopsy [72], which is generating a major increase in 
national awareness. Prognosis is often poor, and treatments are substantially 
influenced by cardiac involvement. Given the prevalence of both AS and ATTR in 
octogenarians, the two are likely to co-exist and the literature has early evidence for 
this. In a cohort of 20 patients with AS, who had undergone TAVI and subsequently 
valve explantation at autopsy (n=17) or surgery (n=3), cardiac amyloid was found in 
a third of these patients and was thought to contribute to death in the majority [73]. 
There are two separate aspects of ATTR in AS. First, ATTR in patients with 
moderate AS may mimic severe AS, (particularly low-flow, low-gradient) causing 
misdiagnosis. Second, ATTR may itself be a disease modifier, leading to a more 
severe phenotype with more heart failure, arrhythmia, and higher mortality.  
1.2 Current dilemmas in the management of AS 
Judicious timing of aortic valve intervention (surgical AVR or transcatheter aortic 
valve implantation [TAVI]) is crucial. Unnecessary morbidity and mortality 
associated with early intervention needs to be balanced against irreversible changes 
in the heart muscle due late intervention, because these can lead to increased post-
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operative complications, the development of heart failure and an adverse long-term 
prognosis.  
Current guidelines using the onset of symptoms and reduced LVEF as primary 
indications for intervention have significant limitations for the timing of surgery, 
because symptoms are often difficult to interpret, especially in the elderly, and 
reduction in LVEF occurs late and is associated with irreversible LV scarring. There 
is therefore a major need for: 
1. A better understanding pathophysiological changes in the LV myocardium 
during the transition from physiological adaptation to pathophysiological 
maladaptation in severe AS.  
 
2. More objective and specific markers of LV decompensation that influence 
outcome and therefore can be used to more accurately define the optimum 
timing of surgical AVR or TAVI. 
CMR may deliver these more specific markers, as it offers a large array of 
techniques that allow accurate quantification of LV volumes, geometry and function 
(bSSFP cine imaging), stress perfusion imaging for quantification of the myocardial 
perfusion reserve, quantification of focal fibrosis (late gadolinium enhancement) and 
diffuse fibrosis (T1 mapping and ECV).  
 
1.3 Myocardial Tissue Characterisation by CMR 
This chapter is based on the following publications: Treibel TA, Moon JC. T1 
mapping in Cardiomyopathy (book chapter) in Cardiovascular Magnetic Resonance, 
3rd Edition by Warren J. Manning and Dudley J. Pennell, Elsevier 2017. 
CMR exploits the inherent difference between tissues in their configuration of atoms 
by generating differing signals – the fundamental tissue properties T1, T2 and T2*. 
Whereas differences in T1 and T2 had to be previously visualised by weighted 
sequences, they can now be measured in a single breath-hold with T1, T2 or T2* 
displayed as pixel maps where each colour coded pixel carries the absolute value.  
Furthermore, if T1 is measured before and after contrast, the myocardial 
extracellular volume (ECV) is mapped, representing the percentage of tissue that is 
extracellular water, a surrogate for the process holding water - fibrosis, amyloid or 
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oedema. In turn, T2 mapping is a highly attractive technique for characterisation of 
myocardial tissue in disease state accompanied by inflammation. T1, T2 and ECV 
change in disease, each being differentially sensitive to pathological processes. The 
potential of these techniques is best appreciated in rare (infiltrations), common 
(oedema) and ubiquitous (diffuse fibrosis) disease processes.  
1.3.1 Cardiovascular Magnetic Resonance for Scar Imaging 
Tissue characterisation and measurement of fibrosis is a mainstay of clinical care in 
Respiratory medicine, Nephrology and Hepatology, but in Cardiology this has been 
limited to the few patients who receive cardiac biopsies. The emergence of CMR is 
changing this. Myocardial fibrosis is inherently an important clinical parameter, as it 
represents one of the hallmarks of pathological remodelling of the myocardium [54, 
74-76]. CMR has established itself over the last decade not only as the gold 
standard for cardiac chamber volume and function quantification, but also for non-
invasive myocardial tissue characterisation. Its strengths lie in the use of multiple 
parameters to characterise the myocardium. The development of imaging 
parameters for the quantification of oedema, infarction and scar has been followed 
by their adoption by the CMR community of non-invasive tissue characterisation, in 
particular in acute and chronic myocardial infarction (MI). During an acute MI, 
occlusion of a coronary artery territory leads to myocyte necrosis, which typically 
spreads from the subendocardial to the subepicardial layers. Without reperfusion, or 
a collateral blood supply, complete necrosis of the territory distal to the occluded 
coronary artery ensues. The majority of animal models are based on myocardial 
ischaemia and infarction, therefore large amounts of histological and 
pathophysiological evidence arise from the exemplar conditions of acute and chronic 
myocardial infarction.  
Magnetic resonance characteristics of protons vary between tissues, depending on 
the configuration of atoms in the tissues. These inherent differences can be 
exploited to generate differing signal from particular tissues: T1 relaxation time 
(longitudinal relaxation time) is determined by how rapidly protons re-equilibrate 
their spins with their environment following a radiofrequency (RF) pulse. The native 
(non-contrast) myocardial T1 varies with water content and increases in cases of 
oedema, fibrosis or infiltration of the extracellular space (e.g. in cardiac amyloid). 
Inherently, it embodies composite signal from both cells and interstitium, and varies 
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with measurement technique and MRI field strength. Regional difference in T1 can 
be visualised by T1-weighted MR sequences or directly estimated by T1 mapping. 
T2 relaxation time (spin-spin relaxation time) is determined by how rapidly the 
refocused transverse signal decays after a RF pulse (in contrast to the rate of spin 
dephasing, which is called T2*). T2 is shorter when water is tightly bound to large 
molecules like collagen, but longer when water is free. T2-weighted images 
emphasize tissues with long T2 or in conditions like where myocardial oedema is 
present; new T2 mapping sequences are able to quantify T2 directly. Technical 
advances in T1- and T2-weighted imaging have allowed in-vivo visualisation and 
accurate quantification of myocardial oedema, a substantial feature of MI with 
ischaemic and reperfusion injury. Preliminary work by Higgins et al in a dog infarct 
model showed T1 and T2 elevation in infarction [77]. The observed changes were 
theoretically consistent with myocardial oedema and correlated with the 
measurements of myocardial water content estimated by wet-weight to dry-weight 
ratios. This early work aimed to develop non-contrast methods for diagnosing MI but 
overestimated infarct size.  
 
1.3.2 Gadolinium contrast agents 
This chapter is based on the following publications: Treibel TA, White SK, Moon JC. 
Myocardial Tissue Characterization: Histological and Pathophysiological Correlation 
(Review). Current Cardiovascular Imaging Reports, 7 (3), 1-9, 2014. 
Historically, myocardial scar has been visualised and measured directly on 
histological sections using stains specific for the connective tissue in the 
extracellular space [54]. However, to allow non-invasive measurement, tracers were 
needed that are confined to the extracellular space. These tracers needed to 
distribute homogeneously through the extracellular space but not enter cells; be 
highly water but not fat soluble; not be adsorbed, actively transported, protein-bound 
or metabolized; be non-toxic, stable and be cleared freely from the body; and finally 
be easily measured. Gadolinium-diethylenetriamine penta-acetic acid (Gd-DTPA) 
fulfils these requirements as a tracer; it diffuses rapidly from the vascular space into 
most extracellular tissue fluid, but not to the intracellular space, leading to the term 
‘extracellular contrast agent’. Gadolinium is a paramagnetic metal and because it 
has the most unpaired electrons [78], is the most efficient T1 relaxing agent, and 
also shortens T2 and T2*. In the presence of gadolinium, T1 of tissues is potently 
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shortened, resulting in increased signal on T1-weighted images and appearing 
bright on a T1 inversion recovery image. The relaxation rate (R1 or 1/T1) is directly 
proportional to the concentration of gadolinium. Gadolinium-based contrast agents 
are safe, with serious adverse events being extremely rare when appropriately used, 
with an incidence less than 1 in 100,000. Its safety profile and effect on the 
fundamental properties of T1 make it an ideal MR contrast agent.  
1.3.3 Gadolinium contrast kinetics 
To understand the pathophysiological basis of gadolinium contrast imaging, the 
pharmacokinetics of Gd-DTPA need to be considered. Following an intravenous 
bolus, gadolinium enters the myocardium down a concentration gradient (“wash-in 
phase”), and later, as the gadolinium has been cleared from the blood pool, it 
returns to the blood pool down the reversed concentration gradient (“wash-out 
phase”). This occurs over seconds to minutes in healthy myocardium, where cells 
are tightly packed and cell membranes are intact. In acute infarction, these kinetic 
effects are delayed due to changes in coronary flow rates, capillary permeability, 
and functional capillary density [79]. As importantly, the volume of distribution is 
larger due to ruptured cell membranes allowing Gd-DTPA to passively diffuse into 
the cellular compartment [80]. In combination with this the Gd-DTPA accumulates 
and lingers in the infarcted tissue shortening the T1.  In chronic infarct (i.e. 
established scar), the volume of distribution is larger because of a significant 
reduction in living myocytes, which are replaced by a dense, hydrated collagen 
matrix, resulting in a higher accumulation of Gd-DTPA.  
In practical terms, following administration of a bolus of Gd-DTPA, an inversion 
recovery sequence is performed, with the inversion time (TI) set manually by the 
operator. The TI is set in order to null “normal” remote myocardium which then 
appears black, resulting in the greatest image intensity difference between normal 
and infarcted tissue [81]. This late gadolinium enhancement (LGE) enables direct 
quantification of the spatial extent of focal scar, but the ability for absolute 
quantification of either diffuse, background fibrosis or density of focal scar is lost. 
Despite the extremely high resolution and correlation between histology and LGE in 
ex-vivo rat hearts at high field strength [82], it remains unknown what the clinical 
minimum “critical mass” of collagen is for LGE detection by. LGE imaging and 
analysis relies on thresholding techniques for quantification. Depending on the 
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disease and technique, there can be a two-fold difference [83]. New T1 mapping 
sequences, which will be discussed later, allow objective quantification of signal 
magnitude, which is potentially directly comparable between studies and patients. 
 
 
Figure 10: Gadolinium kinetics 
Pre- and post-gadolinium (Gd) contrast dispersion in normal versus fibrotic myocardium. 
Adapted from Jellis Cardiovascular diagnosis and therapy 2014 [84]. 
Initial animal work in the 1980s was performed with manganese chloride [85] and 
later gadolinium chelates in canine models of myocardial infarction showing 
differential and time-varying effects on relaxation times of normal and infarcted 
myocardium [86, 87]. The development of inversion recovery LGE MRI [88] and 
extensive preclinical and clinical validation studies established MRI as a reference 
standard method for imaging myocardial infarction and viability. Kim et al published 
a seminal canine infarct study that documented that LGE MRI depicted infarcted 
myocardium with remarkable fidelity [89]. That work was supported by extensive 
validations of gadolinium concentrations in acute infarction [90].  The histological 
Introduction	 Treibel TA, PhD Thesis 2017 
 
Page 30 of 193 
validation of LGE has been taken close to a cellular level by Schelbert et al, who 
performed extremely high resolution ex-vivo LGE imaging on rats at 7 Tesla and 
compared with histological sections showing a remarkable correlation 
(R2=0.96; p<0.001) [82]. Clinical validation studies established that gadolinium 
differentiated viable myocardium from infarcted myocardium in patients. Kim et al 
showed that the transmural extent of infarction predicted the recovery of contractile 
function after revascularisation [91], a study confirmed by Selvanayagam et al [92], 
provided revascularisation did not induce infarction. 
LGE-CMR has now become the gold standard for non-invasive quantification of 
focal fibrosis, in particular infarct size, with the spatial resolution needed to 
determine the transmural extent of infarction. The burden of LGE predicts function 
recovery after MI [93] and revascularization [92], as well as mortality and MACE [94-
96]. Single-photon emission tomography (SPECT) and positron-emission 
tomography (PET) validation studies confirmed that CMR LGE had equal or better 
sensitivity for infarction [97], in particular in small subendocardial infarctions seen on 
histology [98].  
The LGE method has proved to be reproducible [99], and performed with high 
sensitivity and specificity in a multicentre clinical trial [100]. LGE has therefore 
established itself as the gold standard method for assessment of focal scar in both 
ischaemic and non-ischaemic heart diseases including cardiomyopathy [101], 
myocarditis [102], pressure-overload hypertrophy [103] and infiltrative diseases 
[104]. 
1.3.4 Late gadolinium enhancement in Aortic Stenosis 
Various pattern of LGE have been reported in AS ranging from no fibrosis, 
subendocardial infarction-pattern, patchy focal, and linear mid-wall LGE Figure 11. 
Several groups have investigated the role of LGE in AS (see Table 1: LGE papers in 
aortic stenosis): Debl et al showed in 44 patient with severe symptomatic AS that 
27% of patients had LGE and that LGE presence was associated with more severe 
valvular stenosis [105]. Weidemann et al investigated 58 consecutive patients with 
severe AS at baseline and 9 months after AVR (also obtaining intra-operative 
myocardial biopsies), and found that the degree of LGE did not change; they 
concluded that AVR failed to reduce the degree of replacement fibrosis [33]. 
Azevedo et al. showed in a combined biopsy and LGE study of 54 patients with 
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severe aortic stenosis or incompetence undergoing AVR that both histological and 
imaging fibrosis (LGE) was associated with all-cause mortality late (>2 years) after 
AVR. Lee et al investigated 118 patients with moderate to severe AS, and found that 
LGE was associated with parameters of systolic and diastolic function [106].  
 
Figure 11: Late gadolinium enhancement in aortic stenosis. 
(A) No late gadolinium enhancement (LGE). (B) Infarct LGE with a subendocardial pattern 
observed in the septum and anterior wall. (C) Two focal areas of midwall LGE in the lateral 
wall of the left ventricle (red arrows); (D) Midwall LGE in a more linear pattern affecting the 
septum. (E) Short- and (F) long-axis views of midwall LGE (red arrows) of the inferolateral 
wall in the same patient. From Dweck et al JACC 2011.  
Dweck et al showed in a study consisting of 143 patients with moderate-to-severe 
AS that the presence of replacement fibrosis was an independent predictor of 
mortality providing incremental prognostic value over and above that of LVEF, with 
non-ischaemic LGE being a stronger predictor of mortality than infarct-pattern 
fibrosis [103]. Barone-Rochette et al investigated 154 consecutive patients 
undergoing AVR for severe AS, found LGE in 29%, and showed that LGE (non-
ischaemic or infarct-pattern) was an independent predictor of mortality [55]. 
  
Patterns of LGE. Three patterns of LGE were observed:
no gadolinium enhancement (no LGE group); localized
enhancement consistent with prior myocardial infarction
(infarct LGE group); and a midwall pattern of enhancement
(midwall LGE group) (Fig. 1). Interobserver agreement in
determining the pattern of LGE was very good, with a
kappa value of 0.89.
LGE was absent in 49 patients (34%). There was a typical
pattern of prior myocardial infarction in 40 patients (28%)
and midwall fibrosis in 54 patients (38%) (Table 1). In 8
patients (6%), there was a dual pattern of both myocardial
infarction and midwall fibrosis. These patients were cate-
gorized according to their predominant pattern, and the
statistical analysis was performed on this basis. Seven were
placed in the infarct group and 1 in the midwall group. One
patient with midwall LGE who died underwent autopsy.
Assessment of the macroscopic appearance of the cut
surface of the heart showed myocardial fibrosis, which was
confirmed histologically using Trichome stain (Fig. 2).
Patients with no LGE were younger, more likely to be
female, and less likely to be undergoing diuretic therapy.
The severity of aortic stenosis and prevalence of cardiovas-
cular risk factors were similar to the other groups. As
anticipated, patients with an infarct pattern of LGE had
more severe coronary artery disease, lower ejection fractions,
and higher indexed LV volumes than the other groups.
Patients with midwall LGE had the highest indexed LV
mass (p! 0.005) despite the fact that aortic stenosis severity
and hypertension prevalence were similar among all 3
groups. Interestingly, ejection fraction was lower (p !
0.007) in patients with midwall LGE compared with those
with no LGE, even though both groups had a similar degree
of coronary artery disease. Although there was an apparent
trend to a correlation between ejection fraction and the
midwall LGE burden (Pearson’s R! –0.26; p! 0.08), this
finding did not reach statistical significance. Indexed left
atrial volumes were used as a marker of diastolic dysfunction
(25), n there was no signific nt difference in this variable
among the 3 groups (Table 1).
Figure 1 Patterns of LGE in Aortic Stenosis
Images showing the different patterns of late gadolinium enhancement (LGE) observed in patients with aortic stenosis. (A) No LGE. (B) Infarct LGE with a subendocar-
dial pattern observed in the septum and anterior wall. (C) Two focal areas of midwall LGE in the lateral wall of the left ventricle (red arrows); (D) Midwall LGE in a more
linear pattern affecting the septum. (E) Short- and (F) long-axis views of midwall LGE (red arrows) of the inferolateral wall in the same patient.
Figure 2 Histology of the Myocardium, After Trichome Staining,
in a Patient With Midwall LGE
Black arrows demonstrate increased replacement fibrosis in the
midwall region of the myocardium.
1274 Dweck et al. JACC Vol. 58, No. 12, 2011
Midwall Fibrosis and Mortality in Aortic Stenosis September 13, 2011:1271–9
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Author, 
Year of 
Publication 
Inclusion 
Criteria Outcome Findings 
Mean 
Follow-
up Comments 
Debl et al, 
2006 
Moderate to 
severe AS 
n=22 
LGE more common in 
severe than moderate 
AS 
LGE found in 4.5 
of 12 segments 
Cross-
section-
al 
LGE volume was 
larger in HCM 
control patients 
Azevedo et 
al, 2010 
AS referred for 
AVR 
n=28 
Age & LGE were 
independent predictors 
of all-cause mortality 
higher degrees of 
LGE associated 
with worse long-
term survival 
52 ± 17 
months 
LGE and 
histological 
fibrosis measured. 
Also 26 patients 
with AR followed. 
Lee et al, 
2013 
Moderate to 
severe AS 
n=118 
LGE associated with 
more advanced LV 
remodelling and 
decreased LV function 
and LV compliance 
Midwall LGE was 
more common in 
patients with 
reduced LVEF 
Cross-
section-
al 
Potential 
usefulness of LGE 
to detect LV 
deterioration in AS 
Steadman et 
al, 2012 
Severe AS 
n=46 
Myocardial perfusion 
reserve by MRI 
associated with peak 
VO2 
LGE negatively 
associated with 
myocardial 
perfusion reserve 
Cross-
section-
al 
Links reduced 
myocardial blood 
flow with 
increased fibrosis 
Quarto et al, 
2012 
AS referred for 
AVR 
n=63 
Midwall LGE associated 
with greatest MACCE 
risk (P = .01) 
No LGE (n = 25) 
had no 1- or 2-year 
mortality 
30 d, up 
to 2 y 
Postoperative AV 
block more 
common with 
midwall LGE 
Dweck et al, 
2011 
Moderate and 
severe AS 
n=143 
Midwall LGE increased 
mortality by 8-fold 
Midwall LGE and 
LVEF predicted 
mortality 
2 ± 1.4 
years 
Midwall LGE 
associated with 
increased LVMI 
Fairbairn et 
al, 2013 
Severe AS 
n=50 
LGE reduced post-TAVI 
but not post-SAVR  
LGE major 
predictors of 
remodelling. 
6 
months 
FWHM 
quantification 
used. 
Barone-
Rochette et 
al, 2014 
AS referred to 
AVR (n = 154) 
or TAVR (n = 
40) 
Presence of LGE 
increased all-cause 
mortality after AVR (HR, 
2.8), but not after TAVR 
Postoperative 
mortality was also 
greater with LGE 
2.9 
years 
Low statistical 
power for events 
in TAVR group 
 
Table 1: LGE papers in aortic stenosis 
Significance of Late Gadolinium Enhancement by Cardiac Magnetic Resonance Imaging in 
Aortic Stenosis (adapted from Rader et al AJM 2015[107]). 
1.3.5 Tissue Characterization – Moving Beyond Late Enhancement  
The LGE technique has become the gold standard technique for assessing the 
presence of scar on CMR in both ischemic and non-ischemic heart diseases 
including cardiomyopathy [101], myocarditis [102], AS-induced pressure-overload 
hypertrophy [103] and infiltrative diseases [104]. LGE is, however, a difference test 
between normal and abnormal myocardium, and therefore is not able to accurately 
quantify diffuse myocardial disease, provide information the adaptation on non-
scarred areas to the increased workload or indeed if they are at risk of generating 
new scar. There are many pathways active in normal myocardium, and these vary 
with different pathological processes.  Each parameter may be differently sensitive 
to these. Multi-parametric tissue characterization is therefore an attractive strategy 
for non-invasive “biopsy” and “whole heart” sampling, avoiding potential morbidity 
and mortality of biopsy [59].  
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1.4 T1 Mapping and Diffuse Myocardial Fibrosis  
Early in-vitro CMR work by Kehr et al. on human myocardium obtained post-mortem 
compared T1 values, calculated from the inversion recovery signal curves, with 
collagen volume fraction, determined by the picrosirus red method, and showed a 
significant correlation between the two methods [108]. Flett et al then developed an 
extracellular volume technique and showed strong correlation in patients with severe 
aortic stenosis and hypertrophic cardiomyopathy [109]: by calculating pre- and post-
contrast T1 values from inversion recovery signal curves, the ECV was derived by 
incorporating the blood volume of distribution (1-haematocrit). The ECV showed a 
strong correlation with the collagen volume fraction of biopsies obtained intra-
operatively in this cohort. This work has been replicated with shorter protocols and 
with newer, faster T1 mapping sequences (Figure 14; Table 2) in a variety of 
disease processes [110, 111]. After administration of gadolinium, T1 is dominated 
by and inversely proportional to the amount of gadolinium present in a tissue. 
Measuring T1 after contrast provides a value linked to the interstitium and has been 
applied to patients with heart failure [112].  
Reference (et al) Year Population n Parameter Sequence Correlation 
Iles [113] 2008 DCM 25 Post contrast T1 1.5T; IR VAST 
r=-0.7 
p=0.03 
Flett [114] 2010 AS/HCM 26 ECV 
1.5T; EQ-CMR; Multi-
breath-hold FLASH IR 
r2=0.8 
p<0.001 
Sibley [115] 2012 
DCM/IHD/ 
HCM/Amyloid 47 Post contrast T1 1.5T, IR Look Locker 
r=-0.57 
p<0.001 
Mascherbauer 
[116] 2013 HFpEF 9 Post contrast T1 1.5T, IR FLASH 
r=0.98 
p<0.01 
White [117] 2013 AS 18 ECV 
1.5T; EQ-CMR 
ShMOLLI 
 r=0.83 
p<0.01 
Miller [118] 2013 
DCM/IHD 
(Transplant) 6 ECV 1.5T, MOLLI 
r=0.94 
p<0.01 
Bull [119] 2013 AS 19 Native T1 1.5T; ShMOLLI 
 r=0.66 
p<0.01 
Lee [120] 2015 AS 20 Native T1 3T, MOLLI 
r=0.77 
p<0.01 
De Meester [121] 2015 AS/AR/MR 31 T1 & ECV 3T, MOLLI 
r=0.78 
p<0.01 
 
Table 2: Correlation of histology with T1 mapping parameters 
AS, aortic stenosis; AR, aortic regurgitation; DCM, dilated cardiomyopathy; HCM, 
hypertrophic cardiomyopathy; IHD, ischaemic heart disease; IR, inversion recovery. 
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Figure 12: Histological validation of diffuse fibrosis in severe AS 
Graph showing the correlation of extracellular volume (ECV) measured by CMR with 
histological collagen volume fraction in patients with severe aortic stenosis. The dashed lines 
represent 95% confidence intervals. Adapted from White et al. JACC CVI 2013 [117]. 
1.4.1 Native T1, post-contrast T1 and ECV 
Native T1. Native T1 measures the intrinsic signal from the combined cellular and 
interstitial compartments of the myocardium [122]. The advantages are that it does 
not require an exogenous gadolinium based contrast agent. Native T1 relaxation 
time is prolonged with collagen (fibrosis) [109], oedema [123] and amyloid [124].  It 
is shortened with low fibrosis (i.e. cellular hypertrophy) [125], iron [126], fat [127] and 
haemorrhage [128] (Figure 13). Given that native T1 measures both interstitium and 
myocyte T1 – a signal from the interstitium alone is somewhat diluted by the 
myocyte signal so subtle differences (diffuse fibrosis) are harder to detect. 
Moreover, capillary density, capillary vasodilatation and “partial voluming” between 
blood pool and myocardium are also measured – introducing potential bias if the 
signal sought is the matrix or myocyte compartments alone. Native T1 time is 
different with field strength, sequence [129] and scanner type - making comparison 
of native and post-contrast values between centres challenging. Several groups 
have developed T1 phantoms to facilitate multicentre trials (HCMR [130]) or develop 
reference standards (T1MES [131]).  
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Figure 13: Native T1 across health and disease 
Native T1 maps (ShMOLLI) in the basal short axis of healthy volunteer (A): the normal 
myocardium appears homogenously green and the blood is red; Severe iron overload (B): 
the myocardium appears blue as the T1 is low from iron; Fabry disease (C): the myocardium 
has a lower T1 (blue) due to intracellular lipid accumulation, except in the inferolateral wall 
which is red due to fibrosis; ATTR amyloid (D): the myocardium has a higher T1 (red); AL 
amyloid (E): the myocardium has a very high T1 with less hypertrophy then ATTR; and 
hypertrophic cardiomyopathy (F): there is asymmetrical septal hypertrophy with right 
ventricular insertion point scar (red). Adapted from Treibel TA, Moon JC. T1 mapping in 
Cardiomyopathy (book chapter) in Cardiovascular Magnetic Resonance, 3rd Edition by 
Warren J. Manning and Dudley J. Pennell, Elsevier 2017. 
Post-contrast T1. After administration of gadolinium, T1 is dominated by and 
inversely proportional to the concentration of tissue gadolinium. Measuring T1 after 
contrast provides a value linked to the interstitium and has been applied to patients 
with heart failure [112]. Post-contrast T1 also varies with gadolinium dose, time post 
bolus, and importantly with patient specific factors such as heart rate, clearance 
rate, body composition and haematocrit.  
Extracellular volume fraction. If the change in T1 pre- and post-contrast is measured 
in both blood and myocardium after equilibration of the contrast distribution, the 
partition coefficient can be calculated.  By correcting for the haematocrit, the 
myocardial extracellular volume (ECV) is derived and can be calculated by:    
ECV = (1–haematocrit) x  Δ(1/T1myo) / Δ(1/T1blood) 
Introduction	 Treibel TA, PhD Thesis 2017 
 
Page 36 of 193 
Emerging evidence suggests that this ECV measurement is the more robust 
parameter then native or post contrast T1 [132] and early papers on prognosis show 
that, in unselected patients, it predicts outcomes at least as strongly as left 
ventricular ejection fraction ([133, 134]. 
 
Figure 14: ECV and LGE across health and disease 
ECV maps (top row) and corresponding late gadolinium image (LGE - bottom row) in the 
short axis of healthy volunteer: the myocardium appears homogenously blue; global 
myocarditis: note, due to the homogenous oedema, there is no focal LGE, but the ECV map 
shows diffusely elevated ECV; Aortic Stenosis: the ECV maps depicts ECV elevation 
corresponding to scar in the LGE image; Hypertrophic Cardiomyopathy (HCM): the ECV 
maps shows ECV elevation corresponding to scar in the right ventricular insertion points in 
the LGE image; ATTR amyloid; the blood:myocardial interface is lost in the ECV map, 
because the ECV is as high as in the blood pool (i.e.~60%) – the LGE images show classical 
global enhancement. Adapted from Treibel TA, Moon JC. T1 mapping in Cardiomyopathy 
(book chapter) in Cardiovascular Magnetic Resonance, 3rd Edition by Warren J. Manning 
and Dudley J. Pennell, Elsevier 2017. 
1.4.2 ECV dichotomizing the myocardium into cell and matrix components  
ECV divides the myocardium into two compartments (extracellular and cellular), and 
allows therefore non-invasive quantification of the myocardial matrix volume and its 
counter-part, cell volume (Figure 15). The cell volume represents the intact 
myocardial cellular component – providing a way to measure myocyte volume (N.B. 
this also includes fibroblasts, blood cells, macrophages, etc.). How these vary in 
disease (e.g. LVH) is important. For example, in transthyretin-related hereditary 
amyloidosis and light-chain amyloidosis, both have a massive matrix increase – but 
TTR has more matrix and 20% higher cell volume suggesting compensatory 
hypertrophy may permit more tolerance of the amyloid burden [135]. By modelling 
water exchange, there is also some evidence that the contrast kinetics could be 
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used to obtain cell size-dependent parameters particularly if very high doses of 
contrast are used [122].  
                                                                                                                                                                                                                                                  
 
Figure 15: Cell and matrix volume by ECV 
ECV dichotomizes the myocardium into matrix and cell compartments; these can be 
calculated by multiplying the volume of the LV myocardium by ECV or 1 – ECV, respectively. 
1.4.3 Technical advances in T1 mapping and ECV 
1.4.3.1 T1 Mapping Evolution 
The T1 mapping field is rapidly advancing to the point of widespread clinical utility. 
The first to use T1 measurements was Messroghli in 2004 with a pulse-sampling 
scheme known as Modified Look-Locker Inversion Recovery (MOLLI) [136], which 
replaced previous multi breath-hold approaches. This was refined over time 
including new MOLLI variants, ShMOLLI (a shortened variation with long T1 
advantages [136-138]), saturation recovery variants such as SASHA (offering 
complete heart rate insensitivity [138]) or hybrid approaches (ANGIE, QALAS, 
SAPPHIRE [139-141]); see Table 3. Incremental developments such as respiratory 
motion correction [142] gradually increased accuracy and precision [139, 143]. For 
ECV, contrast regimes were simplified from bolus followed by infusion or multi-
timepoint sampling to a single pre and post-contrast T1 map [144, 145]. Split 
contrast dose protocols suitable for stress perfusion imaging have also been 
validated [146]. ECV maps are now routine in some centres [147]. ECV 
quantification is less field and sequence sensitive than native T1 mapping but ECV 
standardization is on-going. Finally, MR finger printing may offer more rapid multi-
parametric tissue characterization in the future by providing myocardial T1, T2, and 
Proton Spin Density in a single breath-hold [148].  
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Sequence 
T1 
preparation  
(sampling) 
Imaging 
readout 
Respiratory 
motion 
correction 
Dura-
tion Advantage Disadvantage 
MOLLI Inversion 3(3)3(3)5  
Single-
shot 
bSSFP 
Single 
breath-hold 17s 
Good image quality, 
high precision, wide 
availability, inter-
centre reproducibility 
T1 dependence 
in T2, MT, 
sequence 
parameters, 
heart rate.  
MOLLI 
variants 
Inversion 
5s(3s)3s; 
4s(1s)3s(1s)
2s 
Single-
shot 
bSSFP 
Single 
breath-hold 11s 
Short breath-hold, little 
heart rate variability, 
optimal precision for 
pre and post contrast 
Different pre-and 
post-contrast 
sequence 
ShMOLLI Inversion 5(1)1(1)1 
Single-
shot 
bSSFP 
Single 
breath-hold 9s 
Very short breath-hold, 
unified sequence for 
pre/post, little heart 
rate variability 
Low number of 
fitted images 
SASHA Saturation 
Single-
shot 
bSSFP 
Single 
breath-hold 10s 
Excellent accuracy, 
invarient to T2, MT 
and inversion 
efficiency 
Low precision, 
prone to artifact, 
low image 
contrast for 
registration 
SAPPHIRE 
Hybrid 
Saturation / 
Inversion 
Single-
shot 
bSSFP 
Single 
breath-hold 10s 
Good accuracy, 
improved precision 
(greater than SASHA)  
Lower precision 
than MOLLI, 
prone to artifacts 
STONE Inversion 
Single-
shot 
bSSFP 
Free-
breathing; 
registration / 
tracking 
55s 
Improved accuracy, 
free breathing, no rest 
periods 
Potential 
susceptibility to 
heavy breathing, 
perturbation of 
blood T1 
ANGIE Inversion 
 Seg-
mented 
bSSFP 
Navigator-
gated, free 
breathing 
41s 
Enables high-
resolution scans, 
motion compensation 
robust to deep 
breathing 
Accuracy as in 
MOLLI, 
elaborated CS 
reconstruction 
required 
Table 3: T1 mapping Techniques - an overview 
Overview of current T1 mapping techniques and sampling schemes (adapted from 
Sebastian Weingaertner, SCMR 2016). MOLLI, Modified Look-Locker Inversion; ShMOLLI, 
Shortened MOLLI; MT, magnetisation transfer; bSSFP, balanced steady-state free 
precession; SASHA, Saturation-recovery Single-SHot Acquisition; SAPPHIRE, Saturation-
Pulse Prepared Heart-rate independent Inversion-REcovery; STONE, slice-
interleaved T1 mapping; ANGIE, accelerated and navigator-gated Look-Locker imaging 
[139-141]. 
For clinical utilization, these developments need to transition to standardized 
methodologies to diagnose disease, define mechanistic pathways of disease 
affecting the interstitium, the myocyte or both, change therapy and employ ECV as a 
surrogate endpoint in trials of drug development. This is the aim underpinning the 
first T1 mapping consensus statement [149]. The conceptual models are simple, but 
there is more going on: effects such as magnetization transfer, diffusion distance 
and time, contrast mechanisms, trans-cytolemmal water exchange rate, flow, T2 or 
T2* relaxation will all require further investigation [150, 151]. This will require global 
support and involvement. Quality control systems, commercial sequences, mega-
registries (e.g. Global CMR Registry, HCM Registry, UK Biobank) are in progress, 
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and will provide high volumes of new insights in what is now the most active CMR 
research area [130, 152]. 
1.4.3.2 Original MOLLI 
T1 Mapping using an ECG triggered MOLLI allows the acquisition of single shot 
bSSFP (balanced steady-state free precession) images acquired at different 
inversion times after a single inversion pulse, all gated to the same cardiac phase, 
thereby enabling a pixel-based T1 quantification in the myocardium.  
 
Figure 16: MOLLI Sampling scheme 
After the inversion, the magnetization following the T1 relaxation curve is repetitively 
sampled in several heartbeats for a small duration until the longitudinal magnetization has 
fully recovered. By combining several (up to 3) inversions with slightly shifted TI times within 
one protocol, the relaxation curve is sampled in an interleaved manner, resulting in a 
sufficient number of points for accurate T1 quantification acquired within a single breath-hold 
(adapted from Messroghli et al 2007). 
1.4.3.3 ShMOLLI 
ShMOLLI was developed as a shortened alternative to MOLLI (hence the name), 
which can generate rapid and high-resolution myocardial T1-maps in a single short 
breath-hold of only 9 heartbeats. It uses a conditional data-fit to ensure recovery. 
The same sequence is used for pre and post contrast, and it has minimal heart rate 
variability.  
1.4.3.4 MOLLI variants 
The most advanced MOLLI variant proposed by Dr Peter Kellman is a combination 
of separate pre-contrast (sampling scheme: 5s(3s)3s)) and post-contrast (sampling 
scheme: 4s(1s)3s(1s)2s). Furthermore, these sequences offer motion correction 
(MOCO), a better inversion pulse, standard deviation maps (error maps) and phase 
ically study the influence of different pulse sequence
parameters on T1 measurements in order to eliminate
heart-rate dependency and further optimize T1 accu-
racy, and to validate these modifications in T1 maps of
human myocardium.
MATERIALS AND METHODS
All studies were performed at a single center. The vol-
unteer study was approved by the local ethics commit-
tee, and all subjects gave written informed consent.
Pulse Sequence
MOLLI was implemented on a 1.5 Tesla MR system
(Magnetom Sonata; Siemens AG Medical Solutions, Er-
langen, Germany). All MOLLI-specific parameters were
accessible via an additional tab widget created next to
the standard tab widgets of the graphics user interface
of the MR system.
MOLLI is an ECG-gated pulse sequence scheme
here a numb r of inversion-recovery–prepared Look-
Locker experiments (usually three) are performed con-
secutively within one breathhold of the patient (7). Dur-
ing each experiment, multiple nonsegmented images
(usually three, three, and five) are acquired at end-
diastole of consecutive heart beats to sample the recov-
ery of longitudinal magnetization after the inversion
pulse. The separate experiments use different inversion
times (TI) between the inversion pulses and the center
of k-space of the first image readouts; the effective TI of
the consecutive images is determined by the initial TI
plus the length of the cardiac cycle hat have occurred
since the acquisition of the first image. Between exper-
iments, there are a number of heart cycles without any
data acquisition to allow for full recovery of magnetiza-
tion. For postprocessing, images are reordered by their
effective TI as if they had been cquired in one exper -
ment.
From the MOLLI tab widget, the following pulse se-
quence parameters could be controlled: number of in-
version-recovery–prepared Look-Locker experiments,
number of ECG-triggered acquisitions specific for each
experiment, number of pausing heart cycles after each
experiment, TI of first experiment, and TI increment
between subsequent experiments.
The following readout parameters were common to all
acquired studies: nonsegmented balanced steady-state
free precession (bSSFP) with 20 startup echoes, TR !
2.5 msec, TE ! 1.1 msec, 6/8 partial Fourier acquisi-
tion with centric reordering, field-of-view ! 340 mm,
matrix size ! 192 " 128, in-plane resolution ! 2.1 "
1.8 mm, slice thickness ! 8 mm, bandwidth ! 1090
Hz/pixel, and acquisition time ! 202 msec.
Phantom Studies
A total of eight gadolinium-doped agarose gel phantoms
were studied. Reference T1 relaxation times of each
phantom ere determined using standard inversion-
recovery–prepared turbo spin echo pulse sequences at
15 different TIs from 30 to 10,000 msec (TR ! 10,000
msec, TE ! 29 msec, turbo factor ! 13, number of
averages ! 4, field-of-view ! 300 mm, matrix size !
256 " 256). MOLLI experiments were performed in four
steps. At each step, one specific parameter critical for
T1 accuracy was varied. MOLLI was performed for each
variation while different heart rates from 50 to 100 with
increments of 10 “beats per minute” were imulated
using an internal ECG generator provided by the man-
ufacturer of the MR system (Fig. 1).
Step 1. Variation of Readout Flip Angle
The flip angle of the bSSFP readout was varied from 5°
to 60° (original: 50°) in increments of 5°. Fixed param-
eters were initial TI ! 100 msec, TI increment ! 120
Figure 1. MOLLI pulse sequence scheme. There are three Look-Locker (LL) experiments, each prepared by a separate 180°
inversion pulse (inv). The inversion time (TI) of the first LL experiment is defined as TIminimum. TI of the second and third LL
experiment are determined by TIminimum # TIincrement and TIminimum # 2 TIincrement, respectively. After the inversion pulses, images
are read out in a nonsegmented fashion with a constant flip angle ($). There is a defined number of pausing heart cycles in
between LL experiments in order to allow for undisturbed signal recovery.
1082 Messroghli et al.
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sensitive inversion recovery (PSIR) fitting (using a 3-parameter model). Finally, this 
sequence is also compatible with an offline ECV map prototype.   
 
Figure 17: ShMOLLI Sampling scheme 
ECG-gated pulse sequence schemes for simulation of ShMOLLI at a heart rate of 60 beats 
per minute (adapted from Piechnik et al 2010). 
1.4.3.5 ECV by Bolus versus Infusion  
The ECV technique has been taken a step closer to routine clinical applicability by 
work removing the requirement for a logistically cumbersome and time consuming 
primed infusion technique for the calculation of ECV. Schelbert et al showed no 
apparent detriment to the relationship with collagen volume fraction in low ECV 
states; White et al confirmed this, but highlighted that in high ECV (>40%) subjects, 
the bolus only approach consistently and increasingly overestimated the ECV [110, 
153]. 
1.4.4 T1 and ECV in Aortic Stenosis 
T1 quantification and mapping was applied early on to aortic stenosis, because of 
the relative ease of obtaining myocardial biopsies during AVR for histological 
validation of the technique. As mentioned above, the first histological validation was 
by Flett et al [109], who used a multi-breath-hold FLASH inversion recovery 
technique in 18 patients with severe AS. He then applied this technique to track 
clinical progression prior to and 6 months post AVR. This showed that diffuse 
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fibrosis was higher in AS patients compared to controls and correlated with 
functional capacity at baseline, but was underpowered to detect an increased 
mortality in those patients with severe fibrosis . Native T1 has also been validated 
against histology and has been shown to track AS severity [154]. ECV using new T1 
mapping techniques shows great promise due to a stronger biological signal and 
higher reproducibility [155]. T1 mapping data in aortic stenosis is summarized in 
Table 4. Prospective outcome data is currently not available, but T1 mapping has 
been incorporated as a secondary end-point to the PRIMID-AS study investigating 
myocardial fibrosis and perfusion reserve in asymptomatic moderate to severe AS 
(n=170) [156]. 
Author n AS group Type Sequence Parameter Comment 
Flett et al, 
2010[114] 18 Severe Histology FLASH IR ECV R
2=0.86 
Flett et al, 
2012[48] 63 Severe Outcome FLASH IR ECV 
ECV predicts 6MWT 
improvement post op 
Bull et al, 
2013[157] 109 
Moderate to 
severe 
Histology & 
mechanistic ShMOLLI Native T1 R
2=0.43 
White et al, 
2013[117] 18 Severe 
Histology & 
technical ShMOLLI ECV 
R2=0.69; bolus as good as 
infusion protocol 
Chin et al, 
2014[158] 20 
Mild to 
severe Technical 
MOLLI 
(3T) ECV + T1 
ECV better reproducibility 
then T1 
Chin et al, 
2014[159] 122 
Mild to 
severe Mechanistic MOLLI ECV 
ECV not independent 
predictor of Troponin 
Dusenbery et 
al, 2015[160] 29 Congenital Mechanistic MOLLI  ECV 
ECV elevation associated 
with diastolic dysfunction 
Mahmod et al, 
2014[161] 26 Severe Mechanistic 
ShMOLLI 
(3T) T1 
Hyperemia substantially 
alter T1 values 
Singh et al, 
2015[162] 40 
Moderate to 
severe  Technical 
MOLLI 
(3T) ECV + T1 
No difference in T1 or 
ECV between AS & 
controls 
Lee et al, 
2015[120] 80 
Moderate to 
severe  Mechanistic 
MOLLI 
(3T) T1 R
2=0.60 
de Meester et 
al, 2015[121] 12 Severe Histology 
MOLLI 
(3T) ECV + T1 R
2=0.61 
Kockova et al, 
2016[163] 31 Severe Histology MOLLI  ECV + T1 R
2=0.15 T1; R2=0.10 ECV 
Nadjiri et al, 
2016[164] 94 
Severe 
(TAVI) Mechanistic MOLLI ECV 
ECV: predictor of heart 
failure post TAVI  (p=0.06) 
 
Table 4: Overview of T1 mapping publications in AS 
 
1.4.5 Challenges for T1 mapping in Aortic Stenosis 
1.4.5.1 Capillary density.  
Rakusan et al reported reduced capillary and arteriolar density with increasing LVH 
on histological examination of myocardial samples [165]. Compensatory 
vasodilatation has been proposed by Mahmod et al as a potential confounder for 
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elevated native myocardial T1 and ECV in severe AS.  They showed that during 
adenosine hyperaemia, patients with severe AS had a blunted stress response, 
however 7 months following AVR, native myocardial T1 and response to adenosine 
stress returned to normal [161]. 
 
1.4.5.2 Fibrosis gradient from endocardium to epicardium.  
Weber [166] showed that in patients with AS the fibrosis percentage was higher in 
the subendocardium than in the subepicardium (19 versus 13%, p<0.05). Cheitlin et 
al then demonstrated a gradient of myocardial fibrosis from the inner to the outer 
third of the myocardium in patients with congenital aortic stenosis (Figure 18)[167]. 
 
Figure 18: Gradient of myocardial fibrosis 
A gradient of myocardial fibrosis from the inner to the outer third of the myocardium in 
patients with congenital aortic stenosis (adapted from Cheitlin et al Circulation 1980) [167].  
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FIGURE 4. Macroscopic distribution of
fibrous tissue in the wall of the left ventricle
in patients with aortic stenosis and coarcta-
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Discussion
The macroscopic myocardial fibrosis in congenital
aortic stenosis is greatest in the subendocardial region
and least in the subepicardial region of the left ven-
tricular wall. A similar distribution of increased inner
wall fibrosis is seen in coarctation of the aorta, but to a
much lesser degree. The reason for this distribution is
not entirely clear, although the distribution is as
predicted by the decrease in subendocardial relative to
subepicardial blood flow seen in experimental aortic
stenosis in animals.'
In aortic stenosis, there is increased myocardial
oxygen demand as a result of increase in systolic wall
tension due to increased left ventricular systolic
pressure, increased systolic ejection time and in-
creased left ventricular mass. The myocardial blood
supply is limited by increased coronary vascular
resistance during systole, as well as by a decreased
diastolic filling period and a relatively low diastolic
coronary perfusion pressure that are seen in both
supravalvular and valvular aortic stenosis. Normally,
blood flow to the subendocardial region is maintained
by autoregulatory vasodilation reducing vascular
resistance and increasing flow to compensate for the
shorter time of perfusion during each cardiac cycle.
Because myocardial oxygen extraction is normally
near-maximal with left ventricular hypertrophy, the
increased requirement for myocardial blood flow is
met by vasodilation.
In severe aortic stenosis, there may be maximal
vasodilation in the subendocardial region due to in-
creased oxygen demand. When this occurs, coronary
blood flow is dependent on the coronary diastolic
blood pressure, which is normal or even lower than
normal, and the diastolic filling time, which is
decreased as a result of the increased systolic ejection
period. Also, the pressure drop across the myocar-
TABLE 3. Microscopic Distribution of Fibrous Tissue in the l.Vall of the Left Ventricle
Iinner 1/3 Middle 1/3 Otiter 1/3 Correlation
(%/c,) (%,,c,) ((-SC!) (inner vs outer)
Aortic stenosis (n = 10)
Muscle 81.8 - 6.1 NS 80.9 - 63 NS 83.3 - 5.1 *
Fibrous 12.5 - 5.3 NS 13.4 - 6.7 NS 8.9 - 4.2 NS
Vessels 5.8 - 3.2 NS 5.7 - 3.5 NS 7.9 - 5.1 NS
Coaretation (n = 5)
Muscle 84.9 3.5 * 81.2 - 2.2 NS 81.4 4.3 NS
Fibrous 9.3 i4.6 NS 10.6 - 4.1 NS 6.5 2.9 NS
Vessels 6.4 2.0 NS 8.1 - 1.9 t 12.2 2.9
Values are mean - so.
*p < 0.05.
tp < 0.025.
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1.5 Myocardial tissue characterisation by Computed Tomography 
Computed Tomography (CT) can also quantify the ECV (CTECV) from pre and post 
contrast measurements of attenuation, and shows good correlation with ECV 
measured by CMR (ECVCMR), as well as histological measures of myocardial fibrosis 
[168-170]. 
1.5.1 Previous CT ECV work 
Previous ECVCT work is limited to two studies by Nacif and colleagues comparing 
heart failure patients with controls and a single histological validation study by 
Bandula and colleagues.  In the first study by Nacif, subjects underwent ECVCMR and 
ECVCT demonstrating results in line with the ECVCMR literature (28.6±4.4% vs 
31.6±5.1%, p = 0.03) [169]. In the second study, whole heart 3D ECV was quantified; 
ECV was significantly higher than in the previous CT study by the same group and 
in CMRECV studies (41±6%, 33±2%; p = 0.02) [170], raising the concern that partial 
voluming of the blood pool may have occurred. Bandula et al. measured ECV by 
using equilibrium CT in patients with aortic stenosis and showed that it correlated 
with histological quantification of myocardial fibrosis and with ECV derived by using 
CMR imaging (r = 0.71, p<0.001 and r = 0.84, p<0.0001, respectively) [168]. 
1.5.2 Reasons to pursue ECV by CCT 
CT has advantages over CMR: although ECV quantification by CMR is accurate and 
feasible, it is not suitable for patients with claustrophobia or commonly implanted 
devices like pacemakers. Furthermore, its widespread implementation into the NHS 
may be limited by cost, lack of widespread scanner access and time constraints 
(demands on NHS MRI resources is high and scans involving ECV quantification 
can take up to 60 minutes, reducing patient throughput). CT is faster and more 
ubiquitously available, with higher spatial resolution and a simple linear relationship 
between attenuation measurement (Hounsfield units, HU) and iodine concentration 
(compared to the non-linear effect on relaxivity of hydrogen following administration 
of gadolinium). Therefore, translation and validation of ECV by CT will aid 
dissemination of the technique throughout the NHS.  
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Chapter 2 Research Aims 
2.1 The RELIEF-AS Study 
REgression in Left ventricular Interstitial Expansion and Fibrosis after Aortic 
stenosis Surgery Study. ClinicalTrials.org Identifier: NCT02174471 
The RELIEF-AS Study was the main project of my PHD and the focus of my original 
funding application, which was granted by both the British Heart Foundation and 
National Institute for Health Research (I accepted the NIHR Doctoral Research 
Fellowship).  The majority of my research time was dedicated to this work and the 
data originating from this is the basis for multiple submitted papers. 
2.1.1 Overview and Study Design 
RELIEF-AS was a large single centre, 180 patient observational outcome study of 
aortic stenosis patients undergoing valve replacement with comprehensive baseline 
assessment, including CMR and biopsy in all and 1-year follow-up for cardiac, 
functional and mortality endpoints.   
2.1.2 Hypotheses 
We hypothesized using clinical invasive and non-invasive quantification that 
I. Extracellular matrix expansion predicts surgical outcome in AS after AVR.  
II. Recovery after AVR is associated with diffuse fibrosis regression at 1 year.  
2.1.3 Aims 
To use dynamic CMR to measure ECV as a marker of extracellular matrix 
expansion in patients with severe AS before and after valve replacement to 
establish if ECV, is predictive of outcome after surgery, and regresses parallel to 
LVH with reduction of afterload at 12 months (post AVR). Furthermore, our aim was 
to gain pathophysiological insights into extracellular matrix expansion in AS by 
invasive myocardial biopsy obtained during surgery.  
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2.1.4 Study design 
This was a single centre, prospective observational cohort study of patients with 
severe AS undergoing AVR in a tertiary referral cardiac centre (Figure 18 for Study 
Flow Chart proposed at study begin). The study was approved by the ethical 
committee of UK National Research Ethics Service (07/H0715/101) and registered 
on ClinicalTrials.gov (NCT02174471). The study conformed to the principles of the 
Helsinki Declaration, and all subjects gave written consent to participate.  
 
Figure 19: Planned study flow chart of RELIEF-AS Study. 
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2.1.5 Patient selection: 
• Inclusion criteria: patients with severe aortic stenosis (2 or more of: AVA<1cm2, 
peak pressure gradient 64mmHg, mean pressure gradient 40mmHg, velocity ratio 
< 0.25; or reclassification of discordant echocardiographic data to severe by 
alternate modality) undergoing AVR+/-CABG at Heart Hospital, consenting for 
study protocol; age 18-90 years, ability to undergo CMR scan. 
• Exclusion criteria: pregnancy/breastfeeding, GFR <30mls/minute, CMR 
incompatible devices, inability to complete the protocol, previous valve surgery, 
severe valve disease other than AS. 
 
2.1.6 Primary outcome measures: 
• Death post AVR. 
• Regression of diffuse myocardial fibrosis at 1-year post AVR. 
2.1.7 Secondary outcome measures: 
Secondary outcome measures were post-operative changes in diffuse fibrosis 
(measured by ECV), LV remodelling, symptoms (NYHA functional class, CCS class 
and quality of live measured by EQ-5DL) functional recovery (measured by 6 minute 
walk test) at 12 months. 
2.1.8 Recruitment 
Patients were recruited from cardiology, cardiothoracic, echocardiography or Heart 
Team meeting reports, were approached in the in- or outpatient setting and given a 
patient information sheet (PIS) if interested. Baseline assessment was co-localised 
with the surgical pre-operative assessment clinics to minimize travel for patients. 
2.1.9 Justification of sample size / Power calculations: 
The study with 150 subjects was calculated to have 80% power (binomial test) to 
show that patients with severe fibrosis (high ECV) have a higher event rate than 
patients with mild to moderate fibrosis (low ECV) at 1 year. The power calculations 
were reviewed by Paul Bassett (Senior Research Associate, UCL Biostatistics 
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Group). We based our sample size calculation on a previous cohort in our institution 
(Flett et al 2012), which was followed up at 6 months with a sample size of 63 
patients, and showed a trend of higher mortality with severe DMF. 
• Patients were to be divided into tertiles of diffuse fibrosis: group 1 comprising 
of patients with mild and moderate fibrosis, group 2 comprising of patients 
with severe fibrosis; Group 1 and 2 represented in a 2:1 ratio (based on a 
similar cohort).  
• Flett et al. described the following mortality figures at 6 months: 
- Group 1: Mild/moderate fibrosis = 2.4% (P1) 
- Group 2: Severe fibrosis = 19% (P2) 
• Power of the test = 80%; Type 1 error = 0.05 (K); ratio p1 : p2 = 2:1 
Adequate power was calculated to be achieved with a group size of 44, equalling a 
total sample size of 132. Furthermore, we decided to extend the follow-up to one 
year, and adjusting the sample size to allow for dropout (or implantation of non-MR 
compatible PPMs) of 10%. Therefore, a sample size of 150 patients was calculated 
to give adequate power our study, and to be a realistic recruitment target for our 
institution (140 AVR/year, 50-60% participation). 
2.2 Sub-studies  
2.2.1 Left Ventricular Remodelling in Severe Aortic Stenosis 
Background: Four main geometric patterns have been defined: normal geometry, 
concentric remodelling, concentric hypertrophy, and eccentric hypertrophy – based 
on left ventricular mass, cavity size and the ratio of these two. 
Aim: To understand the influences on AS remodelling using all available modalities 
to investigate patterns of remodelling at macroscopic and tissue level.  
 
2.2.2 Occult amyloidosis in Aortic Stenosis 
Background: Coexistence of AS and cardiac amyloidosis has been reported but this 
has not been studied systematically and the prognostic significance is unknown.  
Hypothesis:  We hypothesized that unrecognized ATTR amyloid deposits may act 
as a disease modifier in aortic stenosis. We aimed to: 1 – assess the prevalence of 
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occult cardiac amyloid in AS; 2 - identify the amyloid subtype; 3 – determine the role 
of comprehensive imaging; and 4 - elucidate its clinical and prognostic significance. 
 
2.2.3 Combining multimodality phenotyping with advanced histology 
Background: Although new insights are being generated by imaging tissue 
characterisation, the histological basis of LGE and ECV in AS and their association 
with fibrosis subtypes are only partly understood. 
Aims: To investigate myocardial fibrosis in a large series of severe aortic stenosis 
patients using invasive biopsy and non-invasive imaging, assessing simultaneously 
and at scale cardiac status, structure and function and by performing non-invasive 
(ECV and LGE) and histological tissue characterisation.   
2.3 Technical Development 
The following technical developments arose through observations and 
collaborations while setting up the RELIEF-AS study.  
2.3.1 Synthetic ECV 
Background: ECV quantification requires blood haematocrit measurement. This is 
cumbersome, involves blood sampling and delay. However, there is a linear 
relationship between the longitudinal relaxivity (R1=1/T1) of blood and haematocrit.  
Hypothesis: We hypothesized that a CMR native T1 blood could estimate synthetic 
Hct, permitting immediate synthetic ECV calculation and an instantaneous synthetic 
ECV map without blood sampling.  
2.3.2 ECV by Cardiac Computed Tomography 
Background: ECV can be quantified by computed tomography (CT), which has 
advantages over CMR: ubiquitously available equipment, higher spatial resolution 
and a simple linear relationship between attenuation and iodine concentration. We 
developed the ECVCT methodology requiring a complex primed-infusion.  
Aim: This study was designed to simplify the progenitor equilibrium methods by 
using a bolus-only, dynamic equilibrium approach in order to develop a simple 
alternative ECV method to CMR.   
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Chapter 3 Material and Methods 
3.1 Ethical Approval  
All ethics were approved by the UCL/UCLH Joint Committees on the Ethics of 
Human Research Committee; the CMR work-streams were recruited under UK 
National Research Ethics Service 07/H0715/101 (original ethics obtained by Dr 
Andrew Flett, which I amended for the RELIEF-AS Study), whereas the CT work-
streams were recruited under UK National Research Ethics Service 09/H0716/75. 
Both conformed to the principles of the Helsinki Declaration, and all subjects gave 
written consent to participate in the study. The RELIEF-AS Study was registered on 
ClinicalTrials.gov (NCT02174471). 
3.2 Patients 
3.2.1 Aortic stenosis patients  
Patients were recruited prior to pre-operative assessment, which included a 
comprehensive clinical assessment with clinical history, blood pressure, 6-minute-
walk test [171], blood sampling (for haematocrit, renal function, NT-pro-BNP and hs-Tn 
T, electrocardiogram, transthoracic echocardiogram and CMR. Inclusion criteria were 
patients with severe AS (2 or more of: AVA<1cm2, peak pressure gradient 64mmHg, 
mean pressure gradient 40mmHg, velocity ratio < 0.25; or reclassification of discordant 
echocardiographic data to severe by alternate modality) undergoing AVR+/-CABG at 
Heart Hospital, consenting for study protocol; age >18 years, ability to undergo CMR 
scan. Exclusion criteria were pregnancy/breastfeeding, GFR <30mls/minute 
(<45mls/min for CT), CMR incompatible devices, inability to complete the protocol, 
previous valve surgery, or severe valve disease other than AS. 
3.2.2 Amyloidosis Patients 
Patients with systemic amyloidosis were recruited during their visit to the National 
Amyloidosis Centre or to the CMR Department at the Heart Hospital. For ATTR, 
cardiac amyloidosis was defined by presence of ATTR amyloid in a myocardial 
biopsy (Congo red and immunohistochemical staining) or positive DPD scintigraphy 
[172]. Definite cardiac involvement by DPD was defined as DPD grade 2 or 3; 
possible cardiac involvement was defined as grade 1 (i.e. minimal cardiac DPD 
uptake) in the absence of LVH; in practice, none of these patients had LVH. All TTR 
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patients also underwent sequencing of exons 2, 3, and 4 of the TTR gene. For AL, 
systemic AL amyloidosis was proven with biopsies from non-cardiac tissues. 
Cardiac categorization was based on international consensus criteria [173] but with 
an additional “possible involvement” category, as previously described [174].  
3.2.3 Other cohorts 
For the technical development sections, other patient cohorts were utilized to cover 
a wider spectrum of aetiologies of left ventricular hypertrophy. These are further 
described in the specific sections.  
3.3 Cardiovascular Magnetic Resonance Protocol  
All patients also underwent CMR at 1.5 Tesla (Magnetom Avanto, Siemens Medical 
Solutions, Germany) with 32 channel cardiac coil arrays (Figure 20). All images 
were acquired during breath-hold at end expiration, apart from late gadolinium 
imaging which was performed during breath-hold or free-breathing.  
 
Figure 20: CMR protocol for RELIEF-AS 
4/2/3Ch, 4/2/3 chamber long axis; EGE, early gadolinium enhancement; LGE, late 
gadolinium enhancement; LV, left ventricular. 
 
3.3.1 Pilot images 
All studies started with single shot pilot images with the following settings: repeat 
time (TR): 3.39ms, echo time (TE): 1.7ms, slice thickness, 5mm, field of view (FOV) 
360 x 360mm, read matrix 256 and flip angle 60o. 
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3.3.2 SSFP Cine Images 
After piloting, steady state free precession (SSFP) cine imaging was undertaken, 
firstly in the long axis planes with a short axis cut through the aortic valve. A 
standard LV short axis stack was then acquired using a slice thickness of 7mm with 
a gap of 3mm. Retrospective ECG gating was used with 25 phases. Typical fast 
imaging with steady state precession (FISP) imaging parameters were TE: 1.6ms, 
TR: 3.2 ms, in plane pixel size 2.3 x 1.4mm, slice thickness 7mm, flip angle 60°. 
These settings were optimised in cases of arrhythmia or difficulties with breath-
holding. 
3.3.3 Flow quantification 
Aortic flow for calculation of the regurgitant volume was measured 
(echocardiography was however the primary modality scrutinizing the valve severity) 
using cross sectional through-plane velocity encoded phase contrast (VENC) 
images obtained perpendicular to the aortic jet just above the aortic valve tips. 
3.3.4 LGE imaging 
Intravenous Gadoterate meglumine (gadolinium-DOTA, marketed as Dotarem® 
Guerbet, S.A., France) was then administered as a 0.1mmol/kg dose via a pressure 
injector at a rate of 3ml/sec, with a 25ml normal saline flush. LGE assessment was 
then undertaken using a FLASH IR sequence. Magnitude reconstruction was 
available in all patients (MAG-IR) phase sensitive inversion recovery sequences 
(PSIR) reconstructions in all but the first twenty patients. Slice thickness 8 mm, TR: 
9.8 ms, TE: 4.6ms, α: 21o, FOV 340 x 220 mm (transverse plane), sampled matrix 
size 256 x 115-135, 21 k–space lines acquired every other RR interval (21 
segments with linear reordered phase encoding), spatial resolution 1.3 x 2.1 x 8 
mm, no parallel imaging, pre-saturation bands over CSF and any pleural effusions. 
These parameters were optimised according to individual patient characteristics. 
The TI was manually set to achieve nulling of the myocardium between 300 and 440 
ms. When LGE was observed, images were acquired in phase swap and cross cut 
to ensure artefact elimination. Where the LGE distribution appeared particularly 
diffuse, a TI scout was used to ascertain the specific parts of myocardium with the 
highest concentration of gadolinium. If the participant was struggling with the breath-
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hold, FISP imaging or IR-SSFP imaging (single shot or segmented) was used as an 
alternative sequence. 
 
Figure 21: Non-invasive quantification of fibrosis in AS by CMR 
A severe aortic stenosis patient with moderate concentric LVH and modest scar on LGE 
imaging (A). Pre-contrast (B) and post-contrast T1 maps (C) and derived ECV map (D) add 
information: RV insertion point native T1 elevation is seen (B) and there is diffuse 
extracellular expansion, with an ECV of 32%. Adapted from Maestrini et al 2013 [175]. 
3.3.5 T1 mapping 
T1 mapping prior to and after bolus gadolinium contrast (0.1mmol/kg of Gadoterate 
meglumine [gadolinium-DOTA, marketed as Dotarem, Guerbet S.A., Paris, France]). 
Post contrast imaging was performed at 15 minutes. The T1 mapping sequences 
used were balanced-SSFP-based MOdified Look-Locker Inversion Recovery 
(MOLLI)[136] variants (investigational prototypes), both a Shortened MOdified Look-
Locker Inversion recovery (ShMOLLI) sequence and a MOLLI variant with motion-
correction (MOCO) were used [176, 177]. The same ShMOLLI sequence was used 
pre- and post-contrast, and has been described in detail in section 1.4.3.3. The 
MOLLI, we used separate pre- and post-contrast sequences, optimised for the 
differences in T1 range before and after contrast administration. The pre-contrast 
MOLLI was a 5s(3s)3s variant, indicating 2 inversions with acquisition of images for 
at least 5 seconds, followed by a recovery of at least 3 s, and a second inversion 
with images acquired for at least 3 s. The post-contrast MOLLI was a 
4s(1s)3s(1s)2s variant,  indicating 3 inversions with acquisition of images for at least 
4 seconds, followed by a recovery of at least 1 second, a second inversion with 
images acquired for at least 3 s, followed by a recovery of at least 1 second, and a 
final acquisition of at least 2 seconds. 
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Figure 22: Analysis of T1 mapping and LGE images 
Examples of pre-contrast (Panel A) and post-contrast (Panel B) T1 mapping analysis are 
shown. For the regions of interests (ROI), endocardial (red) and epicardial (green) borders 
as well as a blood pool ROI (orange) were manually drawn. Partial voluming of blood was 
minimized by setting an automatic offset of 10% from the endo- and epicardial border. A 
short axis late gadolinium enhancement images is shown in Panel C with exemplar ROIs 
drawn in Panel D. The blue ROI identifies the mean signal intensity of remote myocardium; 
pixels with a signal intensity >3 standard deviations were highlighted and measured.  
3.3.6 Image analysis 
Imaging analysis was performed using CVI42 software (Version 5.1.2[303], Calgary, 
Canada). All analysis was performed by operators blinded to clinical parameters. LV 
volume and mass analysis was performed by manual contouring of the endo- and 
epicardial borders at end-diastole and end-systole with papillary muscle and 
trabeculations included in the LV mass (40); wall and cavity dimensions were 
measured on mid-ventricular (”high basal”) short axis slices at end diastole.  Left 
atrial area and length at end-systole were measured in the horizontal long axis (4-
chamber) and vertical long axis (2-chamber) cine views for calculation of LA 
volumes by the biplane area length method and indexed (40). Aortic flow for aortic 
regurgitant fraction and mitral regurgitant fraction were calculated as previously 
described (41).  Late gadolinium enhancement was quantified in grams (mls x 1.05 
g/ml) and as a percentage of the LV using signal intensity threshold of 5, 3 and 2 
Material and Methods	 Treibel TA, PhD Thesis 2017 
 
Page 54 of 193 
standard deviations (SD)(42) above the mean remote myocardium. For T1 mapping, 
three short axis T1 maps (base, mid and apex) were manual contoured at the endo- 
and epicardial border, segmented into an AHA 16 segment model using the RV 
insertion points. Partial voluming of blood was minimized by setting an automatic 
offset of 10% from the endo- and epicardial border (see Figure 22). Segments with 
myocardial infarction (endocardial LGE) on LGE imaging were excluded.  
ECV was then calculated from the global native and post contrast myocardial T1 
values. ECV was defined as: ECV = (1-Hct) * [ΔR1myocardium] / [ΔR1bloodpool] 
(43). Total LV Matrix and cell volumes were calculated from the product of LV mass 
and ECV or (1 minus ECV), respectively. 
3.4 Cardiac Computed Tomography 
CT examinations were performed on a 64–detector row CT scanner (Somatom 
Sensation 64; Siemens Medical Solutions, Erlangen, Germany). A topogram was 
used to plan CT volumes from the level of the aortic valve to the inferior aspect of 
the heart, typically a 10cm slab. Cardiac scans (tube voltage, 120 kV; tube current–
time product, 160 mAs; section collimation, 64 detector rows, 1.2-mm section 
thickness; gantry rotation time, 330 msec) were acquired with prospective gating 
(65%–75% of R-R interval), and reconstructed into 3-mm-thick axial sections with a 
B20f kernel.   
CT image analysis was performed using a free and open-source Digital Imaging and 
Communications in Medicine viewer (OsiriX v4.1.2; Pixmeo, Bernex, Switzerland) 
independently by two experienced readers blinded to all other study data; this was 
repeated by the second reader to establish inter- and intra-observer agreement. 
Regions of interest (ROIs) were in axial sections in all acquisitions. For myocardium, 
polygonal ROIs were drawn an axial slice containing the greatest area of myocardial 
septum; for the blood pool, circular ROIs were drawn in the LV blood pool away from 
papillary muscles and the myocardial septum to avoid the endocardial edge and 
therefore partial voluming.  Myocardial and blood attenuation values were used to 
calculate the ECV fraction following three steps: first, a CT scan to obtain baseline 
pre-contrast blood and myocardial attenuation in Hounsfield units (HU); second, 
contrast administration and delay so the contrast distributes into a blood:myocardial 
dynamic equilibration; third, a repeat scan to re-measure blood and myocardial 
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attenuation. The ratio of the change in blood and myocardial attenuation (ΔHU) 
represents the contrast agent partition coefficient.  If the blood volume of distribution 
is substituted in (1 minus venous haematocrit; obtained prior to imaging), the 
myocardial extracellular volume, ECVCT, is obtained, reflecting the myocardial 
interstitium:  
 ECVCT  =  (1-Haematocrit) x (ΔHUtissue / ΔHUblood) 
Signal-to-noise ratios (SNR) were measured in five myocardial ROIs per time point 
from the ratio of the average HU attenuation value to the standard deviation of 
the HU attenuation. Radiation exposure was quantified using the dose-length 
product multiplied by a chest conversion coefficient (κ=0.014mSv/mGy.cm)[178]. 
3.5 Echocardiography Protocol 
Echocardiography was performed using a GE Vivid E9 system (GE Healthcare, 
Wauwatosa, USA) with a 4-MHz transducer, following the guidelines for AS 
assessment as recommended by the European and American Societies of 
Echocardiography [17, 30]. Doppler assessment of AS included measurement of 
peak and mean transvalvular velocities and gradients; aortic valve area by the 
continuity equation, indexed for body surface area; pressure recovery adjusted 
aortic valve area (i.e., energy loss index (ELI)); global hemodynamic load by the 
valvulo-arterial impedance index (Zva); stroke work loss; systemic vascular 
resistance and systemic arterial compliance. 
3.6 Definition Of The Patterns Of Remodelling And Hypertrophy 
AS patients were categorized into four pattern of LV geometric adaption by 
echocardiography and CMR: “normal geometry”, “concentric remodelling”, 
“concentric hypertrophy” and “eccentric hypertrophy”; no distinction was made 
between symmetrical or asymmetric pattern (Figure 5 and Figure 37). For 
echocardiography, categories were defined by BSA-indexed LV mass (LVMi), end-
diastolic cavity dimension (EDD) and relative-wall thickness (RWT)[179]. For CMR, 
categories were defined by BSA-indexed LV mass (LVMi), indexed LV end-diastolic 
volume (LVEDVi) and mass-volume ratio (MVR) [25, 180]. Echocardiographic and 
CMR analysis were performed by separate operators, blinded to the other results. 
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3.7 Other investigations 
3.7.1 Six minute walking test (6MWT) 
6MWT was performed at the Heart Hospital (where the test was originally 
developed) along a flat corridor in accordance with current guidelines. Patients were 
asked to walk a 30-metre length of the corridor at their own pace while attempting to 
cover as much ground as possible in the 6-minute period.  
3.7.2 Blood Test 
All participants had blood tests taken prior to the CMR scan. This included a renal 
profile, full blood count, NT-proBNP, high senstitivity troponin T (hsTnT) and 
serum/plasma storage for collagen biomarkers. NT-proBNP and hsTnT were 
measured by ELISA (Roche Diagnostics). The inter-assay coefficients of variation 
were less than 7% for both of them. The lower limit of detection was 5 pg/mL for NT-
proBNP and 3 ng/L for hsTnT. NT-pro-BNP ratio was calculated as the ratio 
between absolute NT-proBNP concentration divided by the upper limit of normal for 
patient’s gender and age [181]. 
3.8 Statistical Analysis  
Statistical analyses were carried out using SPSS 22 and 24 (IBM, Armonk, NY). All 
continuous variables are expressed as mean ± standard deviation. Categorical 
variables are expressed as percentages. Normality was checked using the Shapiro-
Wilk test. Groups were compared using independent-samples t-test for normally 
distributed continuous variables, the Mann-Whitney U test for non-normally 
distributed variables, and the Chi-squared test for binomial variables. Correlations 
were estimated by using the Pearson correlation coefficient once normality was 
demonstrated; otherwise, the Spearman correlation coefficient was used. Log 
transformation was applied to normalize the distribution of NT-proBNP and hs-TnT. 
The influence of potential confounding factors (i.e. age, gender and history of 
coronary artery disease) was evaluated by multivariate linear regression analysis. 
The unstandardized coefficient B and its 95% confidence interval were recorded. A 
two-sided p-value of <0.05 was considered significant.  
Agreement between conventional and synthetic ECV was analysed using the Bland-
Altman method. The significance of the difference between two correlation 
coefficients was tested using the Fisher r-to-z transformation.  
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Survival was evaluated using Cox proportional hazards regression analysis, 
providing estimated hazard ratios (HR) with 95% confidence intervals (CI) and 
Kaplan Meier curves.  
In the synthetic ECV section, survival analyses examined: time to the first HHF after 
CMR, time to death, and time to either HHF or death. First HHF included any HHF 
event after CMR, and required physician documentation of: 1) symptoms and 
physical signs consistent with HF; 2) supporting clinical findings; or 3) therapy for 
HF. Vital status was ascertained by Social Security Death Index queries and 
medical record review (confirmed by two blinded investigators). Mortality was right 
censored for the first HHF after CMR analysis. The log-rank test with ECV 
(categorized arbitrarily in 5% increments) and Cox regression (ECV expressed as a 
continuous variable) examined associations between ECV and outcomes.   
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Chapter 4 Technical Development 
4.1 Synthetic ECV by CMR 
4.1.1 Preface 
This chapter is based on the publication below:  
Treibel TA, Fontana M, Maestrini V, Castelletti S, Rosmini S Simpson J, Nasis A, Bulluck H, 
Abdel-Gadir A, White SK, Manisty C, Spottiswoode BS, Robson MD, Wong TC, Piechnik SK, 
Kellman P, Schelbert EB, Moon JC. Automatic Measurement Of The Myocardial Interstitium: 
Synthetic Extracellular Volume Quantification without Haematocrit Sampling. JACC: 
Cardiovascular Imaging. 2016 Jan;9(1):54-63.  
My contribution was recruiting, consenting and performing the scans of all the AS patients. I 
analysed all the data as first operator, did the statistical analysis and wrote the paper. In 
order to derive and validate this new methodology, this work draws upon my own data and 
data collected by several other researchers. Contributors (by disease) include: Normal 
subjects – Stefania Rosmini; AS – Myself; Amyloidosis – Marianna Fontana; Anthracycline 
toxicity patients – Viviana Maestrini; Hypertrophic Cardiomyopathy – Silvia Castelletti; 
Histology cohort - Steven White; Outcome cohort – Erik Schelbert. 
4.1.2 Introduction 
ECV measurement is useful in CMR as it provides insights into health and disease, 
measuring the interstitial and cell volume (see Introduction). The method relies on 
the administration of an extracellular contrast agent. After sufficient time, the ratio of 
signal change with the contrast agent between blood and myocardium is the 
partition coefficient. If this is multiplied by the blood volume of distributions (1-
haematocrit), the myocardial ECV is derived. Practically however, this is 
cumbersome. It involves blood sampling and delay. Uncertain errors are introduced 
(eg by the blood settling during transit to the lab), and the ECV is not easy to 
visualise – there is no immediacy of the results [136, 137, 143]. 
We knew however that the longitudinal relaxivity (R1=1/T1) of blood has been 
studied since the 1980s and was found to be in a linear relationship with blood Hct. 
It is determined by the water fractions of plasma and the erythrocyte cytoplasm, 
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which undergo fast water exchange [182-189]. This means that native blood T1 
increases with anaemia. 
4.1.3 Hypothesis and aims 
We hypothesize that native T1 blood could estimate synthetic Hct, permitting 
immediate synthetic ECV calculation and an instantaneous synthetic ECV map 
without blood sampling. We formed a network of collaboration with existing key 
patient cohorts to investigate if synthetic ECV (a) was valid compared to 
conventional ECV, (b) correlated with the gold standard collagen volume fraction, (c) 
predicted outcome, and (d) could be automated for in-line point-of-care use.   
4.1.4 Methods 
Patient Populations 
Research was carried out at two centres (Table 5): University College London 
Hospital NHS Trust, UK (proof-of-concept and histology cohorts); and UPMC CMR 
Center, Pittsburgh, USA (outcome cohort). Study approval was granted by local 
ethics committees. The study conformed to the principles of the Helsinki 
Declaration. ECV data of two previously published cohorts was used to validate the 
synthetic ECV methodology (histology and outcome cohorts). 
		 Subjects Location Characteristics 
Proof-of-concept n=427 London, UK Health and Disease, split into derivation and validation cohorts. 
Histology n=18 London, UK 
Severe aortic stenosis patients undergoing 
aortic valve replacement (with 
intraoperative myocardial biopsy) 
Outcome n=1172 Pittsburgh, USA Clinical cohort referred for CMR  
 
Table 5: Overview of synthetic ECV study cohorts 
 
Proof-of-concept of synthetic ECV – cohorts 1 (derivation) and 2 (validation). 
A total of n = 427 subjects gave written informed consent and were scanned 
between January 2012 and October 2014. They were then randomly split into 
derivation and validation sub-groups (Table 6) with equal health and disease 
representation.  
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• Normal healthy subjects (n = 66, median age 45±14 [range 24 to 74 years], 59% 
male), with no history or symptoms of cardiovascular disease or diabetes. All had 
normal blood pressure (defined as <140/90 mmHg), 12-lead electrocardiogram 
and clinical CMR results. 
• Hypertrophic cardiomyopathy (HCM) patients (n = 68, median age 52±14 [range 
23 to 77 years], 81% male). All met previously described diagnostic criteria [190]. 
Hypertrophy was 81% asymmetrical, 9% concentric and 10% apical predominant.  
• Severe aortic stenosis (AS) patients (n = 123, median age 70±10 [range 34 to 84 
years], 55% male). All had undergone clinical evaluation and echocardiography 
for diagnosis of severe AS and were listed for surgical valve replacement.  
• Cardiac amyloidosis patients (n = 74, median age 72±11 [range 38 to 85 years], 
82% male). Cardiac amyloid was only ATTR amyloid. This was defined by either 
a myocardial biopsy, or positive bone scintigraphy. Patients underwent 
sequencing of exons 2, 3, and 4 of the TTR gene. Consensus criteria for definite 
cardiac involvement are pending but not published: definite cardiac ATTR 
amyloid was defined as previously described [172, 191].  
• Patients post-anthracycline chemotherapy for histologically proven breast 
carcinoma at a median follow-up of 6.4 years (n = 96, median age 54 [range 28 
to 71 years], 100% female, 100% Caucasian), with no previous chemo- or 
radiotherapy or any pre-existing cardiovascular disease or drug history. 
Histological validation of synthetic ECV – Histology cohort 
Consenting (same centre) severe AS patients (n = 18, median age 71±10 years 
[range 47 to 84 years], 78% male) were scanned between May 2011 and February 
2012. All had undergone clinical evaluation and echocardiography for diagnosis 
prior to surgical aortic valve replacement, and intra-operative biopsies were obtained 
for histological measurement of collagen volume fraction (CVF) as previously 
described [110]. 
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  Derivation Validation p-value 
Total 214 213   
Male 107 104 0.8 
Age (years) 60±15 60±15 0.6 
BSA (m2) 1.87±0.23 1.87±0.23 0.8 
Healthy Volunteer 33 33   
Aortic Stenosis 62 61   
Cardiac Amyloidosis 37 37   
Hypertrophic Cardiomyopathy 34 34   
Anthracycline 48 48   
  Cardiac       
EDVi (ml/m2) 71±21 70±20 0.9 
ESVi (ml/m2) 25±14 24±13 0.5 
LV mass index (g/m2) 90±35 92±35 0.5 
Stroke Volume index (ml/m2) 47±12 47±13 0.7 
LVEF (%) 66±12 67±12 0.7 
LAAi (cm2/m2) 14±3 14±5 0.5 
  Clinical       
Haematocrit  0.40±0.04 0.40±0.04 0.4 
Creatinine 79±24 78±21 0.9 
eGFR 80±23 78±22 0.4 
SBP (mmHg) 110±44 108±49 0.7 
DBP (mmHg) 65±28 62±31 0.5 
  T1 Mapping       
ShMOLLI ECV (%) 33±10 33±11 0.9 
MOLLI ECV (%) 33±11 33±11 0.8 
 
Table 6: Patient Characteristics for Derivation / Validation of Synthetic Hct  
Values are mean ± SD or %. BSA = body surface area; ECV = extracellular volume fraction; 
EDVi = indexed end-diastolic volume; ESVi = indexed end-systolic volume; eGFR = 
estimated glomerular filtration rate; DBP = diastolic blood pressure; LAAi = indexed left atrial 
area; LVEF = left ventricular ejection fraction; MOLLI = MOdified Look-Locker Inversion 
recovery; ShMOLLI = Shortened MOdified Look-Locker Inversion recovery; SBP = systolic 
blood pressure.  
Correlation of synthetic ECV with Outcome – Outcome cohort 
For external validation of synthetic ECV and comparison with outcome data, we 
applied the method to a large ECV outcome cohort [192]: 1765 consecutive adult 
patients referred for clinical CMR at UPMC CMR Center, Pittsburgh, USA (enrolled 
December 2009 to May 2013; follow-up until July 2013). Inclusion criteria were 
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written informed consent and completion of contrast CMR. Exclusion criteria were 
cardiac amyloidosis (n=27), HCM (n=133), stress-induced cardiomyopathy (n=10), 
adult congenital heart disease (n=195), inadequate image quality (n=4), and missing 
follow-up (n=224). Patients with myocardial infarction were included to maximize 
generalizability (ECV measured in remote non-infarcted myocardium). The final 
cohort included 1172 patients. 
Automated inline ECV – synthetic ECV maps “on-the-fly”. 
An investigational prototype ECV tool, previously developed by Kellman et al [147, 
193], was adapted to measure T1blood, calculate synthetic Hct and generate inline 
synthetic ECV maps as a DICOM images on the CMR scanner; fully automated 
using co-registration and blood pool segmentation.  
CMR scanning 
All subjects underwent CMR at 1.5 Tesla (Magnetom Avanto, Espree and Aera, 
Siemens Medical Solutions) with 32 channel cardiac coil arrays. Exclusion criteria 
were uncontrolled arrhythmia, impaired renal function (estimated glomerular filtration 
rate <30mL/min), or contraindications to MR imaging (e.g. implanted devices). 
Specific details are listed in the individual cohort descriptions. All patients underwent 
standard clinical scan with late gadolinium imaging [194] with T1 mapping prior to 
and after bolus gadolinium contrast: for the proof-of-concept and histology cohorts, 
0.1mmol/kg of Gadoterate meglumine, (gadolinium-DOTA, marketed as Dotarem, 
Guerbet S.A., Paris, France); for the outcome cohort, 0.2 mmol/kg intravenous 
gadoteridol bolus (Prohance, Bracco Diagnostics, Princeton, NJ). Post contrast 
imaging was performed at 15-20 minutes apart from amyloid patients, where we 
acquired equilibrium-contrast T1 maps [110, 195]. The T1 mapping sequences used 
were MOLLI [136] variants (investigational prototypes): in the proof-of-concept 
cohort, both a ShMOLLI sequence and a MOLLI variant with motion-correction 
(MOCO) were used [176, 177]. The histological validation was performed with 
ShMOLLI, whereas the outcome cohort was performed with a MOLLI with MOCO. 
T1 analysis and ECV quantification 
A region of interest (ROI) was drawn in myocardium (septum on SA slice) and blood 
(same slice) on the pre-contrast images and transposed to the post-contrast 
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images. All analysis was performed blinded. We quantified ECM expansion with 
ECV defined as:  
ECV = (1-haematocrit) * [ΔR1myocardium] / [ΔR1bloodpool] 
(where, ∆𝑅1!"#$%&'()! = 𝑅1!"#$%&'()!!"#$!!"#$%&'$ − 𝑅1!"#$%&'()!!"#!!"#$%&'$ , ∆𝑅1!"##$ = 𝑅1!"##$!"#$!!"#$%&'$ − 𝑅1!"##$!!"!!"#$%&'$, and R1=1/T1) [196].  
Laboratory haematocrit variability 
Whole blood for venous Hct was drawn in all subjects by venepuncture and 
analysed as routine clinical samples using a Sysmex XE2100 haematology analyser 
[197]. Repeat sampling variability was tested in 44 patients who underwent two 
samples a median of 4 hours apart. 
Synthetic haematocrit derivation 
The longitudinal relaxivity (R1=1/T1) of blood has a linear relationship with blood 
Hct, and is determined by the relaxivity of the water fractions of plasma (R1P) and 
the erythrocyte cytoplasm (R1RBC): R1Blood = R1P * (1 – Hct) + R1RBC * Hct   
Rearranging gives: Hct  = – R1P /( R1RBC – R1P)   +    R1Blood * (1 / ( R1RBC – R1P)) 
Simplified as:   Hct = Constant#1  + (Constant#2 *  R1blood) 
Therefore, synthetic Hct was derived from the linear relationship between Hct and 
R1blood, in turn used to estimate a synthetic ECV and was then compared to the 
conventional ECV. 
Histological analysis of collagen volume fraction 
Histological quantification of the extracellular space was performed by measuring 
the collagen volume fraction (CVF) as previously described.[110] In summary, an 
intra-operative deep myocardial biopsy (Tru-Cut type biopsy) was taken from the 
basal LV septum, stained with picrosirius red, photographed at high-power 
magnification (200μm) and CVF (%) automatically quantified over an average of 12 
high-power fields with a purpose-written macro in ImageJ. All samples were 
analysed blinded to other findings. 
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Statistical analysis  
Analyses were performed using SAS (Cary, NC) and SPSS (Chicago, IL, USA, 
version 22). Details have been previously described.  
 
4.1.5 RESULTS  
Proof-of-Concept – Derivation and Validation cohorts 
The proof-of-concept cohort was divided randomly into a derivation (n=214) and a 
validation (n=213) cohort (Table 6). In the derivation cohort, there was a broad 
range of Hct (40.3±3.7%; range 32-51%) and native T1blood (ShMOLLI T1blood 
1549±80ms; range 1261-1823ms; MOLLI T1blood 1649±83ms; range 1441-1898ms). 
The regression line between haematocrit and R1blood (1/T1blood) was linear with 
R2=0.51, p<0.001; and 0.45, p<0.001; for MOLLI and ShMOLLI, respectively (Figure 
23). The regression equations were:  
Synthetic HctMOLLI    = (866.0 *  [1/T1blood] ) – 0.1232 
Synthetic HctShMOLLI = (727.1 *  [1/T1blood] ) – 0.0675 
where Hct is haematocrit (0 to 1) and R1blood = [1/T1blood] in milliseconds 
 
Figure 23: Derivation cohort - Correlation R1blood versus Haematocrit  
The proof-of-concept cohort was divided randomly into a derivation (n=214) and a validation 
(n=213) cohort. The regression line between haematocrit and pre-contrast R1blood was linear 
with R2=0.51, p<0.001, and R2=0.45, p<0.001, for MOLLI (A) and ShMOLLI (B) with 
regression equations as given in the graphs.  
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Using these curve-fits in the validation cohort, synthetic and conventional ECV were 
highly correlated (R2=0.97; p<0.001, both mapping techniques) with a 2.8% SD of 
differences and minimal bias on Bland-Altman analysis for fibrosis quantification and 
a slightly higher SD in difference of 5% in extracellular expansion due to amyloidosis 
(Figure 23). Synthetic and conventional ECV correlated equally with clinical markers 
of disease severity (Table 7). 
ECV Method Conventional Synthetic Conventional Synthetic 
Sequence ShMOLLI MOLLI 
NT-pro-BNP 0.6 0.6 0.62 0.63 
Systolic blood pressure -0.64 -0.64 -0.62 -0.63 
LV ejection fraction -0.57 -0.61 -0.56 -0.6 
Stroke volume indexed -0.36 -0.38 -0.31 -0.34 
Left atrial area indexed 0.39 0.41 0.44 0.44 
LV mass index 0.49 0.49 0.52 0.52 
 
Table 7: Synthetic and Conventional ECV versus Clinical Parameters 
Correlation coefficient R, all values significant with a p-value <0.001; ShMOLLI = Shortened 
MOdified Look-Locker Inversion recovery; MOLLI = Modified Look-Locker Inversion 
recovery.  
 
 
Figure 24: Validation Cohort – conventional versus synthetic ECV.  
Using these curve-fits in the validation cohort, synthetic and conventional ECV were 
highly correlated (R2=0.97; p<0.001, both mapping techniques) with a 2.8% SD of 
differences and minimal bias on Bland-Altman analysis for fibrosis quantification and 
a slightly higher SD in difference of 5% in extracellular expansion due to 
amyloidosis.  
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Figure 25: Outcome cohort 
Measured vs synthetic Hct correlation and Bland-Altman comparison. 
Test-retest variability 
Bland-Altman comparison of laboratory Hct vs synthetic Hct in the validation cohort 
revealed a variability of 14%, R2=0.44. To understand the sources of variability 
attributable to laboratory Hct and synthetic Hct (i.e. T1blood), test-retest was 
performed. Test:retest variability of laboratory haematocrit was higher than expected 
(n=44, variability 10% with hct:hct R2=0.86; Figure 26), where test-retest for T1blood 
(and by inference synthetic Hct) in healthy volunteers was low for MOLLI (n=20, 
variability 0.02%, R2=0.95) and ShMOLLI (n=20, variability 0.012%, R2=0.94). Inter-
observer reproducibility for T1blood was also excellent (ICC 0.994, 95% CI 0.984-
0.998).  
 
Figure 26: Variability In Repeated Haematocrit Samples.  
Repeat sampling variability was tested in 44 patients who underwent two samples a median 
of 4 hours apart. Test:retest variability of haematocrit was higher than expected (n=44, 
variability 10% with hct:hct R2=0.86, p<0.001). 
Technical Development	 Treibel TA, PhD Thesis 2017 
 
Page 67 of 193 
Histology Cohort 
The mean histological CVF of the 18 biopsies was 17 ± 8% (range 5% to 40%). 
Synthetic and conventional ECV both correlated well with collagen volume fraction 
(R2 = 0.61, p < 0.001 vs. R2 = 0.69, p < 0.001; Figure 27) and did not differ 
statistically (p=0.70). 
 
Figure 27: Histology Cohort. 
Conventional ECV and synthetic ECV versus CVF. The mean histological collagen volume 
fraction (CVF) of the 18 biopsies was 17 ± 8% (range 5% to 40%). The correlation with 
histology for synthetic extracellular volume fraction (ECV) was slightly lower than the 
conventional ECV (R2 = 0.61, p < 0.0.01 vs. R2 = 0.69, p < 0.001) and did not differ 
statistically (p=0.70). 
Outcome Cohort 
Baseline characteristics are presented in Table 8. The UK derivation resulted in a 
2% bias in synthetic ECV, therefore a local synthetic Hct calibration was obtained. In 
the outcome cohort, conventional and synthetic ECV had similar ranges (16.6-
47.8% and 16.2-50.9%, respectively) with excellent correlation (R2 = 0.82, p<0.001) 
and no significant bias. 
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Demographics n = 1172 
Age, median (Q1-Q3), y  56 (43-66) 
Female, No. (%) 484 48% 
White race, No. (%)  1033 88% 
Black race, No. (%)  112 10% 
Comorbidity     
Diabetes, No. (%) 239 20% 
Hypertension, No. (%)  585 50% 
Dyslipidemia, No. (%) 448 38% 
Atrial fibrillation or flutter, No. (%)  121 10% 
Prior coronary revascularization, No. (%)  217 19% 
Body mass index, median (Q1-Q3), kg/m2  28 (25-33) 
Laboratory and CMR characteristics     
Creatinine, median (Q1-Q3), mg/dL 0.9 (0.8-1.1) 
Glomerular filtration rate, median (Q1-Q3), mL/min/1.73m2 89 (70-94) 
Ejection fraction, median (Q1-Q3), % 57 (45-64) 
Left ventricular mass index, median (Q1-Q3), g/m2  57 (46-71) 
End diastolic volume index, median (Q1-Q3), mL/m2  82 (67-101) 
End systolic volume index, median (Q1-Q3), mL/m2  34 (25-51) 
Myocardial infarction, No. (%)  238 20% 
Non-ischemic fibrosis evident on LGE images, No. (%)  236 20% 
Extracellular volume fraction, median (Q1-Q3), % 28 (26-31) 
 
Table 8: Baseline characteristics of Outcome cohort 
 
Over a median of 1.7 years (Q1-Q3, 1.0-2.4 years), there were 55 HHF events and 
74 deaths after the baseline CMR scan among 111 individuals experiencing adverse 
events in the n=1172 cohort (18 individuals experiencing HHF subsequently died). 
Synthetic and conventional ECV were associated with adverse events with a graded 
response, where higher ECV was associated with higher event rates (Figure 27). 
Conventional and synthetic ECV were comparable to EF in their univariable 
association with HHF but ECV (conventional and synthetic) was better than EF for 
mortality (Table 9).  A post-hoc samples size calculation (based on n=1172 and 111 
events) showed 80% power to detect a HR of 1.346 by increasing one SD of a 
covariate (based on a Cox proportional hazards regression and a type I error rate of 
0.05). 
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Outcome Univariable Cox regression model covariate 
Hazard ratio (CI 
95%)  χ2 
p-value 
HHF  
(n=55) Conventional ECV (5% increase) 2.41 (1.93-3.02) 59.6 <0.001  
 Synthetic ECV (5% increase) 2.30 (1.87-2.81) 64.5 <0.001  
 LVEF (5% decrease)  1.33 (1.23-1.43) 54.3 <0.001  
Death  
(n=74) Conventional ECV (5% increase) 2.13 (1.74-2.61) 53.4 <0.001  
 Synthetic ECV (5% increase) 1.90 (1.55-2.31) 39.8 <0.001  
 LVEF (5% decrease)  1.21 (1.16-1.29) 32 <0.001  
HHF or Death 
(n=111) Conventional ECV (5% increase) 2.25 (1.91-2.64) 96 <0.001  
 Synthetic ECV (5% increase) 2.06 (1.77-2.40) 89.2 <0.001  
 LVEF (5% decrease)  1.26 (1.19-1.33) 71.7 <0.001  
 
Table 9: Outcome variables  
Conventional and synthetic ECV and LVEF were comparable in their univariable association 
with (HHF), mortality or combined. ECV = extracellular volume fraction; HHF = 
hospitalization for heart failure; LVEF = left ventricular ejection fraction. 
 
 
Figure 28: Outcome Cohort – Kaplan-Meier Plot (Death And HHF) for ECV. 
Among 1172 individuals, both conventional and synthetic myocardial extracellular volume 
fraction (ECV) were significantly associated with increased risks of hospitalization for heart 
failure (HHF) or death (n=111) following CMR scanning. 
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Outcome  
Cox regression model covariate Hazard ratio  
(CI 95%)  χ2 p-value ECV (5% increase) 
HHF (n=55)  Conventional – univariable 2.41 (1.93-3.02) 59.6 <0.001  
  Synthetic – univariable 2.30 (1.87-2.81) 64.5 <0.001  
  Conventional – multivariable model 1.77 (1.32-2.36) 14.9 <0.001  
  Synthetic – multivariable model 1.74 (1.32-2.30) 15.2 <0.001  
Death (n=74)  Conventional – univariable 2.13 (1.74-2.61) 53.4 <0.001  
  Synthetic – univariable 1.90 (1.55-2.31) 39.8 <0.001  
  Conventional – multivariable model 1.87 (1.45-2.40) 23.9 <0.001  
  Synthetic – multivariable model 1.70 (1.34-2.16) 18.9 <0.001  
HHF or Death (n=111)  Conventional – univariable 2.25 (1.91-2.64) 96 <0.001  
  Synthetic – univariable 2.06 (1.77-2.40) 89.2 <0.001  
  Conventional – multivariable model 1.85 (1.50-2.27) 33.9 <0.001  
  Synthetic – multivariable model 1.69 (1.38-2.75) 24.9 <0.001  
 
Table 10: Multivariable Cox Regression models. 
In multivariable modelling, conventional and synthetic ECV remained associated with HHF, 
death, or the combined endpoint of HHF/death. Hazard ratios and Chi-Square (χ2) for 
conventional and synthetic ECV are shown unadjusted (univariable) and in a multivariable 
model. The multivariable model stratified by heart failure stage and hospitalization status, 
and adjusted for LVEF, age, glomerular filtration rate, myocardial infarction size, and gender. 
ECV = extracellular volume fraction; HHF = hospitalization for heart failure; LVEF = left 
ventricular ejection fraction. 
Automated inline synthetic ECV cohort – real-world application 
A module was created to generate automatic synthetic ECV maps inline (“on-the-
fly”) as post-contrast T1 maps are acquired (Figure 29; online video 
[http://jaccimage.acc.org/video/2016/1001_VID1.mp4]). The additional processing 
time is less than 1 second per slice for finding paired pre-contrast T1 mapping data, 
performing image co-registration, and generating the blood mask and synthetic ECV 
map. The user is able to analyse images immediately by drawing regions of interest 
on the scanner console, where pixel values represent percentage ECV. 
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Figure 29: Automatic synthetic ECV tool  
ECV mapping “on-the-fly”. An automated inline synthetic ECV tool was implemented as an 
investigational prototype to produce a fast and fully automated approach for generating 
pixel-wise synthetic ECV maps. 
4.1.6 Discussion 
CMR extracellular volume quantification is a promising imaging biomarker [198-200], 
but development and clinical uptake have been slowed by the necessity of venous 
blood sampling, analysis and then offline calculation.  I created a team who 
implemented a simpler, synthetic ECV measured using haematocrit estimated from 
pre-contrast blood T1. Synthetic ECV performed well – it is highly correlated to 
conventional ECV, and has a similar relationship to the histologic gold standard 
collagen volume fraction, other cardiac parameters and predicts outcome similarly – 
even at a different centre. The implementation here as an inline tool on a clinical 
CMR scanner would be an aid to clinical workflow, providing automated immediate 
point-of-care results.  
The technique arose out of need and the observation that pre-contrast blood T1 is 
considerably determined by haematocrit (pre-contrast blood T1 increases with 
anaemia). Indeed, the linear relationship between Hct and R1blood (1/T1blood) has 
been abundantly been described [182-187, 189, 201], and therefore R1blood was 
used for curve fitting. Beyond mathematical derivation, we describe 1/T1blood as it is 
more intuitive for the CMR clinicians and easier to sell to the CMR community. This 
is analogous to the T2* field that uses T2* rather than the R2*. Although the 
correlation of peripheral haematocrit and ventricular cavity pre-contrast R1blood is 
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only moderate (other influences are discussed below), synthetic ECV performance 
is good, which we believe is in part due to considerable error in standard laboratory 
haematocrit when taken as a routine clinical test, and also as the ECV has other 
dependencies which make it robust [132-134, 202, 203]. It may be that an 
overlooked weakness has been the variability of Hct measurement [204]. Here the 
correlation of two Hct samples on the same day to a clinical service (located in a 
different building so with potential settling and re-suspension of red cells during 
transport) was only a R2 of 0.86 – potentially a greater source of inaccuracy than the 
differences contested between T1 mapping approaches [139, 176].  
ECV is gaining recognition as a potentially key biomarker of ECM expansion and 
has been called “non-invasive” or “virtual biopsy” [205]. The near exponential 
increase of evidence for the role of T1 mapping and ECV quantification for 
myocardial tissue characterization calls for the routine clinical use beyond late 
gadolinium enhancement [HCMR Study; NCT01915615]. Separate analysis of pre- 
and post-contrast images is cumbersome. Although implementation of automated 
ECV map tools is simplifying this [206], haematocrit measure is burdensome in busy 
departments, is a source of user error and introduces reporting delay. An inline 
synthetic ECV tool would reduce the barriers to clinical use of ECV and potentially 
increase quality as review is immediate.  
The study has limitations: Although this study was not a multicentre study, following 
validation and derivation in a single centre, we then tested outcome in a separate 
centre. The T1 mapping methods varied across parts of experiments (in line with 
rapid developments within the T1 mapping field) and further comparisons are 
required. As for any other non-contrast mapping parameter, synthetic haematocrit 
requires local calibration, unless T1 mapping sequence, CMR scanner and Hct 
machine are identical. Other sources that affect the relaxation rate of blood like flow, 
oxygen content, body temperature and contributions from other biological variables 
need further investigation (e.g. red cell shape and size, other macromolecules, and 
even added substances e.g. intravenous iron or other paramagnetic 
substances)[182, 183, 186, 187, 207-209]. In iron overload, particular in thalassemia 
patients, the R1:Hct relationship breaks down (unpublished data), which may to be 
due to iron-chelator complexes. Finally, there are additional influences on measured 
T1blood (e.g. residual heart rate dependence with some sequences, where measured 
T1blood decreases with increasing HR). The range of diseases studied was not 
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exhaustive and extreme patients (e.g. very anaemic) are not well represented.  
Variability of repeat synthetic ECV was not tested due to the requirement to give 
gadolinium contrast to assess this, but variability of T1blood and thereby synthetic Hct 
was low across repeated scans, making it a suitable tool for clinical trials [210]. The 
synthetic ECV approach highlights Hct measurement issues that may be easily 
solved without resorting to new approaches, improving the conventional ECV 
method.  
4.1.7 Conclusion 
The CMR biomarker ECV is promising as a measure of the myocardial interstitial 
space and can be simplified and automated by using a synthetic haematocrit. 
Synthetic ECV is validated in health and disease, against histology, across centres 
and predicts outcome as well as the conventional ECV. Automated synthetic ECV 
measures can be implemented inline on the CMR scanner with test performances 
approaching that of conventional ECV measurement – a significant workflow 
improvement bringing ECV closer to routine clinical practice.    
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4.2 Dynamic Equilibrium Cardiac CT  
4.2.1 Preface:  
This chapter is based on the publication below: 
Treibel TA, Bandula S, Fontana M, White SK, Gilbertson JA, Gillmore JD, Punwani S, 
Hawkins PN, Taylor SA, Moon JC. Quantification and diagnosis of cardiac amyloid by 
cardiac computed tomography: Clinical Development And Application Of Extracellular 
Volume Quantification By Dynamic Equilibrium Computed Tomography (DynEQ-CT). J 
Cardiovasc Comput Tomogr. 2015 Jul 10.  
My contribution was recruiting, consenting and performing the scans. I have analysed all the 
data as first operator, did the statistical analysis and wrote the paper. Development of the 
pseudo-equilibrium technique and collection of the data in AS and amyloid was performed 
equally by myself and Dr Steven Bandula.  
4.2.2 Introduction 
Extracellular volume fraction (ECV) quantified by Equilibrium Contrast CMR (EQ-
CMR) tracks amyloid burden[211]. Equilibrium Computed Tomography can also 
quantify the ECV from pre and post contrast measurements of attenuation, and 
shows good correlation with ECV measured by EQ-CMR as well as histological 
measures of myocardial fibrosis [168-170]. CT has advantages over CMR: 
ubiquitously available equipment, higher spatial resolution and a simple linear 
relationship between attenuation (Hounsfield units) and iodine concentration as 
opposed to the nonlinear effect on relaxivity of hydrogen following administration of 
gadolinium.  
4.2.3 Aims and Objectives 
This study was designed to simplify the progenitor equilibrium methods by using a 
bolus-only, dynamic equilibrium approach (DynEQ-CT). Our objective was to 
evaluate optimal post bolus contrast timing for DynEQ-CT. 
4.2.4 Methods 
All research was carried out at University College London Hospital and the Royal 
Free NHS Trusts, London, UK, between January 2013 and December 2013. The 
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study was approved by the ethical committee of U.K. National Research Ethics 
Service (REC reference 09/H0716/75) and conformed to the principles of the 
Helsinki Declaration.  
Amyloid patients.  26 patients with systemic amyloidosis were recruited. Eighteen 
patients had ATTR amyloidosis (16 male, age 68±8 years), and eight patients (5 
male, age 56±12 years) had systemic AL amyloidosis.  
Comparator group. Twenty-seven age- and sex-matched patients with severe 
aortic stenosis (19 male, age 68±8 years) underwent DynEQ-CT and CMR (n=22 
with 5 exclusions due to claustrophobia or pacemaker). AS was chosen as a 
comparator for having LV remodelling and hypertrophy, and allowing for cardiac 
amyloid to be excluded histologically on myocardial biopsy (Congo red staining) 
taken during aortic valve surgery as part of a separate study. Baseline 
characteristics shown in Table 11. 
DynEQ-CT Protocol.  
The DynEQ-CT protocol consisted of three steps (Figure 30 for flow chart): first, a 
CT scan to obtain baseline pre-contrast blood and myocardial attenuation in 
Hounsfield units (HU); second, contrast administration and delay so the contrast 
distributes into a blood:myocardial dynamic equilibration; third, a repeat scan to re-
measure blood and myocardial attenuation. The ratio of the change in blood and 
myocardial attenuation (ΔHU) represents the contrast agent partition coefficient.  If 
the blood volume of distribution is substituted in (1 minus venous haematocrit; 
obtained prior to imaging), the myocardial extracellular volume, ECVCT, is obtained, 
reflecting the myocardial interstitium:   
ECVCT  =  (1-Haematocrit) x (ΔHUtissue / ΔHUblood)  
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Figure 30: PseudoEQ Cardiac CT and EQ-CMR Protocols  
EQ-CMR was performed either after or at least 24 hours prior to the CT to avoid residual 
gadolinium causing an increase in measured attenuation. The CMR protocol for amyloidosis 
is 3.5x longer than the CT protocol. 
CT examinations were performed on a 64–detector row CT scanner (Somatom 
Sensation 64; Siemens Medical Solutions, Erlangen, Germany). A topogram was 
used to plan CT volumes from the level of the aortic valve to the inferior aspect of 
the heart, typically a 10cm slab. Cardiac scans (tube voltage, 120 kV; tube current–
time product, 160 mAs; section collimation, 64 detector rows, 1.2-mm section 
thickness; gantry rotation time, 330 msec) were acquired with prospective gating 
(65%–75% of R-R interval), and reconstructed into 3-mm-thick axial sections with a 
B20f kernel.  
To establish the best timing, post contrast imaging was performed at both 5- and 15-
minutes following a bolus of Iodixanol (652mg/mL) at a standard dose of 1mL/kg 
and injection rate of 3ml/sec without a saline chaser. An additional single 3mm slice 
acquisition at 1-minute (other parameters as previously described) was introduced in 
the amyloid cohort to aid blood:myocardial boundary detection for segmentation of 
the myocardium during analysis.  
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Systemic Comparator with 
p-value 
Amyloidosis Aortic Stenosis 
N 26 27 		
Men/women 21 / 5 19 / 8 		
Age, yrs 64±14 68±8 0.2 
eGFR, ml/min/1.73 m2 71±11 78±19 0.1 
LV structure by CMR 		 		 		
   Indexed LV mass, g/m2 116±40 103±27 0.05 
   Indexed LA area,cm2/m2 15.3±3.4 13.2±3.7 0.05 
LV systolic function by CMR 		 		 		
  LVEF, % 59±15 69±13 0.02 
  Indexed SV,ml/m2 42±10 50±13 0.02 
Echocardiography 		 		 		
E-wave 0.86±0.20 0.73±0.32 0.08 
E/A 1.46±0.94 0.93±0.55 0.02 
E/E’   14.7±7.2 13±8 0.1 
E-deceleration time, ms 178±54 246±76 0.001 
Aortic Valve Peak Gradient 7±1 68±21 0.001 
Clinical Parameters 		 		 		
6 minutes walking test, meters 356±130 469±168 0.01 
SBP (mmHg) 129±22 131±18 0.5 
DBP (mmHg) 76±12 74±11 0.3 
Atrial Fibrillation 3 (11.5%) 2 (8%) 		
Biomarkers 		 		 		
   NT-proBNP, pmol/L 356 (24-1426) 155 (8-568) 0.04 
   Troponin T, pmol/L 0.080 (0.01-0.24) NA 		
Table 11: Baseline characteristics of amyloidosis and AS patients.  
Values are mean +/- SD or %. Patients with systemic amyloidosis encompassing light-chain 
and transthyretin amyloidosis and aortic stenosis patients with severe stenosis awaiting 
valve replacement. eGFR, estimated glomerular filtration rate; NT-proBNP, N-terminal pro-
brain natriuretic peptide; CMR, cardiovascular magnetic resonance; EDV, end diastolic 
volume; ESV end systolic volume; LVEF, left ventricular ejection fraction;  SV, stroke 
volume; LV, left ventricular; LAA left atrial area.  
CT image analysis was performed using a free and open-source Digital Imaging and 
Communications in Medicine viewer (OsiriX v4.1.2; Pixmeo, Bernex, Switzerland) 
independently by two experienced readers blinded to all other study data; this was 
repeated by the second reader to establish inter- and intra-observer agreement. 
Regions of interest (ROIs) were drawn in the contrast-enhanced 1-minute 
acquisition in axial sections and propagated to the pre-contrast, 5-minute and 15-
minute acquisitions. For myocardium, polygonal ROIs were drawn an axial slice 
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containing the greatest area of myocardial septum; for the blood pool, circular ROIs 
were drawn in the LV blood pool away from papillary muscles and the myocardial 
septum to avoid the endocardial edge and therefore partial voluming (Figure 2).  
Myocardial and blood attenuation values were used to calculate the ECV fraction as 
described. 
Signal-to-noise ratios (SNR) were measured in five myocardial ROIs per time point 
from the ratio of the average HU attenuation value to the standard deviation of 
the HU attenuation. Radiation exposure was quantified using the dose-length 
product multiplied by a chest conversion coefficient (κ=0.014mSv/mGy.cm)[178]. 
 
Figure 31: Examples of typical CMR and CT analysis 
Top row displays regions of interest (ROIs) in CMR T1 maps images acquired before (A) and 
after gadolinium contrast (B). Middle and bottom rows show ROIs in gated cardiac CT 
images acquired pre-contrast (C), 1 minute (D), 5 and 15 minutes post iodine contrast (E+F). 
ROIs were drawn in the myocardial septum and blood pool.  
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EQ-CMR protocol. EQ-CMR was performed either after or at least 24 hours prior to 
the CT to avoid residual gadolinium causing an increase in measured attenuation.  
In addition to the standard CMR protocol (Figure 30 for flow chart), T1 mapping 
used ShMOLLI (Shortened Modified Look-Locker Inversion recovery)[137], providing 
single-section T1 map in one breath-hold [109]. For CMR image analysis, a large 
ROI was drawn manually by a reader blinded to the clinical data on each image to 
define the septum and blood pool; source data and error maps were used for quality 
control (Figure 31)[196].  
Statistical Analysis. Analyses were performed using SPSS (Chicago, IL, USA, 
version 22). Details have been previously described.  
4.2.5 Results 
DynEQ-CT ECV performance at 5 and 15 minutes 
Comparison of the signal to noise ratios showed that the SNR was significantly 
higher in the 5 minute rather than 15 minute scan (4.7±0.9 vs 3.9±0.9, p<0.001). 
ECVCT at 5 minutes was strongly correlated with ECVCMR (r2 = 0.85, p<0.001) but 
correlation was weaker at 15 minutes (r2 = 0.74 p<0.001; Figure 32). Bland-Altman 
comparisons of ECVCT and ECVCMR demonstrated no bias at 5 minutes post contrast, 
with slight bias at 15 minutes (4%, no slope), Compared to the 5 minute time point, 
the 95% confidence limits were nearly twice as wide at 15 minutes (95% confidence 
limits: -18%, 22% vs -11%, 11%).  
The mean total calculated effective radiation dose for the whole DynEQ-CT protocol 
(including both post contrast time points) was 1.56mSv±0.58mSv, with a mean 
administered total Iodixanol (Visipaque) volume of 78 mL±11mL. 
For DynEQ-CT, inter- and intra-observer agreement was excellent for myocardial 
(ICC=0.92 and ICC=0.94, respectively) and blood pool (ICC=0.96 and ICC=0.99, 
respectively) attenuation measurements. Similarly for ECV excellent agreement was 
found (ICC=0.95 and ICC=0.98, respectively). 
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Figure 32: Correlation and agreement of ECV derived by CT and CMR 
 Top row show ECVCMR and ECVCT correlations; the 5 minute CT (A) correlates better than at 
15 minutes (B) (r2 = 0.85 vs r2 = 0.74; p<0.001). Bottom row shows Bland-Altman 
comparisons of the ECV measurement by CMR versus CT at 5 minutes (C) and 15 minutes 
(D).  ECV differences are expressed as a percentage, calculated by subtracting ECVCT from 
ECVCMR) against mean ECV (solid thick line), with lower (bottom thin line) and upper (top thin 
line) 95% limits of agreement.  
4.2.6 Discussion 
This study showed that the myocardial extracellular volume, ECVCT, can be 
measured using a simple 5-minute, gated cardiac CT protocol, DynEQ-CT. This 
protocol can simply be added to routine CT coronary angiography protocols with 
only a small increase in radiation dose. It has the potential to offer a unique insight 
into the myocardial interstitium. Our previous protocol using a primed infusion to 
reach contrast equilibrium was logistically cumbersome and time consuming, 
therefore development of a bolus-only approach brings ECV, this promising novel 
biomarker, a step closer to routine clinical applicability. Furthermore, we 
unequivocally demonstrated that imaging at 5 minutes post bolus was superior to 
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acquisition at 15 minutes, with superior SNR. The theoretical advantage of allowing 
equilibration of the iodine concentration in myocardium and blood between the 5 
minute and 15 minute scan is out-weighed by the loss in signal due to overall lower 
iodine concentrations. The addition of a low dose, early arterial phase scan 
facilitated blood myocardial segmentation overall. The resulting triple phase scan 
using a 64-slice scanner had an overall radiation dose of (1.5 mSv) – significantly 
lower than conventionally used bone tracer scintigraphy (4 mSv). 
The ECVCT technique carries some advantages in clinical practice; CMR is not 
suitable in around 10% of patients (due to claustrophobia or many cardiac 
pacemakers). Furthermore, there are concerns that the CMR signal is affected by 
limits to the fast exchange of protons (this does not apply to CT)[196]. The CT 
approach is cheaper, completed in 5 minutes, and widely available, providing high-
resolution 3D ECV volumes with two single breath-hold acquisitions, and the 
scanner design can accommodate patients with obesity and claustrophobia. 
Although it has a lower signal to noise ratio, and probably more dependency on a 
reasonable eGFR, ECVCT therefore has several advantages over ECVCMR. 
4.2.7 Conclusion 
DynEQ-CT is a simple 5-minute, gated, easily implementable contrast-enhanced 
cardiac CT scan that has advantages over cardiovascular MR including scanner 
availability and cost, reduced examination time and applicability to those with CMR 
contraindications. 
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4.3 Synthetic ECV by Cardiac CT  
4.3.1 Preface:  
This chapter is based on the publication below: 
Treibel TA, Fontana M, Steeden JA, Nasis A, Yeung J, White SK, Sivarajan S, Punwani S, 
Pugliese F, Taylor SA, Moon JC, Bandula S. Automatic Quantification of the Myocardial 
Extracellular Volume by Cardiac Computed Tomography: Synthetic ECV by CT. Journal of 
Cardiovascascular Computed Tomography. 2017 Feb 22.  
My contribution was conceiving the idea for the study analysing all the data as first operator, 
performing the statistical analysis and writing the paper. I also recruited, consented and 
performed the scans of the clinical validation cohort. Dr Jennifer Steeden, UCL, developed 
the OsiriX plug-in. 
4.3.2 Introduction 
I have demonstrated the transition of ECV from CMR to CT, and the creation of a 
synthetic ECV approach via CMR – where the haematocrit is estimated from native 
blood T1. Using CCT, a relationship between anaemia and unenhanced blood 
attenuation has been observed [212-217]. For example the “aortic ring sign” and 
“dense intra-ventricular septum“ on unenhanced thoracic CTs suggest underlying 
anaemia [217-219]. Here, I explored creating a synthetic ECV approach by CT. 
4.3.3 Hypothesis and Aims 
We hypothesized that the relationship between haematocrit (Hct) and unenhanced 
blood attenuation (HUblood) could be used to estimate a synthetic Hct, permitting 
immediate synthetic ECV calculation without blood sampling. We used existing 
patient cohorts [168, 220] to investigate how synthetic ECV (a) compares to 
conventional ECV, and (b) correlates with the reference standard collagen volume 
fraction. We also tested implementation of an automated synthetic ECV 
measurement plug-in within the open-source DICOM viewer OsiriX [221]. 
4.3.4 Methods 
This study is a retrospective analysis of prospectively acquired data, received local 
ethical approval and conformed to the principles of the Helsinki Declaration. The 
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study received no industry support.  All participants provided informed and written 
consent. Exclusion criteria were uncontrolled arrhythmia or impaired renal function 
(estimated glomerular filtration rate <45mL/min). Prior to the scan, following insertion 
of an intravenous cannula, a 2-mL blood sample was collected and sent for 
complete blood cell count analysis. 
4.3.4.1 ECV CCT Protocols.  
CCT protocol and imaging analysis have been described above. 
4.3.4.2 Synthetic Haematocrit and ECV Methodology 
1. Derivation of synthetic Haematocrit 
To derive a regression model predicting haematocrit from pre-contrast HUblood, 
clinical unenhanced CT scans of the thorax were retrospectively analysed (120 kV; 
reconstructed at 5mm slice thickness and B70F soft tissue kernel). These were 
consecutive clinical CT scans of the thorax for investigation of malignancy, fibrosis 
or infection. Datasets were included if the patients had a contemporaneous paired 
laboratory measured Hct (within 20 days, median 8 days). HUblood was analysed in a 
single axial slice through the centre of the right atrium. This was chosen to minimize 
beam-hardening artifact from the spine (compared to aortic blood pool) and partial 
voluming of papillary muscles in the left or right ventricular blood pool. Synthetic Hct 
was obtained from the equation describing the linear regression line between 
laboratory HUblood and Hct. 
2. Creation of a synthetic ECV Equation 
Blood haematocrit was substituted by the derived synthetic Hct to derive a synthetic 
ECV:  Synthetic ECV  =  (1 – synthetic Hct) x (ΔHUtissue / ΔHUblood) 
3. Validation of synthetic ECV 
For validation, we used existing patient cohorts to investigate how synthetic ECV (a) 
compares to conventional ECV with laboratory blood haematocrit [220], and (b) 
correlates with the reference standard collagen volume fraction [168]. 
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3a. Clinical Validation Cohort  
In order to test synthetic ECV across a range of ECV values, the cohort used by our 
group to validate ECV by CT in amyloidosis was chosen; this comprised of two sub-
groups with differing degrees of extracellular volume expansion: I. patients with 
cardiac amyloidosis (typically high ECV), comprising of 26 patients with systemic 
amyloidosis (21 males, age 55±10 years; 18 with transthyretin amyloidosis; 8 with 
systemic AL amyloidosis) with varying degrees of cardiac involvement; II. A 
comparator group of 27 age- and sex-matched patients with severe aortic stenosis 
(19 male, age 68±8 years) who typically exhibit only mild ECV elevation. Scans 
were performed between January and December 2013. In the clinical cohort, 
contrast administration was performed using a bolus only approach with a 1 mL/kg 
bolus of iohexol, which had been validated by our group previously [220]. 
3b. Histological Validation Cohort 
For histological validation, the performance of synthetic ECV against a histological 
measure of fibrosis, the collagen volume fraction (CVF), was tested in a second 
smaller cohort of patients with severe AS, who underwent intra-operative biopsy (no 
overlap with clinical cohort). This cohort had been used by our group to validate 
ECV by CT again histology [168]: Consenting severe AS patients (n = 17, median 
age 71±10 years, 76% male) underwent CCT between July 2010 and February 
2012. Biopsies were obtained and stained with picrosirius red for histological 
measurement of collagen volume fraction (CVF) as previously described [114]. In 
the histology cohort, contrast administration followed primed iodinated contrast 
material infusion (bolus plus maintenance infusion) with a 1 mL/kg bolus of iohexol 
followed by a maintenance infusion of at a rate of 1.88 mL/kg per hour for 25 
minutes, when the post contrast imaging was performed [168]. 
4.3.4.3 OsiriX Plugin 
To facilitate offline analysis and to exemplify future inline automation by scanner 
manufacturers, an automatic synthetic ECV plug-in was developed for OsiriX. 
4.3.4.4 Statistical analysis  
Analyses were performed using SPSS (Chicago, IL, USA, version 22). Details have 
been previously described.  
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4.3.5 Results 
Step 1. Derivation cohort 
40 thoracic CT scans with contemporaneous Hct samples within 20 days (mean 
8.8±7.3 days) of the scan were included (n=40, 53% male, age 60±20 years) with a 
broad range of Hct (mean 38.2±6.0%; range 24.7-50.7%) and HUblood (mean 
40.7±8.0; range 19.5-55.2). The linear regression equation was:  (sHct = [0.51 * 
HUblood] + 17.4) with R2=0.47 p<0.001 (Figure 33). 
  
Systemic Aortic  
p-value 
Amyloidosis Stenosis 
N 26 27 		
Men/women 21-May 19-Aug 		
Age, yrs 64±14 68±8 0.2 
eGFR, ml/min/1.73 m2 71±11 78±19 0.1 
Echocardiography 		 		 		
E-wave 0.86±0.20 0.73±0.32 0.08 
E/A 1.46±0.94 0.93±0.55 0.02 
E/E’   14.7±7.2 13±8 0.1 
E-deceleration time, ms 178±54 246±76 0.001 
Aortic Valve Peak Gradient 7±1 68±21 0.001 
Clinical Parameters 		 		 		
6 minutes walking test, meters 356±130 469±168 0.01 
SBP (mmHg) 129±22 131±18 0.5 
DBP (mmHg) 76±12 74±11 0.3 
Atrial Fibrillation 3 (11.5%) 2 (8%) 		
 
Table 12: Validation Cohort.  
Values are mean +/- SD or %. Patients with systemic amyloidosis encompassing light-chain 
and transthyretin amyloidosis and aortic stenosis patients with severe stenosis awaiting 
valve replacement. eGFR, estimated glomerular filtration rate. 
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Figure 33: Derivation of synthetic haematocrit from the attenuation of blood.  
Thoracic CT scans (n=40, 53% male, age 60±20 years) with contemporaneous haematocrit 
samples (mean interval 8.8±7.3 days) of the scan were used to create a regression line 
between haematocrit (Hct; 38.2±6.0%; range 24.7-50.7%) and blood attenuation (HUblood; 
40.7±8.0; range 19.5-55.2). The regression line between Hct and HUblood was linear (R2=0.47 
p<0.001) with a regression equation for synthetic Hct = [0.51 * HUblood] + 17.4). 
Step 2. Creation of the synthetic ECV Equation 
Blood haematocrit was substituted by the derived synthetic Hct to derive a synthetic 
ECV:  Synthetic ECV  =  (1 – ([0.51 * HUblood] + 17.4) x (ΔHUtissue / ΔHUblood) 
Step 3. Validation  
Step 3a. Clinical cohort 
Baseline characteristics of twenty-six systemic amyloidosis and twenty-seven AS 
patients are shown in Table 12. In this cohort, Hct were mean 41.4±3.8% (range 
29.3-47.4%) and HUblood mean 40.2±3.9 (range 29.3-50.1). Synthetic ECV, 
calculated using the regression model to derive HCT, and conventional ECV were 
highly correlated (R2=0.96; p<0.001) with a 5.7% SD of differences and minimal bias 
(2.4%) on Bland-Altman analysis (Figure 34).  
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Figure 34: Validation of synthetic ECV vs conventional ECV in AS and Amyloid 
Synthetic ECV, calculated using the regression model, and conventional ECV were highly 
correlated (R2=0.96; p<0.001; left image) with a 5.7% SD of differences and minimal bias 
(2.4%) on Bland-Altman analysis (right image). 
Step 3b. Histology cohort 
Baseline characteristics of the histology cohort are described in Table 13. The mean 
histological CVF of the 17 biopsies was 18 ± 8% (range 5% to 40%), Hct were 
40.2±4.6% (range 29.4-46.4%) and HUblood 37.7±4.2 (range 29.5-45.1). Synthetic 
and conventional ECV both correlated well with collagen volume fraction (R2 = 0.50, 
p < 0.001 vs. R2 = 0.50, p < 0.001; Figure 35) and did not differ statistically on Fisher 
r-to-z transformation (p = 0.8).  
  Aortic Stenosis Histology Cohort 
N 17 
Men/women (% male) 13/4 (76%) 
Age, yrs 71±10 
eGFR, ml/min/1.73 m2 88±28 
Aortic Valve Peak Gradient (mmHg) 81±15 
Atrial Fibrillation 0 
 
Table 13: Histology Cohort.  
Values are mean +/- SD or %. Patients with aortic stenosis patients with severe stenosis 
awaiting valve replacement. eGFR, estimated glomerular filtration rate. 
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Figure 35: Histological Validation of Synthetic ECV 
Synthetic and conventional ECV both correlated well with collagen volume fraction (R2 = 
0.50, p < 0.001 vs. R2 = 0.50, p < 0.001) and did not differ statistically.  
Step 4. Automatic synthetic ECV plug-in in OsiriX 
Example output of the OsiriX plugin are shown in Figure 36. This plugin involves 
three simple steps: I. Manual segmentation of the blood pool in the pre- and post-
contrast images; II. The plug-in automatically estimates blood haematocrit using the 
attenuation relationship defined above; III. The plug-in produces a three-dimensional 
myocardial ECV volume, where each image voxel represents an ECV value. 
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Figure 36: OsiriX Plugin workflow.  
To facilitate offline analysis and allow future inline automation, an automatic synthetic ECV 
plug-in was developed for Osirix by Dr Jennifer Steeden, UCL. Following manual 
segmentation of the blood pool in the pre- and post-contrast images, the plug-in 
automatically estimates blood haematocrit using the attenuation relationship defined above, 
and produces a three-dimensional myocardial ECV volume from pre- and post-contrast CCT 
data. 
4.3.6 Discussion 
Identifying interstitial heart disease is important for diagnosis and prognosis, and 
myocardial extracellular volume fraction (ECV) can be measured non-invasively by 
CCT [168, 169, 220, 222]. However, its measurement is complicated by the 
necessity for venous blood sampling, image analysis and then offline ECV 
calculation. This process is cumbersome and a major obstacle for implementing this 
technique into routine clinical practice. In this manuscript, we simplify the technique 
by calculating ECV without blood haematocrit. This development arose out of a 
need to simplify ECV measurement to make it more clinically applicable. We utilize 
the relationship between haematocrit and blood attenuation (the attenuation of blood 
decreases with anaemia)[212-214, 217-219] to derive a synthetic haematocrit for 
immediate synthetic ECV calculation without blood sampling. 
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I showed that synthetic ECV was highly correlated to conventional ECV, and had a 
similar association to the histologic reference standard of CVF. The implementation 
of an offline automated processing tool provides a significant aid to workflow, 
allowing for ECV measurement in routine clinical practice.  Automated synthetic 
ECV can be implemented inline on CT scanners with test performances 
approaching that of conventional ECV measurement. ECV by CCT carries some 
advantages in clinical practice; CMR is not suitable in around 10% of patients (due 
to claustrophobia or many cardiac pacemakers) [223]. Furthermore, CMR measures 
water that is influenced by the tracer, gadolinium – the tracer is not directly 
quantified, and there are complex water behaviours (fast exchange) and 
assumptions that could introduce errors. CT is more direct – the tracer is directly 
measured as the iodine concentration and Hounsfield units are proportional [196]. 
The CT approach is cheaper, can be completed in 5 minutes, and scanners are 
widely available. ECV by CCT can provide high-resolution 3D ECV volumes, and the 
scanner design can accommodate patients with obesity and claustrophobia.  
4.3.7 Limitations 
The study has limitations. The control cohort used in this study comprised of 
patients with AS rather then healthy volunteers, but, given the exposure to ionizing 
radiation and contrast, patients with AS were deemed as adequate control cohort, 
avoiding exposure of healthy volunteers. For the same reasons, variability of repeat 
synthetic ECV was not tested.  
Development and validation were performed using a single scanner platform, 
therefore this regression model is only valid for 120 kV and an X-ray tube used in a 
specific CT vendor. Spectrum of the X-rays emitted by a CT X-ray tube substantially 
varies among CT vendors. In addition, low KV scans are increasingly used to reduce 
radiation exposure to the patients. Consequently, multiple regression models for 
different KV settings as well as for different CT vendors should be carefully prepared 
for synthetic ECV by CCT. 
Other factors that may affect the attenuation of blood such as temperature[224] and 
other blood constituents such as macromolecules, fat and iron require further 
investigation. The 64-slice-CT-system employed here reflects commonly available 
systems, but did not offer iterative reconstruction algorithms, dual energy acquisition 
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and larger detector arrays that allow acquisition of whole heart, isotropic volumes of 
in one heart beat and at low radiation dose.  
In single-source 64 detector rows CT, myocardial CT attenuation is not homogenous 
due to artifacts, especially in the inferior wall and lateral wall. In the current study, 
we only included data from ROIs in the left ventricular septum. The accuracy of 
synthetic ECV should be validated in other segments in LV myocardium, if synthetic 
ECV by CT is more widely available and used in patients. Furthermore, 3D image 
registration and processing, reduces the errors of whole heart ECV maps [170]. 
4.3.8 Conclusion 
Synthetic haematocrit derived from the relationship between blood haematocrit and 
blood attenuation allows quantification of the myocardial extracellular volume 
fraction by cardiac computed tomography without the need for blood sampling. ECV 
shows great potential, allowing myocardial tissue characterization with negligible 
effect on workflow and radiation dose. However wider adoption requires 
simplification and automation of the established technique – synthetic ECV offers 
this.  
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Chapter 5 Results 1: Sex Dimorphism in Myocardial Remodelling  
5.1.1 Preface 
This chapter is based on the publication below: 
Thomas A Treibel, Rebecca Kozor, Marianna Fontana, Camilla Tolasco, Patricia Reant, 
Sveeta Badiani, Maria Espinoza, John Yap, Javier Diez, Alun Hughes, Guy Lloyd, James C 
Moon. Sexual Dimorphism in Myocardial Remodelling. JACC: Cardiovascular Imaging. 2017 
(in press at the time of thesis printing).  
My contribution was recruiting, consenting and performing the scans of all patients. I 
performed the T1 mapping analysis as first operator, performed quality control on LV volume 
and function as well as LGE analysis, I performed the statistical analysis and wrote the 
paper. Rebecca Kozor performed the LV volume and function analysis.  
5.1.2 Introduction 
In aortic stenosis (AS), Four main geometric patterns have been defined: normal 
geometry, concentric remodelling, concentric hypertrophy, and eccentric 
hypertrophy – based on left ventricular mass, cavity size and the ratio of these two 
[25, 179, 225]. Sex appears to exert an important influence on this [60-62]. Previous 
work has shown that men are more likely to have higher indexed LV mass, lower 
LVEF, and increased diastolic myocardial stiffness [42, 63], whereas women have 
more concentric remodelling with higher relative wall thickness and LVEF. But to 
date, most studies have relied on echocardiography alone, with only limited 
combined echocardiography and CMR data available . [42] 
5.1.3 Aims 
This study aimed to understand the sex influence on AS remodelling using all 
available modalities to investigate patterns of remodelling at macroscopic and tissue 
level.  
5.1.4 Methods 
This is the baseline assessment of the RELIEF-AS cohort. Recruitment was 
between January 2012 and January 2015. Inclusion and exclusion criteria were as 
planned. Overall 48% of patients undergoing surgical AVR for severe AS at Heart 
hospital in 3 years were recruited.  
Results 1: Sex Dimorphism in Myocardial Remodelling	 Treibel TA, PhD Thesis 2017 
 
Page 93 of 193 
5.1.4.1 Cardiac Imaging 
Echocardiography: Clinical transthoracic echocardiography was performed using a 
GE Vivid E9 system (GE Healthcare, Wauwatosa, USA) with a 4-MHz transducer, 
following the guidelines for assessment of AS severity and diastolic function as 
recommended by the American and European Societies of Echocardiography [226]. 
Assessment of AS included measurement of peak and mean transvalvular velocities 
and gradients; aortic valve area by the continuity equation, indexed for body surface 
area; pressure recovery adjusted aortic valve area (i.e., energy loss index (ELI), 
[227, 228]; global hemodynamic load by the valvulo-arterial impedance index (Zva, 
[229]; stroke work loss [230]; systemic vascular resistance and systemic arterial 
compliance [65]. Left ventricular wall thickness and internal dimensions were 
measured in the parasternal long axis view. Left ventricular mass was calculated 
using the Devereux formula as recommended by the American Society of 
Echocardiography [231]: 
LV mass= 0.8 x (1.04 [(LVEDd + PWTd + SWTd)3 – (LVEDd)3 ]) + 0.6g. 
Relative wall thickness was calculated using the formula: (2 x PWTd) ÷ LVEDd 
 
Figure 37: Remodelling by CMR and Echocardiography.  
Patients were categorized into four pattern of LV geometric adaption: “normal geometry”, 
“concentric remodelling”, “concentric hypertrophy” and “eccentric hypertrophy”. For 
cardiovascular magnetic resonance, categories were defined by BSA-indexed LV mass, 
indexed LV end-diastolic volume and mass-volume ratio. For 2D-echocardiography, 
categories were defined by BSA-indexed LV mass, end-diastolic cavity dimension and 
relative wall thickness.  
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CMR: as described earlier. This main project used MOLLI as the T1 mapping 
method. LGE was quantified in grams and as a percentage of the LV using signal 
intensity threshold of three standard deviations (SD) above the mean remote 
myocardium [232]. ECV was calculated and total LV matrix and cell volumes were 
calculated from the product of LV myocardial volume and ECV or (1 minus ECV). 
5.1.4.2 Patterns of Left Ventricular Remodelling  
AS patients were categorized into four patterns of LV geometric adaption (see 
Figure 37): “normal geometry”, “concentric remodelling”, “concentric hypertrophy” 
and “eccentric hypertrophy”.  
For CMR, categories were defined by BSA-indexed LV mass (LVMi), indexed LV 
end-diastolic volume (LVEDVi) and mass-volume ratio (MVR) [25]: Left ventricular 
hypertrophy was defined as an indexed left ventricular mass >95th percentile of the 
widely-used normal range, corrected for age and gender [233]. LV concentric 
remodelling, when a normal LVMi was combined with MVR ≥1.15; eccentric LVH, 
when increased LVMi was associated with MVR <1.15; and concentric LVH, when 
increased LVMi occurred with MVR ≥1.15.  
For 2D-echocardiography, categories were defined by BSA-indexed LV mass 
(LVMi), end-diastolic cavity dimension (EDD) and relative wall thickness (RWT) 
[179]: Left ventricular hypertrophy was defined as LVMi ≥125 g/m2 in men and ≥110 
g/m2 in women. LV concentric remodelling, when a normal LVMI was combined with 
RWT ≥0.42; eccentric LVH, when increased LVMI was associated with RWT <0.42; 
and concentric LVH, when increased LVMI occurred with RWT ≥0.42. 
5.1.4.3 Statistical Analysis  
As described before. 
5.1.5 Results 
5.1.5.1 Study population 
There were 181 patients with severe, symptomatic AS recruited (age 69±10, 56% 
male) representing 48% of all surgical AVRs at the study institution. Thirteen 
patients were excluded: claustrophobia (n=2), hemodynamic instability (n=1), 
pseudo-severe AS (n=1), severe mitral regurgitation (n=2), significant myocardial 
bystander disease (cardiac amyloidosis n=6; Fabry Disease n=1)[234].  
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  Total Men Women p-value 
n 168 92 (55%) 76 (45%)   
Age 70±10 70±10 70±10 0.9 
Trileaflet* 118 61 (66%) 57 (76%) 0.2 
Bicuspid* 49 31 (34%) 18 (24%) 0.2 
BSA 1.88±0.21 1.98±0.19 1.76±0.17 <0.001 
Co-morbidities         
Hypertension 77% 81% 73% 0.4 
SBP, mmHg 133±18 130±18 137±18 0.01 
DBP, mmHg 75±11 74±10 77±13 0.1 
Diabetes 26% 22% 29% 0.5 
Coronary artery disease 30% 37% 21% 0.03 
Atrial Fibrillation, % 14% 16% 14% 0.7 
Smoker, current/ex/never 50/21/97 28/17/46 22/04/1951 0.2 
Risk Scores         
STS, %  1.43 (0.98-2.37) 1.31 (0.88-2.32) 1.62 (1.04-2.39) 0.3 
EuroScore II, %  1.49 (1.01-2.44) 1.42 (0.98-2.47) 1.54 (1.02-2.40) 0.6 
Drug History         
ACE-I / ARB 43% 53% 31% 0.006 
Beta-blocker 34% 32% 56% 0.5 
Statin 61% 63% 59% 0.8 
Aspirin 44% 47% 41% 0.4 
Symptomatic (yes/no) 161/7 87/5 74/2 0.3 
NYHA functional class  2.3±0.7 2.2±0.8 2.4±0.6 0.1 
I 30 23 10   
II 79 40 39   
III 54 26 28   
IV 5 4 1   
Chest pain by CCS      0 115 60 55 0.9 
                                  1 14 12 2   
                                  2 29 9 20   
                                  3 10 8 2   
Syncope 14 (8%) 7 (8%) 7 (9%) 0.7 
Six minute walk test  480 (338-600) 510 (360-630) 420 (300-510) 0.02 
ECG         
LVH by Cornell criteria 43 (26%) 25 (27%) 18 (24%) 0.3 
ECG Strain 29 (17%) 17 (19%) 12 (16%) 0.5 
Blood         
NT-pro-BNP, ng/L  71 (29-238) 94 (36-304) 50 (28-143) 0.04 
NT-pro-BNP ratio  0.18 (0.08-0.69) 0.33 (0.09-1.12) 0.11 (0.05-0.35) 0.04 
hs-Troponin T, pmol/L;  14 (9-20) 15 (11-25) 12 (7-16) 0.02 
Creatinine, micromol/l 85±25 94±26 74±18 <0.001 
eGFR, mls/min/1.73m2 77±22 79±23 74±18 0.3 
Haematocrit, % 40±4 41±5 39±4 0.01 
Table 14: Baseline characteristics.  
*one patient had unicupid AS (female). Values are given as mean ± SD or n (and percentage), unless stated. BSA 
means body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, New York Heart 
Association; IQR, interquartile range; STS, Society of Thoracic Surgeons' risk model score; EuroScoreII, European 
System for Cardiac Operative Risk Evaluation II score; ACE-I, angiotensin-converting-enzyme inhibitor; ARB, 
angiotensin-receptor blocker; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-brain natriuretic peptide; 
hs-TnT, high sensitivity troponin T; eGFR, estimated glomerular filtration rate. 
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Characteristics of the remaining 168 patients (age 70±10 years, 55% male; 70% 
trileaflet AS) are summarized in Table 14 and Table 15. All but seven patients were 
symptomatic (96%) with dyspnoea (82%), chest pain (32%) and/or syncope (8%).  
CMR was suggestive of LV decompensation in 55 patients with pericardial effusions 
(>5mm) in 47 patients and pleural effusions (>1cm) in 36 patients (22 with both). 
There were no sex differences in the aortic valve regurgitant fraction (14% vs 10%, 
p=0.1), or mitral valve regurgitant fraction (3% vs 6%, p=0.4). Furthermore, there 
were no sex differences in age, smoking status, diabetes or hypertension 
prevalence, although office systolic blood pressure (130±18 vs 137±18, p=0.01) and 
glycosylated hemoglobin (HbA1c; 38±9% vs 44±20%, p=0.003) were higher in 
women. Coronary artery disease (stenosis >50%) was more prevalent in men (37% 
vs 21%, p=0.03). 
5.1.5.2 Aortic Stenosis Severity and Sex 
There were no sex differences in standard echocardiographic parameters of AS 
severity (valve area, gradient or velocity ratios; Table 15). Advanced 
echocardiographic parameters revealed subtle sex differences in AS severity and 
vascular load: men had a trend towards lower energy recovery measured by the 
energy loss index (0.46±0.17 vs 0.53±0.30cm2/m2, p=0.06)[227] with larger aortic 
dimensions (6.4±1.7cm2 vs 4.6±1.6cm2, p<0.001). Furthermore, men had lower 
mean arterial pressure (93±11 vs 97±12mmHg, p=0.02) and systemic vascular 
resistance (1252±376 vs 1419±361 dyne*s*cm-5, p=0.005), though global afterload 
assessed by valvulo-arterial impedance (p=0.2) was not different.  
5.1.5.3 Pattern of Remodelling and Sex 
The geometry and function by CMR (Table 15) differed by sex: Men had larger LV 
dimensions, even when indexed (EDVi: 73±23ml vs 61±19ml vs, p<0.001; ESVi: 
27±22g vs 18±16g, p=0.004), and greater LVMi (98±23 vs 75±20g/m2, p<0.001; also 
when indexed to height^2.7)[235], and mass-volume ratio (MVR; 1.44±0.39 vs 
1.30±0.28, p<0.001). There were also marked sex differences in remodelling (χ2 = 
34, p<0.001): normal geometry (82% female) and concentric remodelling (60% 
female) were predominantly seen in women, whereas concentric hypertrophy (71% 
male) and eccentric hypertrophy (76% male) in men; this was not apparent by 
echocardiography (p=0.4; female: normal geometry 56%, concentric remodelling 
51%, concentric hypertrophy 38%, eccentric hypertrophy 39%; Figure 38).  
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Figure 38: Sex Differences In Left Ventricular Pattern of Remodelling  
Cardiovascular Magnetic Resonance (A) found marked sex differences in left ventricular 
remodelling (χ2 = 34, p<0.001): Normal geometry (82% female) and concentric remodelling 
(60% female) were predominantly seen in women, whereas concentric hypertrophy (71% 
male) and eccentric hypertrophy (76% male) in men. This was not apparent by 2D-
echocardiography (B; female: normal geometry 56%, concentric remodelling 51%, 
concentric hypertrophy 38%, eccentric hypertrophy 39%; χ2 = 2.7, p=0.4). 
 
Figure 39: Sex, Left Ventricular Hypertrophy And Decompensation.  
Panel A shows indexed left ventricular mass (LVMi) and left ventricular ejection fraction 
(LVEF) by sex: Men had greater LVMi (98±23 vs 75±20g/m2, p<0.001) and lower LVEF than 
women (67±16% vs 74±13%, p<0.001). Panel B shows LVMi and LVEF by NT-pro-BNP ratio 
greater or less then 1, which were higher in men than women (0.33 [IQR 0.09-1.12] vs 0.11 
[0.05-0.35]; p=0.04).  
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Echocardiography Total Men Women p-value 
Vmax (m/s) 4.33±0.59 4.38±0.59 4.27±0.59 0.3 
Peak gradient (mmHg) 76±20 78±21 75±19 0.4 
Mean gradient (mmHg) 47±14 49±15 46±13 0.3 
AVAi (cm2/m2) 0.40±0.13 0.39±0.13 0.41±0.13 0.3 
VTI ratio 0.23±0.08 0.22±0.07 0.24±0.08 0.1 
Energy loss index (cm2/m2) 0.48±0.19 0.46±0.17 0.53±0.30 0.06 
Systemic vascular resistance (dyne*s/cm5) 1326±379 1252±376 1419±361 0.005 
Systemic arterial compliance (ml/mmHg*m2) 1.35±0.47 1.28±0.49 1.42±0.43 0.06 
Zva (mmHg/ml*m2) 4.2±1.2 4.1±1.3 4.4±1.0 0.2 
E-wave 0.85±0.30 0.83±0.30 0.87±0.29 0.4 
E/A ratio 0.97±0.49 1.03±0.59 0.89±0.32 0.1 
E deceleration time (ms) 237±75 236±82 238±66 0.9 
E/e' ratio 13.6±5.9 13.5±6.2 13.8±5.6 0.8 
    PASP (mmHg) 31±8 31±9 31±8 0.8 
CMR parameters         
EDVi (ml/m2) 67±22 73±23 61±19 0.001 
ESVi (ml/m2) 23±20 27±22 18±16 0.001 
LVMi (g/m2) 88±25 98±23 75±20 0.001 
Septal wall thickness (mm) 14±3 15±2 13±2 <0.001 
Left ventricular diameter (mm) 50±7 52±7 47±6 <0.001 
Mass:Volume Ratio 1.37±0.35 1.44±0.39 1.30±0.28 0.001 
LAAi_preop (cm2/m2) 13.5±3.7 13.6±3.3 13.4±4.1 0.8 
LVEF (%) 70±15 67±16 74±13 0.001 
SVi (ml/m2) 45±10 46±12 43±8 0.3 
Myocardial Contraction Fraction (%) 0.53±0.15 0.48±0.13 0.59±0.14 0.001 
Wall Stress index (kPa) 1.40±0.29 1.35±0.29 1.46±0.27 0.008 
Pattern of Remodelling by CMR         
Normal Geometry 28 (17%) 5 (18%) 23 (82%)   
Concentric Remodelling 45 (27%) 18 (40%) 27 (60%) χ2 = 34 
Concentric Hypertrophy 70 (41%) 50 (71%) 20 (29%) p<0.001 
Eccentric Hypertrophy 25 (15%) 19 (76%) 6 (24%)   
CMR flow         
Aortic regurgitant fraction % (IQR) 12 (4-35) 14 (6-47) 10 (3-24) 0.1 
Mitral regurgitant fraction % (IQR) 5 (1-23) 3 (0-24)  6 (1-22)  0.4 
Late gadolinium enhancement         
3SD method (g) 11.0±17.1 14.3±19.5 7.2±12.8 0.007 
T1 mapping (ShMOLLI)         
T1 myocardium (native, in ms) 978±31 977±33 979±28 0.7 
ECV (%) 28.7±2.9 28.7±3.1 28.6±2.5 0.8 
Cell volume, indexed (ml/m2)   73±17 55±13 <0.001 
Matrix Volume, indexed (ml/m2)   29±9 21±6 <0.001 
Table 15: Imaging Parameters (Echocardiography and CMR).  
Values are given as mean ± SD or n (and percentage), unless stated. Vmax, peak velocity through the aortic valve; 
AVAi, aortic valve area index; VTI ratio, velocity-time-integral ratio; Zva, valvulo-arterial impedance; E, peak early 
velocity of the transmitral flow; DT, deceleration time; E´, peak early diastolic velocity of the mitral annulus 
displacement; PASP, pulmonary artery systolic pressure measured by echocardiography; EDVi, end-diastolic 
volume index; ESVi, end-systolic volume index; LVMi, left ventricular mass index; LVEF, left ventricular ejection 
fraction; SVi, stroke volume index, LAAi, left atrial area index; IQR, interquartile range; 3SD, three standard 
deviations; ECV, extracellular volume.  
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5.1.5.4 Symptoms and Myocardial Response  
No sex differences in NYHA functional class were found (p=0.2). Although men were 
able to walk further than women on 6MWT assessment (510 [IQR 360-630] m vs 
420 [IQR 300-510] m, p=0.02), the percentage-predicted 6MWT distance [236] was 
not significantly different between men and women (97±34% vs 96±40%, p=0.6). 
LVEF was lower in men then in women (67±16% vs 74±13%, p<0.001, see Table 
15). Men had lower minute work (15.6±4.7 vs 17.7±4.5ml*mmHg/min, p=0.005) and 
myocardial contraction fraction (48±13% vs 59±14%, p<0.001). Furthermore, both 
NT-pro-BNP and hsTnT were higher in men (NT-pro-BNP: 94 [IQR 36-304] vs 50 
[IQR 28-143] pmol/L, p=0.04; hsTnT: 15 [IQR 11-25] vs 12 [7-16] pg/L, p=0.01). 
Figure 3 displays the distribution of LVEF vs indexed LV mass by gender and by 
BNP clinical activation, defined as a NT-pro-BNP ratio >1 (absolute NT-proBNP 
concentration indexed for the 95th centile of normal range for age and sex [181]).  
5.1.5.5 Myocardial Fibrosis and Sex 
Examples of LGE pattern are shown in Figure 40. There was more LGE in men by 
both prevalence (71% vs 46%, p<0.01) and extent (16.5±11.2 vs 10.5±8.9g, 
p<0.001), although these differences were not statistically significant when 
expressed as a percentage of the LV mass (8.6±5.6 vs 7.7±5.9%, p=0.1). No sex 
differences in native myocardial T1 or ECV (T1: 1041±42ms vs 1051±47ms, p=0.2; 
ECV: 28.6±3.1% vs 28.2±2.7%, p=0.2) were observed. However, using the ECV to 
dichotomize the LVMi into matrix and cell compartments, both indexed matrix 
(28.5±8.8 vs 21.4±6.3ml/m2, p<0.001) and cell volumes (72.7±16.7 vs 
54.7±13.0ml/m2, p<0.001) were higher in men.  
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Figure 40: Late gadolinium enhancement in aortic stenosis. 
A – No late gadolinium enhancement (LGE). B – Focal Papillary muscle and RV insertion 
point LGE. C – Focal mid-wall LGE in the anterolateral wall. D-F – diffuse, patchy myocardial 
LGE ranging from mild (D) to moderate (E) to severe LGE burden (F), associated with 
papillary muscle RV insertion and RV free wall LGE. G – Non-infarct, subendocardial and 
papillary muscle LGE. H – dilated cardiomyopathy-pattern LGE. I – Full thickness infarct in 
the thinned inferior wall. 
5.1.6 Discussion 
In this prospective multimodality study of 168 patients with symptomatic severe AS 
at baseline referred for surgical AVR, despite the same referral age, valve severity 
and functional status, there were major sex differences in myocardial remodelling, 
fibrosis and resultant left ventricular function. Our data highlights the importance of 
the myocardial response in AS encompassing a wide geometric and functional 
range (Figure 41), which is neither associated with the hemodynamic severity of the 
aortic valve stenosis nor observed by conventional echocardiography: Men 
predominantly had concentric or eccentric LVH as well as a less favourable, 
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maladaptive ventricular phenotype (lower LVEF, higher NT-pro-BNP and hs-TnT, 
more myocardial fibrosis). In contrast, women exhibited a possibly more favourable 
phenotype with less hypertrophy, less fibrosis, and a higher prevalence of normal 
geometry or concentric remodelling with higher LVEF. 
 
Figure 41: Left Ventricular Remodelling in AS by Multimodality Imaging. 
This panel shows four images each for all four patterns of remodelling: continuous wave 
Doppler assessment of aortic stenosis severity (top left); SSFP short axis cine clip 
demonstrating the pattern of remodelling (as described in Figure 1; top right); phase-
sensitive inversion recovery late gadolinium enhancement image for focal fibrosis (bottom 
left); extracellular volume fraction map for diffuse fibrosis (bottom right). 
These findings raise a few key issues: Firstly, given the stark differences in 
myocardial remodelling, how do these affect the interpretation of the hemodynamic 
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severity of the valve stenosis? Secondly, these changes may be adaptive or 
maladaptive – can LVEF, NT-pro-BNP and hs-Troponin adequately highlight the 
transition into maladaptation, or are other biomarkers needed? And are blood 
biomarkers more informative than imaging? Finally, what are the mechanisms 
driving the sex differences in remodelling? 
 
Figure 42: Sex Dimorphism in Myocardial Response to Aortic Stenosis.  
Aortic stenosis (AS) is a disease of both valve and left ventricle (LV). Sex difference may 
play a role in disease phenotyping. This study investigated 168 patients with severe 
symptomatic AS by echocardiography, cardiovascular magnetic resonance (CMR) and 
biomarkers. There were no sex differences in AS severity or functional capacity, but CMR 
captured a sex dimorphism in LV remodelling pattern; missed by 2D-echocardiography and 
more adverse in men with more LV dysfunction (by LVEF, NT-pro-BNP, hsTnT) and 
myocardial fibrosis (focal and diffuse). Given equal valve severity, LV associations with AS 
appear more maladaptive in men, with more extreme sex differences then previously 
reported. AVAi, indexed aortic valve area; CMR, cardiovascular magnetic resonance; ECV, 
extracellular volume fraction; hsTnT, high-sensitivity troponin T; LGE, late gadolinium 
enhancement; LV, left ventricular; LVEF, left ventricular ejection fraction; NT-proBNP, N-
terminal pro-brain natriuretic peptide; Vmax, peak velocity. 
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5.1.6.1 Sex dimorphism in myocardial response 
In our study, women appeared to tolerate a similar level of valve-related afterload 
better (women even had higher blood pressures and fewer cardioprotective drugs), 
with better-preserved wall stress and better systolic pump performance (LVEF and 
myocardial contraction fraction) then men. Sex-related differences in myocardial 
remodelling have been reported in the elderly with or without AS [60, 61, 237-239]. 
In animal models, sex dimorphism exists in the baseline findings of the heart 
(difference in size, physiology, gene profiles, contractile properties), response to 
pressure or volume overload (more hypertrophy and dilatation, respectively), and 
cardiomyocyte response to aging and modification of cardiac gene expression [240]. 
Cellular, molecular and neurohormonal mechanisms for the differential response in 
men have been proposed, including increased interstitial fibrosis, greater activation 
of profibrotic and inflammatory pathways, and differential expression of androgen 
and oestrogen receptors [63, 241-243]. Although the interplay of protective effects of 
oestrogens and deleterious effects of androgens may play a key role in the sex 
dimorphism, the majority of female patients in our study were post menopausal and 
none were on hormone replacement therapy. Sex differences in the renin-
angiotensin system, nitric oxide activity and norepinephrine release may contribute 
to differences in LV remodelling [244]; similar differences in cardiac function and 
arterial haemodynamics to those observed here have also been seen in community 
based samples of older men and women [245]. A less explored possibility is that the 
myocardium could have been sex-patterned during cardiac foetal formation to adapt 
differently during adult life.  
5.1.6.2 Discordance with previous echocardiographic data 
Sex dimorphism in cardiac remodelling in AS is present in the literature, but has not 
been emphasized; for example in an echocardiographic study of 2017 patients (36% 
female) awaiting AVR [246], LV impairment had a 3.5 to 1 male to female ratio and 
LVEF >70% had a 1:1 male to female ratio. Given the study entry gender ratios, if 
there had been no sex dimorphism, both of these ratios should have been 1.7 to 1. 
However, the sex dimorphism of cardiac remodelling found by CMR here was much 
more extreme than by echocardiography (Figure 2). Modality specific ascertainment 
differences that could explain this: cross-sectional echocardiography uses derived 
wall thickness to cavity width ratios whilst CMR uses a 3D derived mass to volume 
ratio [25]. Each technique also has indexed gender specific reference ranges and 
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cut-points, which could be inaccurate and magnify differences. These may be 
differently sensitive to gender influenced confounders (such as a basal septal 
bulge).  Such explanations appear however inadequate and the impression is that 
an echocardiography-based approach to cardiac remodelling has induced an 
underestimation of biological sex dimorphism in cardiac remodelling in AS. 
5.1.6.3 Perspective – do we need sex-specific thresholds for AVR? 
Timing of aortic valve intervention is one of the greatest challenges in AS, in 
particular in asymptomatic patients. Recent focus has turned towards the complex 
interplay between AoV stenosis, vascular load and myocardial response 
(inappropriate hypertrophy, myocardial stress [NT-proBNP], fibrosis [troponin, LGE, 
ECV], myocardial perfusion reserve). Our data supports the notion that we may 
need to treat men and women differently as they experience a different cardiac 
“milieu”, different combined (valve and vasculature) afterload and display a different 
myocardial response. Crucially, data showing reverse remodelling after valve 
replacement and its impact on outcome is required and pending. 
5.1.7 Limitations 
This study has several limitations. Only patients with severe disease referred for 
surgery at a specialist centre were included and the study is therefore not 
representative of patients treated medically or by transcatheter aortic valve 
intervention. CMR inclusion criteria excluded patients with pacemakers and 
eGFR<30; this only excluded 7% of patients and is unlikely to have biased our 
findings. No invasive LV pressure data was obtained; due to stroke risk associated 
with crossing the AoV [247], this is not routinely performed in our institution. 
5.1.8 Conclusion 
CMR reveals sex differences in associations between AS and myocardial 
remodelling that are not evident from conventional echocardiography and that we 
had been missing. Given equal valve severity, the myocardial response to AS 
appears more maladaptive in men then previously reported. This data suggests that 
more detailed phenotyping of patients with AS is required – resultant uncovering of a 
maladaptive ventricular response may be influential in the current debate regarding 
immediate or deferred intervention for severe AS. 
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Chapter 6 Results 2: Occult Cardiac Amyloid in Aortic Stenosis 
6.1.1 Preface 
This chapter is based on the publication below: 
Treibel TA, Fontana M, Gilbertson JA, Castelletti S, White SK, Scully PR, Roberts N, Hutt 
DF, Rowczenio DM, Whelan CJ, Ashworth MA, Gillmore JD, Hawkins PN, Moon JC. Occult 
Transthyretin Cardiac Amyloid in Severe Calcific Aortic Stenosis: Prevalence and Prognosis 
in Patients Undergoing Surgical Aortic Valve Replacement. Circulation Cardiovascular 
Imaging. 2016 Aug;9(8). 
My contribution was recruiting, consenting and performing the scans of all patients, as well 
as collecting the myocardial biopsies at time of surgery. I analysed all data as first operator, 
did the statistical analysis and wrote the paper. Histological processing and analysis was 
performed at Great Ormond Street Hospital and the National Amyloidosis Centre, Royal 
Free Hospital, UCL. This work has also led to the granting of a BHF research fellowship to 
Dr Paul Scully (FS/16/31/32185) to continue to explore occult amyloid in the elderly with AS. 
6.1.2 Introduction 
In RELIEF-AS, there was a likelihood of occult amyloid. Coexistence of AS and 
cardiac amyloidosis has been reported but this has not been studied systematically 
and the prognostic significance is unknown [248, 249]. It has been suggested that 
occult amyloid might account for the frequent need for pacemakers among TAVI 
patients, and the high prevalence of CMR LGE [250], but this has not been studied 
systematically. It has not hitherto been possible to reliably detect the presence of 
cardiac amyloidosis without recourse to biopsy, but this is now possible in most 
patients using a combination of multiparametric CMR incorporating native T1 
mapping [251], estimation of ECV [135], and the Phase Sensitive Inversion 
Recovery (PSIR) LGE technique [252], coupled with bone scintigraphy [253]. This is 
all the more important given that several specific drug therapies for ATTR 
amyloidosis are now in clinical trial [254, 255]. 
6.1.3 Hypotheses and Aims 
We hypothesized that unrecognized ATTR amyloid deposits may act as a disease 
modifier in aortic stenosis. We aimed to: 1 – assess the prevalence of occult cardiac 
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amyloid in AS; 2 - identify the amyloid subtype; 3 – determine the role of 
comprehensive imaging; and 4 - elucidate its clinical and prognostic significance. 
6.1.4 Methods 
In the RELIEF-AS Study 146 patients (81%) underwent intra-operative myocardial 
biopsies. CMR and echo were performed as previously described. DPD bone 
scintigraphy was conducted during subsequent specialist clinical evaluation of 
subjects found to have amyloid on biopsy (see later). Prior to AVR, all patient 
underwent a clinical transthoracic echocardiogram (TTE), primarily to assess aortic 
valve mean gradient, peak jet velocity and effective orifice area, i.e. assessment of 
AS severity, as well as systolic and diastolic function [226]. Global longitudinal strain 
was not performed routinely as and was therefore not available prior to AVR. 
Analysis was performed retrospectively in patients with adequate endocardial border 
definitions as previously described [256].   
6.1.4.1 CMR scanning 
As described before in section 3.3. In addition, two amyloid specific indices, 
myocardial contraction fraction (the ratio of stroke to myocardial volume) and ECG-
voltage/LV mass ratio, were calculated [257, 258].  
6.1.4.2 Histological analysis  
An intra-operative septal biopsy (typically tubular, measuring 1.6x1.6x10mm) was 
harvested from the basal left ventricular septum under direct vision by the surgical 
team using a 14-gauge coaxial needle, formalin fixed and paraffin embedded 
(FFPE). Histological analysis was performed by Congo red staining on 6µm FFPE 
sections and viewed in brightfield and cross polarized light [259]. When amyloid was 
confirmed by displaying apple green birefringence under cross polars, 
immunohistochemistry (IHC) was carried out on the Shandon Sequenza™ system 
using a panel of monospecific antibodies against known amyloid-forming proteins, in 
an attempt to identify the amyloid fibril.  Antigen retrieval was not performed with the 
exception for TTR antibodies which uses oxidation with 1% aqueous Na-m-
periodate (10 min) and 0.1% di-NA borohydride (10 min) followed by 6 M guanidine 
(4h). Sections were blocked for endogenous peroxidases and with normal serum, 
incubated overnight at 4°C with the primary antibodies. Antibodies were detected 
with the appropriate species-specific IMMPRESS (Vector Laboratories) polymer 
Results 2: Occult Cardiac Amyloid in Aortic Stenosis	 Treibel TA, PhD Thesis 2017 
 
Page 107 of 193 
detection kit and labelled using metal-enhanced 3,30-diaminobenzidine chromagen 
(Thermo Scientific). Interpretation was carried out initially without any clinical 
information by two people independently using a Leica DMLB with and without 
crossed polars. Diagnosis was confirmed by laser microdissection and mass 
spectroscopy (LDMS) [260, 261]. 
6.1.4.3 Clinical assessment of patients with amyloid on myocardial biopsy 
Patients found to have amyloid were referred for full clinical assessment at the 
National Amyloidosis Centre, London, UK. A particular emphasis was to exclude AL 
amyloid, which can be treated with chemotherapy. Clinical work-up included: serum 
and urine immunofixation, serum free light chain analysis, comprehensive 
transthoracic echocardiogram, 123I-labeled serum amyloid P component scintigraphy, 
sequencing of the transthyretin gene, and cardiac scintigraphy using the 99mTc-
labelled DPD bone tracer. This was graded on the Perugini scale: Grade 0 - no 
myocardial uptake; Grade 1 - minor cardiac uptake of less intensity than uptake in 
the bony skeleton; Grade 2 - moderate cardiac uptake with greater signal intensity 
than the bone; Grade 3 - strong cardiac uptake with little or no bone uptake visible 
[172, 253]. 
6.1.4.4 Statistical Analysis 
As described in the main methods section 3.8. Survival was evaluated using Cox 
proportional hazards analysis, providing estimated hazard ratios (HR) with 95% 
confidence intervals (CI) and Kaplan Meier curves. Due to the low number of events 
(deaths) multivariable Cox regression models were not tested. 
6.1.5 Results 
146 patients with severe AS awaiting aortic valve replacement (AVR) were recruited. 
All patients had echocardiography, CMR with LGE and T1/ECV mapping as well as 
intra-operative myocardial biopsy. 112 patients had calcific AS (cAS) [75±6years; 
58% male]; 32 patients had bicuspid AS (bAS) [59±6years; 66% male], one patient 
each rheumatic (65, female) and unicuspid AS (35, female). The treatment received 
was tissue or mechanical valve in 71% and 29%, respectively, with additional 
bypass grafting in 23%, aortic intervention in 6% (interposition graft, reduction 
aortoplasty, replacement of the ascending aorta) and mitral valve replacement in 
1.4%. Baseline characteristics are shown in Table 16. 
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  Calcific AS Other Etiologies* p-value 
N 112 34   
  Men 64 (58%) 21 (58%) 0.9 
  Age, years 75±6 59±7 <0.001 
  BMI, kg/m2 28±5 27±7 0.2 
Cardiovascular MR       
   Indexed EDV, ml/m2 64±21 74±21 0.02 
   Indexed ESV, ml/m2 21±17 25±20 0.6 
   Indexed LV mass, g/m2 85±24 94±24 0.2 
   LVEF, % 69±15 70±15 0.5 
   Myocardial contraction fraction, % 0.53±0.16 0.55±0.14 0.5 
   Voltage-mass ratio 0.13±0.06 0.11±0.04 0.3 
   Indexed LA area, cm2/m2 14±4 13±3 0.08 
Echocardiography       
  Aortic Valve Peak Velocity 4.3±0.6 4.4±0.5 0.8 
  Aortic Valve Mean Gradient 46±15 47±15 0.8 
  Aortic Valve Area, indexed 0.41±0.17 0.42±0.15 0.2 
  E-wave 0.84±0.29 0.89±0.29 0.4 
  E-deceleration time (ms) 240±79 224±63 0.3 
  E/A 0.92±0.42 1.18±0.65 0.06 
  E/E’   13±6 15±7 0.3 
Clinical Parameters       
  Hypertension (%) 87 (78%) 31(90%) 0.1 
  Diabetes (%) 26 (23%) 6 (18%) 0.5 
  Coronary Artery Disease (%) 37 (33%) 9 (27%) 0.6 
  STS score 1.9±1.4 1.6±0.9 0.3 
  EUROscore II 2.3±2.1 1.6±0.9 0.02 
Bloods       
   NT-proBNP, pmol/L 186 (5-1307) 177 (8-1400) 0.7 
  eGFR, ml/min/1.73 m2 72±18 88±20 0.03 
Surgery       
  Tissue AVR 82 (73%) 21 (62%)   
  Mechanical AVR 30 (27%) 13 (38%)   
  CABG 29 (26%) 5 (17%)   
  Aortic intervention 4 (3.6%) 4 (11.8%)   
Table 16: Baseline Characteristics.  
*Bicuspid AS n=32; unicuspid AS n=1; rheumatic AS n=1. Values are mean +/- SD or %. AS, aortic stenosis; eGFR, 
estimated glomerular filtration rate; NT-proBNP, N-terminal pro-brain natriuretic peptide; CMR, cardiovascular 
magnetic resonance; EDV, end diastolic volume; ESV end systolic volume; LVEF, left ventricular ejection fraction; 
SV, stroke volume; LV, left ventricular; LAA left atrial area.  
6.1.5.1 Histological and Genetic Analysis 
Of the 146 biopsies, six contained amyloid (prevalence 4.1% all-comers).  All six 
were cAS aged >65 (prevalence 5.4% for cAS and 5.6% for >65). Typing by IHC, 
supported by LDMS, confirmed ATTR amyloid type in all six cases (Figure 43 and 
Figure 44). Genetic sequencing confirmed non-hereditary wild-type transthyretin 
sequence in each case.  
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Figure 43: Myocardial biopsy in severe AS and overt ATTR amyloid deposits.  
Histological slides stained with Congo red under brightfield light (Congo Red), under cross 
polars with typical apple green birefringence (AGB) and under fluorescent (FL) microscopy. 
Separate slide prepared by transthyretin-specific immunohistochemistry (TTR) showing 
widespread ATTR amyloid staining (brown).  
 
Figure 44: Myocardial biopsy in patient without clinical evidence of amyloid 
Histological slides stained with Congo red under brightfield light (Congo Red), under cross 
polars with typical apple green birefringence (AGB) and under fluorescent (FL) microscopy. 
Separate slide by TTR immunohistochemistry. All showing patchy ATTR amyloid deposits.  
Results 2: Occult Cardiac Amyloid in Aortic Stenosis	 Treibel TA, PhD Thesis 2017 
 
Page 110 of 193 
Table 17: Summary of findings in patients with severe AS and wtATTR 
*DPD scintigraphy = Tc-99m-3,3-diphosphono-1,2-propanodicarboxylicacid (DPD) scintigraphy; †SAP scan = serum 
amyloid-P scan; ‡AVAi = indexed aortic valve area; §AoV = Aortic Valve; ||LGE pattern = late gadolinium 
enhancement pattern; #LV = left ventricular. 
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6.1.5.2 Clinical Assessment of patients with amyloid 
Clinical evaluation of the six patients with amyloid was scheduled at the National 
Amyloidosis Centre, UK, but two patients died prior to their appointment. 
Assessment revealed carpal tunnel syndrome in one patient but no other extra-
cardiac manifestations, which is typically the case. AL amyloidosis was excluded in 
all cases. Summary findings are shown in Table 17. 
6.1.5.3 Multimodality Imaging 
Figure 45 and Figure 46 summarize the findings of multimodality imaging.  
 
Figure 45: Patient with clinical features of cardiac amyloidosis.  
Although the echocardiogram showed LVH (B), this was attributed to the myocardial 
response to severe AS. DPD scintigraphy showed Perugini Grade 2 cardiac uptake on bone 
scan (C) and SPECT (B). CMR showed overt LVH and impaired systolic function (D), and 
transmural LGE with higher signal from the myocardium then the blood pool (E). 
Echocardiography. Pre-operative routine transthoracic echocardiography did not 
raise any suspicion of amyloid among the 6 patients in whom amyloid was identified 
histologically, and were consistent with severe AS by indexed valve area (mean 
AVAi 0.41±0.17cm2/m2) and/or transvalvular peak velocity (4.3±0.6 m/s). Clinical 
reporting identified significant concentric left ventricular hypertrophy (LVH) with 
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impaired longitudinal shortening and diastolic dysfunction in 3 out of 6 patients but 
this was attributed to AS afterload. No suspicion of a dual pathology was raised. 
Retrospective analysis of global longitudinal strain (GLS; not performed routinely in 
our clinical AS work-up) was markedly reduced GLS in patient 1 and 2 (-6.4% and -
11.6%, respectively), but could only be obtained in a minority of patients in our 
cohort due to poor endocardial wall definition in many patients  (Table 17).  
 
Figure 46: Patient with amyloid deposits on biopsy but no clinical features.  
Neither pre-operative echocardiogram nor CMR highlighted any features consistent with 
cardiac amyloidosis. DPD scintigraphy showed Perugini Grade 1 cardiac uptake on bone 
scan (C – there is subtle uptake in the basal third of the left ventricle [see arrows]), which is 
more obvious on SPECT (B). There was no LVH and good LV systolic function on CMR cine 
imaging (D), and only subtle patchy, non-ischemic LGE in the basal lateral wall (E). 
CMR. In two patients, the pre-operative research multiparametric CMR study 
identified the dual pathology of AS and cardiac amyloidosis. This was based on the 
combination of severe LV hypertrophy out of proportion for the degree of AS, and 
(more definitively) tissue characterization findings of cardiac amyloid (global 
transmural late gadolinium enhancement with blood pool nulling after the 
myocardium on the TI scout, elevated native myocardial T1 (here >5SD above 
normal) and ECV >50%). These research findings were communicated to the 
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surgical team but a multidisciplinary decision was made to proceed with AVR and to 
conduct further evaluation of amyloidosis afterwards (patients 1 and 2, table 2). The 
myocardial contraction fraction (MCF) was also markedly reduced in both these 
patients (25% and 33%, respective) despite preserved LVEF; in the other four 
patients, MCF fell within one SD of the overall AS cohort (53±13%; see Table 17). 
DPD Scintigraphy. DPD bone scintigraphy was performed in the four surviving 
patients during the post-operative amyloid evaluation and was positive in all cases, 
with Perugini Grade 2 uptake in both patients with features of amyloidosis on CMR, 
and Perugini Grade 1 uptake in the two without.   
 
Figure 47: Outcome with occult amyloid 
Kaplan-Meier plot of cumulative survival comparing aortic stenosis patients (n=146) with 
ATTR amyloid on myocardial biopsy and those without. At median follow-up of 2.3 years 
(0.02-4.7 years), 11 patients with calcific aortic stenosis (AS) had died whereas all patients 
with bicuspid AS were alive. Three out of six cAS with wild-type ATTR amyloid (50%) died 
compared to 8 out of 106 (7.5%) in the remaining calcific AS cohort.  
6.1.5.4 Outcome 
As of 31st of December 2015, at median follow-up of 2.3 years (0.02-4.7 years), 11 
cAS patients had died whereas all of the bAS patients were alive. Three out of six 
cAS with wtATTR (50%) died compared to 8 out of 106 (7.5%) in the remaining cAS 
cohort, 7 out of 101 (6.9%) in those over the age of 65, and 8 out of 140 (5.7%) in 
overall cohort (Figure 51). Of all parameters assessed, the presence of ATTR 
amyloid had the highest hazard ratio for death (HR 9.5 [2.5-35.8], p=0.001, 
univariable Cox regression analysis, see Table 24).  
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cAS and bAS (n=146)   
p-value 
cAS only (n=112) p-value 
HR (95%CI) HR (95%CI) 
ATTR amyloid deposits 9.5 (2.5-35.8) 0.001 6.5 (1.7-24.7) 0.006 
Age (years) 1.1 (1.02-1.23) 0.02 1.1 (1.0-1.2) 0.18 
Gender 1.8 (0.5-6.9) 0.37 1.9 (0.5-7.2) 0.34 
Aortic Valve         
  Peak Velocity (m/sec) 0.5 (0.2-1.1) 0.09 0.5 (0.2-1.2) 0.11 
  Mean Gradient (mmHg) 0.96 (0.92-1.00) 0.06 0.96 (0.92-1.00) 0.07 
  Area, indexed (cm/m2) 0.42 (0.01-23.2) 0.7 0.6 (0.01-39.7) 0.8 
CMR parameters         
  LVEF (%) 0.97 (0.94-1.00) 0.07 0.97 (0.94-1.01) 0.1 
  LV mass, indexed (g/m2) 1.03 (1.00-1.52) 0.05 1.03 (1.01-1.06) 0.02 
  Myocardial Contraction 
Fraction (%) 0.04 (0.001-1.74) 0.1 0.07 (0.002-2.45) 0.14 
Blood parameters         
  NT-proBNP, pmol/L 2.1 (1.3-3.6) 0.004 2.2 (1.2-4.0) 0.006 
  eGFR, ml/min/1.73 m2 0.99 (0.97-1.03) 0.8 1.0 (0.9-1.0) 0.7 
 
Table 18: Univariate Predictors of Outcome.  
At median follow-up of 2.3 years (0.02-4.7 years), 11 calcific aortic stenosis (cAS) patients 
had died whereas all of the bicuspid aortic stenosis (bAS) patients were alive. Of all 
parameters assessed, the presence of ATTR amyloid had the highest hazard ratio for death 
(HR 9.5 [2.5-35.8], p=0.001, univariable Cox regression analysis). 
6.1.6 Discussion 
In this single centre study of 146 severe AS undergoing surgery, to which 70% of all 
patients undergoing surgery were recruited, cardiac amyloid deposits were found at 
biopsy in 6 cases.  All had wild-type ATTR (formerly senile systemic) amyloidosis.  
The youngest was 69, and all had calcific AS indicating a 6% prevalence of amyloid 
among this latter group. Comprehensive imaging was performed which showed a 
diagnostic hierarchy with non-contributory echocardiography, CMR detecting a third 
of cases, and cardiac DPD scintigraphy positive in all four patients who had this 
latter investigation.  Biopsy showing wtATTR amyloid deposits was prognostic and 
its presence was the strongest predictor of adverse outcome after surgical aortic 
valve replacement – suggesting that the presence of cardiac amyloid is a disease 
modifier in AS. Two aspects of the coexistence of wtATTR and AS stand out: 
incorrect interpretation of the severity of AS, and modification of outcome. First, 
wtATTR amyloid in patients with moderate AS may cause severe hypertrophy and 
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LV impairment, which can be misdiagnosed as severe AS (as low-flow-low-
gradient). This was highlighted by Rapezzi et. al. in a recent communication [248], 
who presented data on 43 elderly cAS patient with at least 1 “red flag” on 
echocardiography, performed DPD on 5 patients identified in this way (all positive) 
and confirmed diagnosis of wtATTR amyloid through biopsy and genotyping. 
Second, rather than leading to a misdiagnosis of severe AS, wtATTR amyloid may 
be a disease modifier, which exhibits a more severe phenotype with more heart 
failure and arrhythmias, and possibly amyloid involvement of other organ systems. 
 
Figure 48: Coexistent ATTR amyloid in severe aortic stenosis.  
Wild-type transthyretin cardiac amyloid (wtATTR) is a disorder of ageing individuals, and 
therefore may coexist in elderly patient with aortic stenosis (AS). Invasive diagnosis (A) of 
wtATTR is made by cardiac biopsy (stained with Congo red showing typical apple green 
birefringence [AGB]). In this study of 146 patients with severe AS undergoing surgical aortic 
valve replacement, coexistent wtATTR amyloid was found in 6% of elderly (age >65). 
Although echocardiography (B) was key for diagnosis and grading of AS, it was non-
contributory for the diagnosis of ATTR. Cardiac magnetic resonance (CMR) detected a third 
of cases (C), and cardiac scintigraphy with bone tracers (D) was diagnostic in all four 
patients studied (*two died prior). Dual pathology appeared to modify outcome (E) and may 
lead to incorrect interpretation of the severity of AS (Note: Cardiac figure adapted from 
Barone-Rochette JACC 2015 for illustration). 
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6.1.6.1 Implications for management of Aortic Stenosis 
Identification of cardiac amyloid is important for many reasons. The presentation of 
amyloid (LVH and diastolic then systolic function dysfunction) has substantial 
overlap with the changes of AS, particularly as systemic features are limited with 
only carpal tunnel syndrome as a common red flag [262]. Other traditional red flags 
(pericardial effusion, aortic valve thickening, concentric hypertrophy) are common in 
severe, symptomatic AS. Whilst it is possible that minor cardiac amyloid deposits 
might have no significant consequences in many individuals, the clinical syndromes 
caused by cardiac amyloid deposition of sufficient magnitude, i.e. overt cardiac 
amyloidosis of both ATTR and AL types, have a very poor prognosis from just 
months to a few years.  Accurate typing of amyloid is essential since chemotherapy 
directed towards the plasma cell dyscrasias underlying AL amyloidosis can prolong 
life, and several specific therapies for ATTR amyloidosis are now at late stage of 
clinical development [254, 255]. The consequences of isolated sub-clinical cardiac 
wtATTR amyloid deposits are unknown; here we focus on wtATTR and severe AS. 
Possible changes in clinical management could include minimizing bypass time 
during open valve surgery (e.g. by using rapid deployment valves), switching to 
TAVI and influence the fundamental decision regarding medical management 
versus intervention [263]. Interestingly, perioperative mortality was not affected by 
the presence of wtATTR. In addition, although there are few systematic data, clinical 
experience has suggested avoiding calcium channel blockers and digoxin in the 
presence of cardiac amyloid.  
6.1.6.2 ATTR amyloid and Heart Failure 
Wild-type ATTR amyloid is emerging as an unrecognized, important bystander and 
potential disease modifier not only in AS but also in Hypertrophic Cardiomyopathy 
(HCM) and Heart Failure with preserved Ejection Fraction (HFpEF). Historically the 
requirement for histology has been a major obstacle to elucidating the significance 
of cardiac ATTR amyloid, but the remarkable diagnostic capability of non-invasive 
bone scintigraphy has lately yielded much new information. A large Italian non-
selective endomyocardial biopsy study (n=4221 over 28 years) found amyloid 4% of 
cases [264]. More specific studies investigated autopsy specimens in a TAVI cohort 
in which amyloid was present in 5 out of 17 cases and thought to have contributed 
to progressive heart failure and the deaths of 3 patients [249], and examination of 95 
specimens obtained at septal myectomy for LV outflow tract obstruction with 
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congenital or acquired aortic stenosis in which 7% contained ATTR amyloid deposits 
[265]. Cardiac amyloidosis is also a differential diagnosis for hypertrophic 
cardiomyopathy, especially in patients with predominantly basal involvement and 
outflow tract obstruction. Incidental deposits of amyloid have been reported in 1% of 
surgical septal myectomy specimens from patients with HCM [266, 267]. 
Mohammed et. al. reported 17% prevalence of ATTR amyloid in HFpEF patients on 
autopsy with a substantial (80%) male predominance [268]. In contrast to this series 
and the wider clinical impression, half of the patients with amyloid in our cohort were 
female; this was also a finding in a recent cohort of HFpEF patients who were 
studied with DPD scintigraphy [269], suggesting that the incidence may be 
underestimated in females generally, possibly due to a lower frequency of extreme 
hypertrophy that serves as the main red flag. 
6.1.6.3 Relative strength of imaging modalities to identify amyloid 
Comprehensive imaging here showed a diagnostic hierarchy comprising non-
contributory echocardiography, CMR detecting a third of cases, and bone 
scintigraphy being diagnostic in all four patients studied. Bone scintigraphy (99mTc-
DPD or 99mTc-PYP)[172, 270] is an attractive, low cost modality with high sensitivity 
and specificity for cardiac ATTR amyloid. It is more practicable than cardiac biopsy 
for exclusion of ATTR amyloid in HCM, HFpEF and AS, and its sensitivity for occult 
ATTR amyloid appears to be greater than CMR. Focal myocardial uptake of these 
tracers may occur transiently following myocardial infarction, and diffuse uptake 
does occur in a small proportion of patients with cardiac amyloid of AL type.  
6.1.7 Limitations 
Our study has limitations: patients were recruited from a single cardiothoracic 
centre. The entry criterion was surgical AVR with no CMR contraindications leading 
to some under-representation of older patients (undergoing TAVI instead of sAVR), 
renal impairment and pacemaker patients (though in reality only 18 patients were 
excluded due to pacemaker [n=8] or eGFR<30 [n=10]). With a recruitment rate of 
76% of all sAVR performed for AS (81% had myocardial biopsy), the RELIEF-AS 
study was indeed representative of a surgical AVR cohort in a major UK 
cardiothoracic centre. DPD/PYP bone scintigraphy was not performed in all-comers 
due to limited availability at our centre at the start of the study, but should be part of 
any future studies. It is possible that other patients with wtATTR amyloid may have 
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died before their AS had been deemed severe enough to warrant intervention. Our 
echocardiographic analysis did not include strain rate imaging consistently (apically 
spared impaired longitudinal strain is characteristic of amyloid) – the markedly 
reduced GLS in two patients could have raised red flags at time of 
echocardiography. Finally, the study did not include a large proportion of Afro-
Caribbean individuals, 3-4% of whom possess the transthyretin V122I variant [271] 
that causes hereditary cardiac ATTR amyloidosis and up to 10% of hospital 
admissions for heart failure in this ethnic group in South London [272]. 
6.1.8 Future outlook 
The prevalence and adverse clinical outcomes here suggest that wtATTR amyloid is 
important in elderly individuals with AS. More work is needed.  TAVI is mostly 
performed in older age, where there is greater risk, worse renal function and more 
heart failure (reflected by higher EuroScore II and STS score). Biopsy for amyloid is 
not practicable but bone tracer scintigraphy could be used. The data here suggests 
it could have a routine role in selected patients and influencing their management in 
terms of decisions surrounding intervention, procedure performance and specific 
amyloid therapies. Wider use of cardiac scintigraphy with bone tracers, by detecting 
early amyloid, is likely also to improve our understanding of conventional testing, 
such as echocardiography.  
6.1.9 Conclusion 
Six percent of patients over the age of 65 undergoing surgical AVR for cAS had 
wtATTR amyloid deposits on cardiac biopsy, which was associated with poor 
outcome. There appears to be a hierarchy of imaging diagnostic performance for 
identification of wtATTR amyloid, with DPD bone tracer scintigraphy superior to 
CMR, which was superior to echocardiography. 
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Chapter 7 Results 3: Myocardial Fibrosis by CMR and Histology 
7.1.1 Preface 
With the work described in this chapter I won the Early Career Award (Translation) at the 
20th Annual Meeting of SCMR, Washington DC, 2017, and is based on the publication below:  
*Thomas A. Treibel, *Begoña López, *Arantxa González, Katia Menacho, Rebecca S. 
Schofield, Susana Ravassa, Marianna Fontana, Steven K. White, Carmelo DiSalvo, Neil 
Roberts, Michael T. Ashworth, Javier Díez, James C. Moon; Reappraising myocardial 
fibrosis in severe aortic stenosis: an invasive and non-invasive study in 133 patients. Eur 
Heart J 2017 ehx353. doi: 10.1093/eurheartj/ehx353. *equal contribution. 
This work is the result of a collaboration with Prof Javier Diez, Dr Arantxa Gonzalez and Dr 
Begona Lopez, CIMA, Pamplona, Spain. I conceived this study, recruited and scanned all 
the patients, collected 90% of the myocardial biopsies in theatre, coordinated the image and 
histological analysis. Rebecca Kozor performed the LV volume and function analysis. 
Rebecca Schofield performed the LGE analysis. Together with Dr Arantxa González and Dr 
Begoña López, I performed the statistical analysis and wrote the manuscript. I also 
discovered the gradient of fibrosis and thickening of the endocardium during research visits 
to Pamplona, Spain. Dr Katia Menacho, María González and Sonia Martínez performed the 
collagen volume fraction analysis and measurement of the endocardial thickness.  
7.1.2 Introduction 
In aortic stenosis (AS), patient symptoms and outcome are determined by the 
severity of the valve stenosis, but also by the myocardial response, particularly 
myocardial fibrosis (MF). Pathophysiologically, the myocardium is assessed 
histologically on tissue samples. It is believed that a complex interplay of cellular 
changes (including hypertrophy and cell death by apoptosis or autophagy), 
microvascular ischaemia, and alterations of the extracellular matrix occurs with final 
common pathways leading to MF. Most of the evidence for this has been from a few 
small biopsy or autopsy studies. Whereas autopsy descriptions of MF can provide a 
global view, in in-vivo studies, sampling is limited by biopsy size, and fibrosis is 
typically described only by the quantity of collagen deposition (collagen volume 
fraction, CVF). However, histological analysis of heart tissue also allows 
differentiation of fibrosis subtypes based on location and morphological 
characteristics of collagen deposits (focal microscopic scars, diffuse interstitial and 
perivascular strands), with the functional impact of MF not only depending on the 
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amount of collagen tissue, but also on the characteristics of collagen deposits [273]. 
Although new insights are being generated by imaging tissue characterisation (the 
late gadolinium enhancement [LGE] technique permits quantification of focal 
interstitial expansion [33, 55, 58, 103, 274], and diffuse interstitial expansion can be 
measured by extracellular volume fraction [ECV][109, 110, 120, 121]) the 
histological basis of LGE and ECV in AS and their association with fibrosis subtypes 
are only partly understood. 
7.1.3 Aims 
We investigated myocardial fibrosis (MF) in a large series of severe aortic stenosis 
(AS) patients using invasive biopsy and non-invasive imaging. We simultaneously 
and at scale assessed cardiac status in severe symptomatic AS patients by 
measuring functional capacity and blood biomarkers (cardiomyocyte stress/damage 
markers), by imaging structure and function (echocardiography and CMR), and by 
performing non-invasive (ECV and LGE) and histological (fibrosis location, pattern 
and CVF) tissue characterisation.   
7.1.4 Methods 
7.1.4.1 Study Cohort 
Details of AS patients are as described before. Control myocardial samples were 
obtained from autopsies of 10 subjects (7 male, 3 female; all Caucasian, age: 60±7 
years) who died of non-cardiovascular causes with no macroscopic and microscopic 
cardiac lesions.  
7.1.4.2 Cardiac Imaging 
Details of imaging acquisition by echocardiography and CMR as well as the imaging 
analysis have been described previously. 
7.1.4.3 Histomorphological Studies 
Biopsies were harvested under direct vision from the basal anteroseptum when the 
native valve was removed by one of six surgeons using either a 14-gauge coaxial 
needle system (Temno evolution, Carefusion, USA) or a surgical scalpel, as per 
surgeon’s choice (as per ethics) and fixed in 10% buffered formalin and embedded 
in paraffin. Histological analysis was performed blinded to clinical and imaging data. 
For MF, the fraction of myocardial volume with positive staining for collagen, CVF, 
was determined by quantitative morphometry (Cell^D, Olympus Soft imaging 
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Solutions GmbH, Münster, Germany) in sections stained with collagen-specific 
picrosirius red. All available myocardial tissue was analysed (average area was 
5.21±3.62 mm2/sample)[109]. Endocardial thickness was quantified as the mean 
value of 5 to 15 measurements. 
 
Figure 49: AS, myocardial hypertrophy and fibrosis by imaging and biopsy.  
Four exemplar patients with symptomatic severe aortic stenosis (AS) showing continuous-
wave Doppler echocardiography recordings through the aortic valve with maximum velocities 
>4m/s (AV Vmax, column 1), short axis SSFP cine stills in the left ventricular short axis 
demonstrating degrees of left ventricular hypertrophy (Cine; column 2), matching late 
gadolinium enhancement images (LGE, column 3), matching extracellular volume fraction 
images of the same short axis view (ECV, column 4), myocardial biopsy obtained during 
valve replacement and stained with picrosirus red (CVF, column 5).  Patient A has minimal 
LVH, no LGE, an ECV of 28.4% and minimal subendocardial fibrosis on biopsy (CVF 4.6%). 
Patient B has concentric LVH, patchy non-ischemic LGE, an ECV of 29.9% and moderate 
fibrosis on biopsy (CVF 19.3%).  Patient C has concentric LVH, widespread non-ischemic 
LGE, an ECV of 36.5%, and severe fibrosis on biopsy (CVF 24.5%). Patient D has mild 
concentric LVH, subtle subendocardial LGE (white arrow), an ECV of 24.5%, thickened 
endocardium and subendocardial scarring. Scale bars in the CMR imaging in columns 2-4 
are equivalent to 5 cm; the scale bars in the histology column are indicated in the image. 
7.1.4.4 Statistical Analysis 
As described in the main methods section 3.8. Log transformation was applied to 
normalise NT-proBNP and hs-TnT. The influence of potential confounding factors 
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(age, gender, history of coronary artery disease) used multivariate linear regression 
analysis. 
 
7.1.5 Results 
7.1.5.1 Baseline Characteristics 
The 133 patients with biopsy and no exclusion (cardiac amyloidosis n=6; Fabry 
Disease n=1) are shown in Table 14 [234]. 
7.1.5.2 Non-Invasive Assessment by CMR  
Focal fibrosis, measured by LGE, was commonly seen, affecting 71% of men and 
46% of women, with a similar split in ischemic vs non-ischemic split (males 19% vs 
59%; females 13% vs 37% - some had both). The pattern of non-ischemic LGE was 
patchy mid-myocardial (18%), RV insertion point (60%), papillary muscle (19%) 
and/or patchy focal (26%). Mean enhanced LV myocardial mass was 14.3±11.2 g 
(median 10.5 g; IQR 6.0-20.3 g). Extracellular volume fraction was 28.4±2.9%.  
7.1.5.3 Invasive Assessment by Biopsy 
There were 53 myocardial biopsies with endocardium (60% from scalpel versus 
29% from needle biopsies; p<0.01) and 80 samples with no identifiable 
endocardium. The endocardium was thickened due to collagen deposition in most 
biopsies, with a mean endocardial thickness of 228±129 microns versus 40±16 
microns in the control samples (p<0.001; Figure 50A). Subendocardial fibrosis was 
caused predominantly by microscars, whereas midmyocardial fibrosis was due to 
interstitial bands preferentially located around cardiomyocytes (Figure 50B).  
CVF was elevated in severe AS (11.5±8.6% vs 1.95±0.20% controls, p<0.001) and 
was higher in men than in women (12.9±8.8 vs 9.9±8.0%, p<0.05). Biopsies with 
endocardium showed higher CVF than biopsies without endocardium (15.0±12% vs 
8.99±6.7% p<0.001; Figure 3). Segmental analysis of endocardium-containing 
biopsies (in those structurally feasible; n=40) revealed a decreasing gradient of 
fibrosis from the endocardium, (20.4±11.3% vs 15.2±8.7% vs 13.0±7.8%, p<0.001 
and p<0.05 respectively; p for trend<0.01; Figure 51).  
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Figure 50: Patterns of fibrosis on histology 
A- Representative images of endocardial thickness in one control subject (left panel) and in 
two aortic stenosis patients in picrosirius red-stained sections. The green arrows point to the 
endocardium in the control sample. The black arrows show the thickness of the endocardium 
in AS patients. B- Detail showing interstitial fibrosis in the subendocardial region of one 
control subject (left panel) and microscars and interstitial fibrosis in two aortic stenosis 
patients in picrosirius red-stained sections.   
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Figure 51: Biopsies with endocardium showing a gradient of fibrosis.  
A- Collagen volume fraction in biopsies with and without endocardium. B- Collagen volume 
fraction in samples with endocardium divided in tertiles. Box plots show the 5th and 95th 
(vertical lines), 25th and 75th (boxes) and 50th (horizontal line) percentile values for collagen 
volume fraction. C- Representative images of 3 biopsies with endocardium (left panel needle 
and middle and right panel scalpel). D- Representative images of 4 biopsies without 
endocardium (needle). 
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7.1.5.4 Analysis of Associations  
LGE quantification correlated with CVF in all samples (r=0.50, p<0.001), but this 
association was stronger in endocardial containing samples (r=0.71, p<0.001; 
Figure 52). These associations were independent of age, gender and history of 
coronary artery disease.  
Figure 52: Association of LGE with collagen volume fraction.  
Late gadolinium enhancement (LGE) quantified in grams by a three standard 
deviation method correlated strongest with collagen volume fraction (CVF) in 
endocardial containing samples (linear fit: y= 0.814x + 3.109). 
 
CVF quantification was weakly associated with NT-proBNP (r=0.24, p<0.05) and hs-
TnT (r=0.27, p<0.01) levels in all patients. The correlation between CVF and NT-
proBNP improved slightly when we considered only the endocardial samples 
(r=0.35, p<0.05). These associations were lost when adjusting for confounding 
factors. 
With regards to LV structure and function, both LGE and ECV correlated with LV 
end-diastolic volume index (LVEDVi; r=0.20, p<0.05 and r=0.26, p<0.01, 
respectively), LV end-systolic volume index (LVESVi; r=0.26, p<0.01 and r=0.34, 
p<0.001, respectively) and LVEF (r=-0.24, p<0.01 and r=0.31, p<0.01, respectively); 
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but the associations were only independent of confounding factors for ECV. LGE 
was independently correlated with LVMi (r=0.30, p<0.01); ECV was not (p=0.06).  
With regards to biomarkers, both LGE and ECV were independently correlated with 
NT-proBNP (r=0.46, p<0.001 and r=0.55, p<0.001, respectively; Figure 53 A-B) and 
hs-TnT (r=0.45, p<0.001 and r=0.36, p<0.001, respectively; Figure 53 C-D).  
AS valve severity did not associate with CVF, endocardial thickness, LGE, ECV, NT-
proBNP levels or the degree of LV remodelling. Of LGE, ECV and CVF, only ECV 
correlated weakly with the patient functional limitation (6-minute-walk test distance 
[6MWT]; r=-0.21, p<0.05), but this association was lost when adjusting for 
confounding factors.  
 
 
Figure 53: Associations of imaging and blood biomarkers.  
Late gadolinium enhancement (LGE) and extracellular volume fraction (ECV) correlated with 
NT-proBNP (Panels A and B) and with hs-TnT (Panels C and D) (linear fit: A y= 0.119x – 
1.498; B y= 0.037x + 0.103; C y= 0.025x + 1.567; D y= 0.110x + 1.008).  
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  LGE    ECV 
  <10.5 g >=10.5 g   <28.4% >=28.4% (n=65) (n=66) (n=58) (n=58) 
Age (years) 68.8±10.4 71.7±8.8   70.3±10.0 70.1±9.7 
Gender (male/female) 28/37 45/21**   34/24 31/27 
BMI (kg/m2) 28.7±5.5 28.2±4.7   27.8±5.0 29.3±5.0 
Comorbidities, n (%)           
        HTN 44 (68%) 56 (89%)**   43 (75%) 49 (84%) 
        AF 6 (9%) 13 (20%)   7 (12%) 11 (19%) 
       CAD 13 (20.3%) 26 (40%)*   17 (29%) 20 (34%) 
Symptom, n (%)           
      Syncope 6 (9%) 4 (6%)   6 (10%) 4 (7%) 
      NYHA     
  
    
           I 8 (12%) 9 (14%) 8 (14%)     5 (9%) * 
          II 33 (51%) 28 (42%) 34 (59%) 24 (41%) 
          III 17 (26%) 23 (35%) 13 (22%) 21 (36%) 
         IV 2 (3%) 2 (3%) 0 (0%) 4 (7%) 
      Chest pain     
  
    
0 41 (63%) 39 (59%) 35 (60%) 37 (64%) 
1 3 (5%) 7 (11%) 5 (9%) 5 (9%) 
2 15 (23%) 8 (12%) 12 (21%) 4 (7%) 
3 4 (6%) 5 (8%) 4 (7%) 5 (9%) 
Valve type, bi/tri (n) 20/45 18/48   16/42 17/41 
AVAi (cm2/m2) 0.41±0.14 0.40±0.13   0.42±0.15 0.39±0.11 
Mean gradient (mmHg) 44.8±11.9 47.8±14.7   47.1±14 44.8±13 
Mitral regurgitation (%) 7.4±11.2 15.2±14.3*   9.1±12.7 11.5±12.9 
EDVi (mL/m2) 63.2±20.9 70.2±21.9*   61.0±19.1 71.4±24.7* 
ESVi (mL/m2) 19.0±15.6 25.6±20.7*   16.9±12.0 27.7±23.3** 
LVMi (g/m2) 83.9±27.5 90.7±20.7*   83.7±24.4 91.8±25.6 
LVEF (%) 72.4±13.2 67.1±15.4*   73.9±11.4 65.6±17.0** 
MAPSE (mm) 10.7±3.5 9.8±3.6   11.0±3.2 9.53±3.7* 
LAAi (cm2/m2) 12.7±3.3 14.5±4.2**   12.8±3.3 14.4±4.6 
E/A 0.91±0.42 1.08±0.58   0.87±0.38 1.10±0.59* 
DT (ms) 245±69 227±82   236±72 237±81 
E/e' 13.57±6.28 13.94±6.11   12.46±6.27 14.94±5.96* 
6MWT (m) 468±190 412±187   488±145 393±210** 
ECV (%) 27.5±2.6 29.5±2.8***   26.0±1.7 30.7±1.8*** 
LGE (g) 5.84±2.5 22.8±9.9   11.5±9.1 15.4±12.2 
CVF (%) 7.3±4.7 15.7±9.8***   10.4±7.5 10.9±8.5 
NT-proBNP (pg/mL) 96±139 277±341***   99±154 262±335*** 
hs-TnT (ng/L) 15±10 21±20**   15±13 21±18* 
 
Table 19: Patients stratified according to LGE or ECV median value.  
LGE means late gadolinium enhancement; ECV, extracellular volume; BMI, body mass index; HTN, hypertension; 
AF, atrial fibrillation; CAD, coronary arterial disease; EDVi, end-diastolic volume index; ESVi, end-systolic volume 
index; LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction; MAPSE, Mitral annular plane 
systolic excursion; LAAi, left atrial area index; E, peak early velocity of the transmitral flow; A, peak late velocity of 
the transmitral flow; DT, deceleration time; E´, peak early diastolic velocity of the mitral annulus displacement; 
6MWT, 6-minute-walk test; bi, bicuspid; tri, tricuspid; AVAi, aortic valve area index; CVF, collagen volume fraction; 
NT-proBNP, N-terminal pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T. Values are given as mean 
± SD or n (and percentage). *, P<0.05; **, P<0.01; ***, P<0.001 vs. patients with LGE<10.5 or ECV<28.4%, 
respectively. 
7.1.5.5 Clinical and Structural Impact of LGE and ECV Stratification 
To compare LGE and ECV with clinical and structural parameters, we dichotomized 
the variables (above and below median: 10.5 g for LGE, 28.4% for ECV) with results 
shown in Table 19. Patients with high versus low LGE had more advanced LV 
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remodelling with higher LVESVi, LVEDVi, LV mass index, left atrial area index 
(LAAi), lower LVEF (all p<0.01) and more mitral regurgitation (p<0.05). High LGE 
patients had a higher prevalence of hypertension (p<0.01) and coronary artery 
disease (p<0.05). In accordance with the association analysis, these patients 
presented higher CVF values (p<0.001), NT-proBNP  (p<0.001) and hs-TnT 
(p<0.01) levels. 
Patients with high vs low ECV also had greater LV remodelling with increased 
LVEDVi (p<0.05), LVESVi (p<0.01) and lower LVEF (p<0.01). Although the LAAi 
was not significantly different (p=0.08), diastolic function was worse (E/A and E/e’ 
ratio, p<0.05). Moreover they also had an impaired 6MWT and a higher NYHA 
functional class. In accordance with the association analysis these patients 
presented higher NT-proBNP  (p<0.001) and hs-TnT (p<0.05) levels. 
Combining LGE and ECV added value (Table 20). With increasing abnormality in 
these parameters, cavity dimensions (LVEDVi, LVESVi, LAAi) increase, LVEF 
decreases, NT-proBNP and hs-TnT levels increase, CVF increases, and patient 
functional capacity (6MWT) decreases (p<0.05).  
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  ECV-/LGE- ECV-/LGE+ & ECV+/LGE- ECV+/LGE+ 
P for 
trend 
  (n=37) (n=46) (n=32)   
Age (years) 68.6±11.0 71.4±9.0 70.4±9.8   
Gender (male/female) 19/18 24/22 22-Oct   
BMI (kg/m2) 28.3±5.3 28.4±5.4 29.0±4.5   
Comorbidities, n (%)         
        HTN 24 (65%) 38 (83%) 29 (91%) <0.05 c2=6.41 
        AF 3 (8%) 7 (15%) 8 (25%)   
       CAD 6 (16%) 17 (37%) 13 (41%) 0.063 c2=5.53 
Symptom, n (%)         
      Syncope 5 (14%) 2 (4%) 3 (9.7%)   
      NYHA       
  
           I 5 (14%) 6 (13%) 2 (6%) 
          II 24 (65%) 17 (37%) 16 (50%) 
          III 16 (43%) 18 (39%) 10 (31%) 
         IV 0 (0%) 2 (4%) 2 (6%) 
      Chest pain       
  
0 23 (62%) 27 (59%) 21 (66%) 
1 2 (5%) 4 (9%) 4 (13%) 
2 9 (24%) 9 (20%) 5 (16%) 
3 1 (3%) 6 (13%) 2 (6%) 
Valve type, bi/tri (n) Dec-25 Dec-34 Sep-23   
AVAi (cm2/m2) 0.42±0.16 0.40±0.12 0.39±0.13   
Mean gradient (mmHg) 45.2±14.1 46.7±11.2 45.8±16.6   
Mitral regurgitation (%) 6.8±12.3 10.3±11.4 15.1±15.2 <0.05 
EDVi (mL/m2) 59.5±20.8 66.8±18.7 73.9±27.2* <0.01 
ESVi (mL/m2) 15.5±11.3 22.5±17.1 30.5±25.9** <0.005 
LVMi (g/m2) 81.8±26.5 87.3±26.1 95.7±20.9* <0.05 
LVEF (%) 75.4±9.4 69.0±15.0 63.6±17.4** <0.005 
MAPSE (mm) 11.3±3.2 10.1±3.5 9.2±3.8* <0.05 
LAAi (cm2/m2) 12.4±3.3 13.3±3.1 15.6±5.2** <0.005 
E/A 0.84±0.26 0.97±0.54 1.24±0.63** <0.005 
DT (ms) 240±68 243±76 220±88   
E/e' 13.09±6.83 13.04±5.47 15.60±6.51   
6MWT (m) 512±136 420±207 391±188** <0.05 
ECV (%) 25.6±1.6 28.7±2.1 31.2±1.9*** <0.001 
LGE (grams) 6.01±2.48 12.64±9.67 23.16±11.22*** <0.001 
CVF (%) 7.84±5.01 10.26±8.03 14.45±9.45** <0.005 
NT-proBNP (pg/mL) 60±90 160±189 342±394*** <0.001 
hs-TnT (ng/L) 13.5±14.5 17.5±12.2 23.6±20.4** <0.01 
 
Table 20: Patients stratified according to ECV and LGE combined.  
LGE means late gadolinium enhancement; ECV, extracellular volume; BMI, body mass index; HTN, hypertension; 
AF, atrial fibrillation; CAD, coronary arterial disease; EDVI, end-diastolic volume index; ESVI, end-systolic volume 
index; LVMI, left ventricular mass index; LVEF, left ventricular ejection fraction; MAPSE, Mitral annular plane 
systolic excursion; LAAi, left atrial area index; E, peak early velocity of the transmitral flow; A, peak late velocity of 
the transmitral flow; DT, deceleration time; E´, peak early diastolic velocity of the mitral annulus displacement; 
6MWT, 6-minute-walk test; bi, bicuspid; tri, tricuspid; AVAi, aortic valve area index; CVF, collagen volume fraction; 
NT-proBNP, N-terminal of pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T. Values are given as 
mean ± SD or n (and percentage). *, P<0.05; **, P<0.01; ***, P<0.001 vs patients with ECV-/LGE- 
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7.1.6 Discussion 
In this, the largest prospective AS biopsy and multimodality imaging/biomarker study 
to date, the main findings are: (1) Histological assessment of the myocardium in 
severe AS revealed three patterns of fibrosis: thickened endocardium with a 
massive fibrotic layer; a fibrosis gradient in the subendomyocardium from superficial 
to deep regions with abundant microscopic scars; and diffuse interstitial fibrosis. (2) 
The main parameters here assessed captured different aspects of MF: CVF best 
captures the transmural gradient of fibrosis and microscars; LGE captures mainly 
microscars; and ECV appears to capture interstitial changes in the mid-myocardium. 
(3) The combination of LGE and ECV identified better those AS patients presenting 
with more adverse LV remodelling, more altered blood biomarkers and histological 
parameters, and a more reduced functional capacity than each parameter alone. 
These findings were independent of the presence of CAD. 
 
Figure 54: Myocardial fibrosis in AS.  
 
7.1.6.1 Biopsy findings 
In the last 40 years, several studies have described MF as histological hallmark of 
severe AS, documenting relevant clinical correlations and an important prognostic 
role [58, 273, 275-279]. However, detailed and systematic histological evaluation of 
the morphological characteristics of MF in severe AS are lacking. 
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We report the existence of a decreasing collagen gradient from endocardium to the 
mid-myocardium in severe AS, supporting prior studies [275, 276]. Importantly, the 
scalpel biopsies showed this better than needle biopsies as they have higher yield 
of endocardium (needed to orientate the sample).  
The different patterns of collagen in severe AS may have different pathogenic 
mechanisms and possible consequences. Most collagen deposits exist as a 
thickened endocardial layer and subendocardial scattered microfoci and trabecular 
fibrosis. Mid-myocardial fibrosis appears as a diffuse network around 
cardiomyocytes and bundles. The fibrosis gradient may be related to low 
endocardial perfusion [276], thus reflecting a reparative response (i.e., replacement 
fibrosis) to ischemia and subsequent cell loss. This is supported by previous 
findings showing that reduced capillary density, in absolute terms as well as in 
relation to the number of cardiomyocytes, accompanies MF in patients with severe 
AS [280]. On the other hand, the diffuse MF located around cardiomyocytes may be 
reactive to pressure overload-induced mechanical stimulation of local fibroblasts, as 
well as to paracrine factors produced by mechanically-stressed (strain) 
cardiomyocytes that, in turn, stimulate fibroblasts (i.e., reactive fibrosis) [281].  
7.1.6.2 CMR Findings 
CMR tissue characterisation has developed over two decades, initially with the LGE 
technique for focal fibrosis [33, 55, 58, 103, 274], later with the ECV technique for 
diffuse fibrosis [109, 110, 119-121]. Combined biopsy and CMR study are rare and 
limited by small sample size. Instead, myocardial tissue characterisation in AS has 
been described by presence or absence and pattern of LGE (subendocardial infarct 
vs mid-wall non-infarct LGE). In the light of these histological findings of thickened 
endocardium and a gradient of myocardial fibrosis from endo- to epicardium suggest 
that these descriptive LGE pattern need to be revisited, possibly by utilizing the 
latest motion-correction or dark blood techniques [282]. 
Here, LGE correlated with CVF (although the biopsy was obtained from the basal 
anteroseptum which was not infarcted in any patient), especially on endocardial 
biopsies (r=0.7), which capture more of the subendocardial microscars. The ECV 
was only mildly elevated with broadly proportional increase in the cellular and 
extracellular components of the myocardium (as observed by Schwarz et al in 1978) 
[275], and, unlike other papers,, did not correlate with CVF. However, ECV is 
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capturing functionally important consequences, given that patients with high ECV 
showed worse NT-ProBNP, 6MWT and NYHA functional class [109, 110, 119-121]. 
There are a number of possible reasons for this discordance with other studies 
including the underestimation of subendocardial microscar and fibrosis gradient due 
to avoidance of the endo- and epicardium (for ECV we eroded 10% from the edge to 
avoid blood pool contamination); recruitment of a less severe (more representative) 
phenotypes with less extensive scarring (we recruited 50% of all AVR in our 
institution); reduced capillary density (lower ECV) or compensatory vasodilatation 
(higher ECV) may confound ECV measurements, which captures all extracellular 
space including the intravascular plasma [161, 165].  
We suspect that LGE is a marker of the reparative fibrotic response to 
cardiomyocyte injury and loss. On the other hand, diffuse reactive interstitial fibrosis 
is intimately linked to its local environment and depends on cardiomyocyte function, 
strain and the cardiomyocyte-fibroblast interaction. ECV may therefore be more 
closely linked to the cardiomyocyte functional stress, and accordingly could be 
considered more a measure of cardiomyocyte-interstitial relationship than the 
current mainstream concept of ECV being a pure interstitial marker.  
 
7.1.6.3 Clinical Impact 
MF in severe AS has a characteristic pattern and distribution. When measuring by 
biopsy or CMR, location, sampling and technical aspects of analysis matter. 
Invasive biopsy is limited by size and sampling error, whereas LGE and ECV 
capture different regions of myocardium and provide complementary information. 
Both ECV and LGE track cardiomyocyte stress (NT-proBNP) and injury (hs-TnT). 
LGE is known to track troponin concentrations in AS which has been associated 
with advanced hypertrophy, replacement fibrosis and outcome [283]. Data on BNP 
vs ECV in AS is lacking. Blood biomarkers reflect “whole heart” cardiomyocyte 
stress and injury, but need to be interpreted in conjunction with structural and 
functional parameters from non-invasive imaging, as they can be elevated due to 
other causes. Imaging biomarkers LGE and ECV offer global but also regional 
insights. The combination of LGE and ECV – a multi-parametric approach – better 
identified worse adverse LV remodelling, altered biochemical and histological 
parameters, and functional capacity than each parameter alone. Timing of aortic 
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valve intervention is one of the challenges in AS, in particular in asymptomatic 
patients. Recent focus has turned towards the complex interplay between the 
degree of the valve stenosis, hemodynamic load and myocardial response. The 
combination of LGE and ECV may prove to help in a better understanding of this 
interplay. 
7.1.6.4 Strengths and Limitations 
This is the largest combined histology-multimodality imaging study in AS, with even 
sub-groups larger then previous small (n<20) validation studies. The analysis of the 
imaging and histological data was performed completely blinded by independent 
groups. To make this study as applicable as possible, we recruited all-comers (50% 
of all AVR for AS in our institution) rather then the severe end of the spectrum and 
thereby included patient with CAD, hypertension and diabetes. The effect of CAD 
was adjusted for as detailed in the methods. Furthermore, the location of the biopsy 
(basal anteroseptum) was never infarcted in this study. To achieve a standardized 
biopsy procedure, all biopsies were obtained under direct vision from the basal 
anteroseptum by a team of experienced surgeons using either a scalpel or needle 
technique. 
7.1.7 Conclusion 
In conclusion, this study supports that the combination of invasive and non-invasive 
techniques at scale is relevant to better characterize MF in severe AS patients. 
Whereas CVF best captures the transmural gradient of fibrosis and microscars, LGE 
appears to capture mainly microscars. ECV captures mid-myocardium-related 
functional changes beyond LGE. Importantly, the combination of LGE and ECV 
allows a better phenotyping of AS patients according to their myocardial structural 
and functional response to AS.   
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Chapter 8 Results 4: Fibrosis Regression after Valve Replacement 
8.1.1 Preface 
At time of printing of this thesis, a version of this section was under peer review.  
Thomas A Treibel, Rebecca Kozor, Rebecca Schofield, Giulia Benedetti, Marianna 
Fontana, Amir Sheikh, Begoña Lopez, Arantxa Gonzalez, Charlotte Manisty, Guy Lloyd, 
Peter Kellman, Javier Díez, James C Moon. Reverse Myocardial Remodeling in Aortic 
Stenosis: Cellular Hypertrophy and Diffuse but not Focal Fibrosis Regress Following Aortic 
Valve Replacement 
My contribution was recruiting, consenting and performing the scans of all patients. I 
performed the T1 mapping analysis as first operator, performed quality control on LV volume 
and function as well as LGE analysis, I performed the statistical analysis and wrote the 
paper. RK performed the LV volume and function analysis. RS performed the LGE analysis.  
8.1.2 Introduction 
Following aortic valve replacement (AVR; surgical or transcatheter), LVH regresses 
by 20% to 30% by 1 year [37-41]. Whether this regression is cellular or interstitial 
has until recently been hard to differentiate because it requires paired biopsies for 
histology. ECV dichotomizes myocardium into cellular (myocytes, fibroblast, 
endothelial, red blood cells) and extracellular (extracellular matrix, blood plasma) 
compartments (see Figure 55) [109, 284, 285], and offers the opportunity to track 
dynamic changes in the cell and matrix compartments. In AS, outcome is predicted 
not only by LVH at baseline or its regression post AVR [26, 28, 29, 39], but also by 
focal (using LGE) [55, 58, 103], and diffuse fibrosis (using ECV) [286]. Histological 
studies show that myocardial fibrosis accompanies cellular hypertrophy,[275] and 
limited invasive studies suggest both may regress after AVR [45]. We hypothesised 
that human myocardial fibrosis is plastic and can regress, and that this regression 
can be measured non-invasively.  We used patients pre and post AVR as a natural 
model of afterload reduction, measuring the valve gradient reduction by 
echocardiography, LVH by CMR cine imaging, focal fibrosis by LGE, DMF and cell 
hypertrophy by ECV, plus the functional consequences of AVR by NYHA functional 
class, 6-minute-walk test and blood biomarkers. 
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Figure 55: ECV dichotomizes the myocardium into cell and matrix. 
A- The in-vivo myocardium consists of cells and the surrounding extracellular matrix. 
Reactive fibrosis is characterized by expansion of the extracellular matrix, whereas 
replacement fibrosis follows cell death by focal scar. B- Cardiovascular magnetic resonance 
(CMR) measures both focal fibrosis (scar) by late gadolinium enhancement (LGE) imaging, 
where scar appears bright, and diffuse fibrosis by extracellular volume fraction (ECV) 
imaging. ECV divides the myocardium into cell and matrix compartments and allows 
calculation of cell and matrix volumes. C- A patient with a left ventricular volume of 100mL 
and an ECV of 25% would have a cell volume of 75mL and a matrix volume of 25mL. 
Regression of left ventricular mass following aortic valve replacement can either be driven by 
matrix regression alone, where the ECV reduces; by cellular regression alone, where the 
ECV increases; or by a proportional regression in cellular and matrix compartments, where 
the ECV is unchanged. 
8.1.3 Methods 
Total LV matrix and cell volumes were calculated from the product of LV myocardial 
volume (LVM divided by the specific gravity of myocardium [1.05g/mL]) and ECV or 
(1- ECV), respectively – see Figure 55.  
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8.1.3.1 Statistics 
As described before in Statistical Analysis 3.8. Changes between pre- and post AVR 
visits were compared using paired t-tests for continuous variables and using Wilcox 
signed rank test for categorical variables. Log transformation was applied to 
normalize the distribution of NT-proBNP and hsTnT. To identify predictors of matrix 
regression, all clinical parameters were proposed for inclusion in a univariate linear 
regression model and the most significant predictors per domain were then entered 
into a forward stepwise multivariable model to identify significant independent 
predictors. A two-sided p-value of <0.05 was considered significant. 
8.1.4 Results 
8.1.4.1 Study population 
A total of 181 patients with severe, symptomatic AS (age 69±10, 56% male) were 
recruited. Overall 48% of patients undergoing surgical AVR for severe AS at our 
institution were recruited (Figure 56 for flowchart). Three patients did not undergo 
AVR and were treated medically. Following AVR, 14 patients were excluded 
(cardiac amyloid n=6 [234], claustrophobia n=4, severe mitral regurgitation n=2, 
pseudo-severe AS n=1, Fabry disease n=1). By one year, there were 11 deaths, 16 
patients with pacemakers and 21 declined follow-up. A total of 116 patients 
underwent 1-year follow-up assessment and were included in the analysis (for Study 
Flowchart see Figure 2). There was no significant difference in baseline 
characteristics between patients that completed the follow-up and those that did not, 
in particular with regards to age, sex, aortic valve stenosis severity or surgical risk 
score (all p>0.05).  
8.1.4.2 Baseline Findings 
Baseline demographic, clinical, echocardiographic and CMR characteristics of the 
follow-up study cohort (n=116) are shown in Table 21 and Table 22, respectively. 
Valve Stenosis Severity. All patients had severe AS by echocardiography (AVAi 
0.40±0.13cm2/m2; mean gradient 48±14mmHg, peak velocity 4.4±0.6m/sec). The 
etiology of AS was determined as calcific AS (n=83, 72±8years; 52% male), bicuspid 
AS (n=32, 59±6years; 66% male) and unicuspid AS (n=1, 35-year-old female) by a 
combination of echocardiography, CMR and direct inspection during surgery.  
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Symptoms and functional capacity. All but seven patients were symptomatic 
(94%) with dyspnea (95%), chest pain (32%) and/or syncope (8%). Median 6MWT 
distance was 500m (IQR 390-600m).  
 
Figure 56: Study Flow Chart.   
181 patients with severe, symptomatic aortic stenosis (AS) were recruited (48% of all 
surgical aortic valve replacements [AVR] at our institution [UCL]). Prior to AVR, 10 patients 
were excluded (claustrophobia n=4, cardiac amyloid n=2, severe mitral regurgitation n=2, 
pseudo-severe AS n=1, Fabry disease n=1), and three patients did not undergo AVR and 
were treated medically. Following AVR (164 surgical, 4 transcatheter), four further patients 
were excluded due to cardiac amyloid. By one year, there were 11 deaths, 16 patients with 
pacemakers and 21 declined follow-up. A total of 116 patients underwent 1-year follow-up 
assessment.  
8.1.4.3 Intervention 
The AVR was carried out using cardiopulmonary bypass with blood cardioplegia 
arrest. The valve received was a tissue (n=103, 61%), sutureless (n=7, 4%) or 
mechanical valve (n=54, 32%), with additional bypass grafting in 30 patients (24%) 
and intervention on the aorta in 11 (7%; interposition graft, reduction aortoplasty, 
replacement of the ascending aorta). Mean bypass and cross-clamp times were 
91±26 and 72±25 minutes, respectively. Four patients initially referred for surgical 
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valve replacement underwent transcatheter AVR after review by the heart valve 
team, and were included in the final analysis.  
  Total Men Women p-value 
n 116 63 (%) 53 (%)  
Age 70±10 68±11 71±8 0.1 
Trileaflet* 83 40 (63%) 43 (81%) 
 Bicuspid* 33  23 (37%) 10 (19%) 0.04 
BSA (m2) 1.90±0.22 2.00±0.20 1.77±0.16 <0.001 
Six minute walk test (m) 500 (390-600) 540 (420-660)   435 (240-510) <0.001 
NYHA Functional Class 2.3±0.7 2.1±0.6 2.4±0.7 0.02 
Co-morbidities        
Hypertension 75% 79% 71% 0.3 
   SBP (mmHg) 133±17 129±17 137±16 0.005 
   DBP (mmHg) 76±10 74±9 77±12 0.2 
Diabetes 20% 21% 19% 0.8 
Coronary artery disease 29% 35% 21% 0.09 
Risk Scores        
STS, (%) 1.3 (1.0-2.1) 1.1 (0.8-1.9) 1.7 (1.1-2.4) 0.02 
EuroScoreII (%) 1.4 (1.0-2.4) 1.1 (0.8-2.3) 1.7 (1.1-2.5) 0.05 
Drug History        
ACE-I / ARB  44% 55%  31% 0.01 
Beta-blocker 37%   37%  37% 0.9 
Statin  64%  65% 63%  0.9 
Aspirin  44%  50% 37%  0.2 
Blood        
NT-proBNP (ng/L) 50 (26-173) 91 (31-266) 40 (25-105) 0.01 
hs-Troponin T (pmol/L) 13 (9-19) 15 (11-22) 12 (7-17) 0.12 
Creatinine (µmol/L) 85±26 95±27 73±18 <0.001 
eGFR (mL/min/1.73m2) 77±21 78±21 76±22 0.6 
Hematocrit, % 40.4±4.5 41.7±4.6 38.8±3.7 <0.001 
 
 
Table 21: Baseline Clinical Characteristics 
*one patient had unicupid AS (female). Values are given as mean ± SD, median (and interquartile range) or n (and 
percentage).BSA means body surface area; SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, 
New York Heart Association; IQR, interquartile range; STS, Society of Thoracic Surgeons' risk model score; 
EuroScoreII, European System for Cardiac Operative Risk Evaluation II score; ACE-I, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin-receptor blocker; LVH, left ventricular hypertrophy; NT-proBNP, N-terminal pro-
brain natriuretic peptide; hs-TnT, high sensitivity troponin T; eGFR, estimated glomerular filtration rate. 
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  Total Men Women p-value 
Echocardiography         
Vmax (m/s) 4.4±0.6 4.4±0.6 4.3±0.6 0.5 
Peak gradient (mmHg) 77±20 78±21 76±19 0.7 
Mean gradient (mmHg) 48±14 49±15 47±13 0.5 
AVA (cm2) 0.75±0.26 0.77±0.29 0.72±0.23 0.2 
AVAi (cm2/m2) 0.40±0.13 0.38±0.13 0.41±0.13 0.4 
LVOT:Aortic valve VTI ratio 0.23±0.08 0.21±0.09 0.24±0.09 0.07 
E-wave (m/s) 0.83±0.29 0.80±0.29 0.87±0.29 0.2 
E/A ratio 0.94±0.49 1.00±0.29 0.87±0.29 0.2 
E deceleration time (ms) 234±72 228±74 240±69 0.4 
Mean e' (m/s) 6.5±2.1 6.7±2.1 6.1±2.0 0.2 
E/e' ratio 13.2±5.8 12.8±5.8 13.8±5.7 0.4 
CMR parameters         
LVEDVi (mL/m2) 66±23 72±24 59±20 0.001 
LVESVi (mL/m2) 22±21 27±23 16±17 0.008 
LVEF (%) 71±16 67±17 75±13 0.003 
LVMi (g/m2) 88±26 101±25 73±20 <0.001 
Septal wall thickness (mm) 14±3 15±3 13±2 <0.001 
Left ventricular diameter (mm) 49±7 52±7 46±6 <0.001 
Mass:Volume Ratio 1.42±0.37 1.50±0.42 1.33±0.29 0.01 
LAAi_preop (cm2/m2) 13.2±3.0 13.4±3.2 12.9±2.6 0.4 
CMR flow         
Aortic regurgitant fraction (%) 10 (3-29) 13 (4-46) 9.0 (2-23) 0.09 
Mitral regurgitant fraction (%) 5 (0-20) 0 (0-21) 5.9 (0-20) 0.9 
Tissue Characterization         
LGE 3SD method (g) 12.4±10.3 15.1±11.1 9.2±8.1 0.002 
T1 myocardium (native; ms) 1039±40 1036±39 1043±40 0.4 
ECV (%) 28.2±2.9 28.6±3.2 27.6±2.4 0.09 
Cell volume (mL/m2) 64±18 72±17 53±17 <0.001 
Matrix Volume (mL/m2) 25±9 29±9 20±7 <0.001 
 
 
Table 22: Baseline Imaging Characteristics 
Values are given as mean ± SD, median (and interquartile range) or n (and percentage). Vmax, peak velocity 
through the aortic valve; AVAi, aortic valve area index; LVOT, left ventricular outflow tract; VTI ratio, velocity-time-
integral ratio; Zva, valvulo-arterial impedance; E, peak early velocity of the transmitral flow; DT, deceleration time; 
E´, peak early diastolic velocity of the mitral annulus displacement; EDVi, end-diastolic volume index; ESVi, end-
systolic volume index; LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction; SVi, stroke volume 
index, LAAi, left atrial area index; LGE, late gadolinium enhancement; 3SD, three standard deviations; ECV, 
extracellular volume. 
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8.1.4.4 Follow-up 
At 1-year post-AVR, there was a marked afterload reduction (valve gradient reduction 
48±16 to 12±6mmHg, p<0.001). Patients were less breathless (NYHA functional class 
improved by nearly one class [p<0.001]) and could walk further (6MWT improvement 
90m; p<0.001). In addition, both left atrial pressure, reflected by a reduction in E/e’ 
ratio (13±6 to 11±4 cm/s, p=0.003) and NT-proBNP levels reduced (50 (IQR 26-173) to 
38 (IQR 23-99) ng/L; <0.001). The changes in pre- to post-operative parameters are 
summarized in  
Table 23. There were no significance differences in these parameters in patients 
undergoing isolated AVR versus patient undergoing AVR+CABG. 
 
Figure 57: Left ventricular remodelling 1-year after aortic valve replacement. 
At 1-year post aortic valve replacement (AVR), there was a 19% reduction in indexed left 
ventricular mass (88±26g/m2 to 71±19g/m2, p<0.001; panel A). Focal fibrosis (LGE) did not 
change at follow-up. Calculated ECV increased unexpectedly (28.2±2.9 to 29.9±4.0%, 
p<0.001; panel B). This was because the 16% reduction in matrix volume (25±9 to 
21±7ml/m2, p<0.001; panel D) was proportionately less than the 22% reduction in cell 
volume (64±18 to 50±13ml/m2, p<0.001; panel C).  
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8.1.4.5 LV mass, cellular hypertrophy and myocardial fibrosis changes 
There was a 19% reduction in indexed LV mass (88±26g/m2 to 71±19g/m2, p<0.001) 
as well as a reduction in LVEDVi and LVESVi, resulting in a reduction in the mass-
volume-ratio. LVEF increased modestly (71±16 to 74±12%, p<0.006). LV mass 
regression occurred regardless of the baseline level of hypertrophy (i.e. also in 
patients with normal geometry), though both absolute and percentage LVMi 
regression were greatest in those patients with the highest LVMi at baseline.  
Calculated ECV increased unexpectedly (28.2±2.9 to 29.9±4.0%, p<0.001). This 
was because the 16% (4.1±5.8ml/m2) reduction in matrix volume (25±9 to 
21±7ml/m2, p<0.001) was proportionately less than the 22% (14.0±11.6ml/m2) 
reduction in cell volume (64±18 to 50±13ml/m2, p<0.001; see Figure 57). Native 
myocardial T1 was unchanged (1039±40 vs 1035±42ms, p=0.3). Focal fibrosis in 
absolute terms (LGE in grams) did not change at follow-up (12.4±10.3 vs 12.6±8.9g, 
p=0.9), but expressed as a percentage of the regressed LV mass, focal fibrosis 
(LGE as %) increased post-AVR (7.2±5.1 vs 8.9±4.9%, p=0.001). Therefore, both 
DMF and cardiomyocyte hypertrophy decreased after AVR, whereas focal fibrosis 
(LGE) remained comparable to findings at baseline. There were no differences in 
ECV, cell or matrix volume changes according to CAD status. 
At univariate analysis, matrix regression was associated with baseline LV 
parameters (LV size, hypertrophy, systolic and diastolic function), baseline 
biomarkers (hs-TnT and NT-proBNP) and post-operative changes LV parameters, 
biomarkers as well as change in valve size and haemodynamics (Table 24). At 
multivariate analysis, matrix regression was only independently associated with 
baseline LVMi and ECV, as well as improvement in LVEF, hs-TnT level and indexed 
valve area (Table 25). 
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n=116 Pre-AVR Post-AVR p-value 
NYHA functional class 2.3±0.7 1.4±0.6 <0.001 
Six minute walk test (m) 477±177* 571±171 <0.001 
NT-proBNP (ng/L) 50 (26-173) 38 (23-99) <0.001 
hs-Troponin T (pmol/L) 13 (9-20) 11 (7-17) 0.002 
Echocardiography    
Vmax (m/s) 4.4±0.6 2.4±0.5 <0.001 
Peak gradient (mmHg) 77±20 24±11 <0.001 
Mean gradient (mmHg) 48±14 13±6 <0.001 
EOAi (cm2/m2) 0.40±0.13 0.84±0.21 <0.001 
LVOT:Aortic valve VTI ratio 0.23±0.08 0.51±0.12 <0.001 
E-wave (m/s) 0.83±0.29 0.83±0.23 0.2 
E/A ratio 0.94±0.49 0.91±0.26 0.6 
E deceleration time (ms) 234±72 242±67 0.7 
Mean E/e' ratio 13.2±5.8 10.8±4.2 0.001 
Zva (mmHg/ml*m2) 4.3±1.2 3.6±0.9 <0.001 
CMR parameters    
LVEDVi (mL/m2) 66±23 62±19 0.03 
LVESVi (mL/m2) 22±21 18±13 0.003 
LVEF (%) 71±16 74±12 0.006 
LVMi (g/m2) 88±26 71±19 <0.001 
Myocardial contraction fraction (%) 52±15 65±16 <0.001 
Mass:Volume Ratio 1.42±0.37 1.19±0.27 <0.001 
LAAi (cm2/m2) 13.2±3.0 12.1±2.2 0.09 
Tissue characterization    
LGE 3SD method (g) 12.4±10.3 12.6±8.9 0.9 
LGE 3SD method (%) 7.2±5.1 8.9±4.9 0.001 
T1 myocardium (native, in ms) 1039±40 1035±42 0.3 
ECV (%) 28.2±2.9 29.9±4.0 <0.001 
Cell volume, indexed (mL/m2) 64±18 50±13 <0.001 
Matrix Volume, indexed (mL/m2) 25±9 21±7 <0.001 
 
Table 23: Changes in Baseline Characteristic after Aortic Valve Replacement. 
 
	 	 	*n=85; Values are given as mean ± SD, median (and interquartile range) or n (and percentage). Vmax, 
peak velocity through the aortic valve; AVAi, aortic valve area index; LVOT, left ventricular outflow 
tract; VTI ratio, velocity-time-integral ratio; Zva, valvulo-arterial impedance; E, peak early velocity of the 
transmitral flow; DT, deceleration time; E´, peak early diastolic velocity of the mitral annulus 
displacement; EDVi, end-diastolic volume index; ESVi, end-systolic volume index; LVMi, left ventricular 
mass index; LVEF, left ventricular ejection fraction; SVi, stroke volume index, LAAi, left atrial area 
index; LGE, late gadolinium enhancement; 3SD, three standard deviations; ECV, extracellular volume. 
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Domain Parameter beta 95%CI p-value 
Baseline Age  0.078 -0.034 - 0.191 0.2 
 
Sex -2.229 -4.396 - -0.62 0.04 
 
Type of valve (bicuspid/tricuspid) 1.554 -0.844 - 3.953 0.2 
 
Six minute walk test distance 0.003 -0.003 - 0.01 0.3 
 
NYHA functional class 0.123 -1.543 - 1.79 0.9 
 
Hypertension -2.103 -4.706 - 0.499 0.1 
 
SBP (mmHg) 0.043 -0.023 - 0.109 0.2 
 
DBP (mmHg) 0.014 -0.095 - 0.122 0.8 
 
Diabetes -0.562 -3.318 - 2.195 0.7 
 
Coronary artery disease -0.138 -2.618 - 2.342 0.9 
 
Atrial Fibrillation -2.369 -5.446 - 0.707 0.1 
 
STS score -0.157 -1.11 - 0.795 0.7 
 
EuroScore II -0.438 -1.217 - 0.342 0.3 
 
ACE/ARB -0.011 -2.243 - 2.22 0.9 
 
Beta-blocker 0.615 -1.683 - 2.912 0.6 
 
Statin 0.021 -2.28 - 2.321 0.9 
 
Aspirin -2.005 -4.207 - 0.197 0.07 
CMR EDVi -0.079 -0.124 - -0.034 0.001 
 
ESVi -0.093 -0.143 - -0.044 <0.001 
 
LVMi -0.117 -0.152 - -0.082 <0.001 
 
LVEF 0.136 0.069 - 0.204 <0.001 
 
SVi -0.016 -0.118 - 0.086 0.8 
 
LAAi -0.425 -0.791 - -0.059 0.023 
 
LGE -0.116 -0.222 - -0.01 0.032 
 
Native T1 -0.053 -0.077 - -0.029 <0.001 
 
ECV -0.872 -1.188 - -0.557 <0.001 
Baseline AS severity Vmax (m/s) -1.297 -3.153 - 0.558 0.2 
 
Peak gradient (mmHg) -0.035 -0.089 - 0.019 0.2 
 
Mean gradient (mmHg) -0.054 -0.130 - 0.023 0.2 
 
AVAi (cm2/m2) 4.002 -4.345 - 12.349 0.3 
 
LVOT:Aortic valve VTI ratio 8.083 -5.108 - 21.274 0.2 
 
E-wave (m/s) -3.19 -6.897 - 0.516 0.09 
 
E/A ratio -3.988 -6.331 - -1.644 0.001 
 
E deceleration time (ms) 0.02 0.005 - 0.036 0.008 
 
E/e' ratio -0.193 -0.391 - 0.005 0.06 
 
Zva (mmHg/ml*m2) 0.352 -0.540 - 1.244 0.4 
Biomarkers hs-TnT (ln) -2.904 -4.465 - -1.343 <0.001 
 
NT-proBNP (ln) -1.917 -2.666 - -1.167 <0.001 
 
Crea -0.026 -0.068 - 0.016 0.2 
 
eGFR -0.008 -0.061 - 0.045 0.8 
 
Hct 0.146 -0.11 - 0.40 0.3 
Operation CABG (y/n) -0.627 -3.144 - 1.889 0.6 
 
Type of valve  -1.039 -3.406 - 1.329 0.4 
 
Size of valve -0.547 -0.970 - -0.123 0.012 
Post op Time to follow-up -0.009 -0.021 - 0.003 0.1 
Change in EDVi 0.162 0.110 - 0.215 <0.001 
 
ESVi 0.202 0.147 - 0.257 <0.001 
 
LVMi 0.27 0.227 - 0.313 <0.001 
 
LVEF -0.48 -0.623 - -0.337 <0.001 
 
SVi -0.005 -0.106 - 0.096 0.9 
 
LGE -0.251 -0.554 - 0.52 0.1 
 
NYHA FC -0.219 -3.048 - 2.610 0.9 
 
6MWT -0.002 -0.010 - 0.005 0.5 
 
Vmax (m/s) 1.604 0.198 - 3.010 0.026 
 
Peak gradient (mmHg) 0.047 -0.002 - 0.096 0.06 
 
Mean gradient (mmHg) 0.071 0.002 - 0.139 0.04 
 
AVAi (cm2/m2) -3.44 -5.668 - -1.211 0.003 
 
LVOT:Aortic valve VTI ratio -5.629 -14.191 - 2.932 0.2 
 
E-wave (m/s) 5.094 1.188 - 9.000 0.011 
 
E/A ratio 3.386 1.272 - 5.501 0.002 
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E deceleration time (ms) 0.019 0.006 - 0.032 0.004 
 
E/e' ratio 0.228 0.044 - 0.413 0.016 
 
Zva (mmHg/ml*m2) -0.065 -1.072 - 0.941 0.9 
 
hs-TnT (ln) 3.643 1.496 - 5.789 0.001 
 
NT-proBNP (ln) 2.645 1.784 - 3.506 <0.001 
	
Table 24: Univariate Predictors of Matrix Regression. 
 
EDVi, end-diastolic volume index; ESVi, end-systolic volume index; LVMi, left ventricular mass index; 
LVEF, left ventricular ejection fraction; SVi, stroke volume index, LGE, late gadolinium enhancement; 
ECV, extracellular volume; Vmax, peak velocity through the aortic valve; AVAi, aortic valve area index; 
LVOT, left ventricular outflow tract; VTI ratio, velocity-time-integral ratio; Zva, valvulo-arterial 
impedance; E, peak early velocity of the transmitral flow; E/A ratio, early to late ventricular filling 
velocities; DT, deceleration time; E´, peak early diastolic velocity of the mitral annulus displacement; 
Zva, valvulo-arterial impedance; SBP, systolic blood pressure; DBP, diastolic blood pressure; NYHA, 
New York Heart Association; STS, Society of Thoracic Surgeons' risk model score; EuroScoreII, 
European System for Cardiac Operative Risk Evaluation II score; ACE-I, angiotensin-converting-
enzyme inhibitor; ARB, angiotensin-receptor blocker; NT-proBNP, N-terminal pro-brain natriuretic 
peptide; hs-TnT, high sensitivity troponin T. 
 
 
 
Univariate Multivariate 
Domain Parameter beta 95%CI p-value beta 95%CI p-
value Baseline Sex -2.229 -4.396 - -0.62 0.044 
  
NS 
CMR LVEF 0.136 0.069 - 0.204 <0.001 
  
NS 
 
LVMi -0.117 -0.152 - -0.082 <0.001 -0.05 -0.083 - -0.017 0.004 
 
ECV -0.872 -1.188 - -0.557 <0.001 -0.407 -0.756 - -0.058 0.02 
Echo E/A ratio -3.988 -6.331 - -1.644 0.001 
  
NS 
Biomarkers hs-TnT (Ln) -2.904 -4.465 - -1.343 <0.001 
  
NS 
 
NT-proBNP (Ln) -1.917 -2.666 - -1.167 <0.001 
  
NS 
Operation Size of valve -0.547 -0.970 - -0.123 0.012 
  
NS 
Change in ΔLVEF -0.48 -0.623 - -0.337 <0.001 -0.118 -0.189 - -0.046 0.002 
 
ΔAVAi -3.44 -5.668 - -1.211 0.003 -1.611 -3.184 - -0.039 0.045 
 
ΔE/A ratio 3.386 1.272 - 5.501 0.002 
  
NS 
 
Δhs-TnT (ln) 3.643 1.496 - 5.789 0.001 2.591 0.429 - 4.753 0.02 
 
ΔNT-proBNP (ln) 2.645 1.784 - 3.506 <0.001 
  
NS 
 
Table 25: Multivariate Predictors of Matrix Regression. 
 
LVMi, left ventricular mass index; LVEF, left ventricular ejection fraction; ECV, extracellular volume; 
E/A ratio, early to late ventricular filling velocities; AVAi, aortic valve area index; NT-proBNP, N-terminal 
pro-brain natriuretic peptide; hs-TnT, high sensitivity troponin T.  
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8.1.5 Discussion 
In this study we sought to understand the dynamic nature of cellular and matrix 
components in myocardial hypertrophy by exploring reverse myocardial remodeling 
in AS at 1-year post-AVR. We show that myocardial cellular hypertrophy and 
extracellular matrix expansion (diffuse fibrosis) regress and is accompanied by 
structural, functional and biomarker improvement (Figure 58). Furthermore, it 
establishes that cardiomyocyte loss is irreversible as evidenced by the persistence 
of focal replacement fibrosis (LGE) after AVR. Moreover, these findings provide 
validation that CMR can be used to characterize and monitor the extent of cellular 
hypertrophy and myocardial fibrosis, differentiating between focal fibrosis (scar) and 
diffuse fibrosis due to accumulation of ECM, and importantly confirming myocardial 
fibrosis regression non-invasively similar to that reported more than 25-years ago 
requiring invasive myocardial biopsies [277, 278].  
The concept of reverse myocardial remodeling after removal of a pathological insult 
has been studied both by echocardiography and CMR. LVH (i.e. combined cell and 
matrix compartments) is known to regress by 20% to 30% by 1-year post-AVR [37, 
39, 41]. We now show that both cell and matrix regression contribute to the 
reduction in LVH over this period. Combined with our previous data showing that at 
6 months post-AVR only cellular hypertrophy regresses [48], this suggests that the 
timeline for cardiomyocyte and extracellular matrix responses to afterload reduction 
are different, with remodeling of the extracellular matrix being slower. Diffuse fibrosis 
enhances myocardial tensile strength and three-dimensional force delivery but at the 
expense of reduced distensibility. Dense collagen meshwork within the 
subendocardium seen in AS can be considered pathological in that it entraps 
muscle fibers causing active stiffness to fall while impairing distensibility [287]. 
Previous data by Villari et al [45] suggested no change in interstitial fibrosis at 2 
years post-AVR, but these data were from subendocardial samples rather than a 
global, “whole heart” measure as in our cohort. Location of the biopsy is crucial, as 
we have shown in previous work [288] where the subendocardial portion of the 
myocardium was predominated by replacement focal fibrosis with a decreasing 
superficial to deep such that reactive fibrosis predominates in the midmyocardium.  
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The ability to measure diffuse fibrosis regression non-invasively by CMR not only 
reflects a key biological response, but also has the potential to be used in drug 
development to validate proof-of-concept efficacy of drugs targeting myocardial 
fibrosis. The possibility of influencing myocardial (cellular and interstitial) remodeling 
with pharmacological interventions [67, 289, 290] requires a better understanding of 
the intricate interplay throughout all stages of disease. Non-invasive tracking of 
cellular and extracellular components may potentially establish the transition point 
between adaptive and maladaptive remodeling and provide a reliable method to 
monitor the response to matrix modulating therapies (anti-fibrotic, anti-amyloid) in 
the search for new individualized heart failure therapies [291]. 
Focal fibrosis identified by LGE is indicative of cardiomyocyte necrosis with 
replacement fibrosis (i.e., ranging from foci of necrosis to larger myocardial infarcts). 
Our data suggest that focal fibrosis, reflected by LGE, does not regress; this is 
consistent with previous findings reported post-AVR implying that AVR failed to 
reduce the degree of focal replacement fibrosis [33, 43]. In contrast, the reactive 
diffuse fibrosis did regress. These findings highlight the dynamic nature of the 
extracellular matrix in AS contributing to the pathobiology because changes in 
collagen turnover occur as a result of the reaction of cardiac fibroblasts to both 
mechanical and local humoral factors [292, 293]. Matrix volume and fraction (ECV) 
quantification may add more predictive information, particularly as our data clearly 
show that this method identifies measurable reversibility. This is also important from 
an outcome perspective, because recent data by Chin et al showed that both focal 
(LGE) and diffuse fibrosis (matrix volume) were univariate predictors of outcome 
[294]. 
Current management strategies for AS mainly rely on waiting until the onset of 
symptoms. However, it is recognized that for some this is too late; furthermore, there 
is a discrepancy between symptom development and markers of long-term outcome 
post AVR (e.g. LGE).  While existing models of AS may be simplistic, our current 
understanding is that AS is a disease of both the valve and myocardium. Thus, 
treatment strategies need to assess both haemodynamic insult imposed by the 
valve lesion [286] and the extent of myocardial structural remodeling, particularly 
when seeking to quantify irreversible changes and predict outcome. Reduced LVEF, 
excessive LVH, abnormal response to exercise and critical AS (peak velocity 
>5m/sec)[23, 26], as well as LGE [55, 58, 103] are markers for this and have been 
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shown to predict adverse outcome. Whilst LVH regression occurs early post-AVR 
[295, 296], myocardial normalization is not always possible. We show that focal 
replacement fibrosis is not plastic but irreversible, which is not surprising, but may 
represent a point in the clinical progression of AS at which valve replacement should 
be recommended to prevent further irreversible damage. If this transition point to 
maladaptive remodeling could be anticipated then intervention could be performed 
before the emergence irreversible focal replacement scar – a combination of blood 
and imaging biomarkers may be able to identify these transition points in the future. 
Finally, drug therapies could be used post-AVR to augment or accelerate 
normalization of both cell hypertrophy and diffuse fibrosis.  
There are limits to an exclusively non-invasive approach. The ECV technique is 
measuring extracellular water, which tracks fibrosis, but there are other 
explanations: vasodilatation, edema and amyloid. Compensatory capillary 
vasodilatation (hyperemia) would artifactually cause elevated native myocardial T1 
and ECV [161]. However, AS is believed to have a reduced capillary density [165], 
and the changes found here are too large for blood volume – 16% of total 
myocardial volume. We also saw no predicted change in native T1. Edema could be 
a cause, which has been described in increased afterload [297]. However, these 
patients had normal baseline myocardial T2. Dual pathology with occult amyloid was 
specifically sought and excluded (n=6), so it was not present [234]. ECV 
quantification excluded infarct LGE but included non-ischemic LGE, as per guideline 
recommendation [196]. Although exclusion of all areas of LGE may appear 
theoretically attractive, it would be practically challenging to limit the ECV 
measurement area to exclude pixels of non-infarct LGE (highlighted by our 
thresholding method). Ultimately, the inclusion of areas of non-infarct LGE in the 
ECV measurement did not affect the overall regression trend, as the amount of LGE 
did not change at follow-up.  
Other limitations of the present study include it being a single center and focused on 
surgical AVR by non-invasive CMR assessment without paired histology. Pressures 
were determined by non-invasive, echocardiography-derived values only. Renal 
failure and pacemaker patients are not represented (this excluded 7% of possible 
patients). Some patients declined follow-up – but there was no significant difference 
in baseline characteristics between patients that completed the follow-up and those 
that withdrew. 
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8.1.6 Conclusion 
In aortic stenosis, cell hypertrophy but also of diffuse fibrosis are plastic and 
measurable non-invasively by CMR. Following AVR, both cellular hypertrophy and 
diffuse fibrosis regress, and are accompanied by structural, functional and 
biomarker improvement.  Focal replacement fibrosis is irreversible. Together these 
suggest that therapeutic strategies should potentially aim for intervention before the 
emergence of irreversible focal scar, with the aim to normalize diffuse fibrosis, which 
is here seen to be plastic and measurable non-invasively. 
 
Figure 58: Myocardial Reverse Remodeling after Aortic Valve Replacement. 
66-year-old male with severe aortic stenosis (peak velocity 4.66m/s, mean gradient 
57mmHg, AVA 0.5cm2). CMR prior to aortic valve replacement (AVR) showed concentric left 
ventricular hypertrophy (252g). Late gadolinium enhancement (LGE) demonstrated limited 
non-ischemic focal scar. Extracellular volume fraction (ECV) was 27.5%. 1-year after AVR 
(mechanical bileaflet valve), there was a 22% reduction in LV mass (to 201g). The LV mass 
regression was due to 22% reduction in cell and a 15% reduction in matrix volume, so the 
ECV rose to 29.1%. The focal fibrosis (LGE) was unchanged.   
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Chapter 9 Results 5: ECV as a Predictor of Outcome following AVR 
9.1.1 Preface 
In this section, the 1-year outcome data is presented. A more extensive analysis with longer 
follow-up will be pursued during post-doctoral work.  
My contribution was recruiting, consenting and performing the scans of all patients. I 
performed the T1 mapping analysis as first operator, performed quality control on LV volume 
and function as well as LGE analysis, I performed the statistical analysis and wrote the 
manuscript. RK performed the LV volume and function analysis. RS performed the LGE 
analysis.  
9.1.2 Hypotheses and Aims 
We hypothesized that extracellular matrix expansion predicts outcomes post AVR. 
To be clinically useful, this would need to be measured non-invasively, so we aimed 
to assess whether non-invasive (CMR ECV) measurement predicts outcome (death) 
one year post-AVR for severe AS. 
9.1.3 Methods 
The cohort investigated is the same as in the baseline paper (section Chapter 5) 
and the methods have been detailed in section 5.1.4. Additional details below:  
9.1.3.1 Samples size 
As detailed in 2.1.9, we based our sample size calculation on a previous cohort in 
our institution [114], which was followed up at 6 months with a sample size of 63 
patients, and showed a trend of higher mortality with severe DMF with 6 month 
mortality in mild and moderate fibrosis of 2.4% and in severe fibrosis of 19%.  The 
requirements were an 80% power (binomial test) to show that patients with severe 
fibrosis (highest ECV tertile) have a higher event rate than patients with mild to 
moderate fibrosis (lowest and mid ECV tertile) at 1 year, and calculated a group size 
of 44 to achieve this, equalling a total sample size of 132. Furthermore, we decided 
to extend the follow-up to one year, and adjusting the sample size to allow for 
dropout (or implantation of non-MR compatible PPMs) of 10%. Therefore, a sample 
size of 150 patients was calculated to give adequate power our study, and is a 
realistic recruitment target for our institution (140 AVR/year, 50-60% participation). 
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9.1.3.2 Outcome measures 
All deaths were identified through the NHS National Spine Database. We also 
assessed aortic stenosis–related mortality. This was established from the official 
death certificate and defined as any death in which AS was listed as either the 
primary cause or a contributing factor to that death by the clinical care team. 
9.1.3.3 Statistical Analysis 
As described before in Statistical Analysis 3.8. Survival was evaluated using Cox 
proportional hazards analysis, providing estimated hazard ratios (HR) with 95% 
confidence intervals (CI) and Kaplan Meier curves. Due to the low number of events 
(deaths), multivariable Cox regression models were not tested. A two-sided p-value 
of <0.05 was considered significant. 
9.1.4 Results 
9.1.4.1 Baseline characteristics 
There were 181 patients with severe, symptomatic AS recruited (age 69±10, 56% 
male) representing 48% of all surgical AVRs at the study institution. Thirteen 
patients were excluded: claustrophobia (n=2), hemodynamic instability (n=1), 
pseudo-severe AS (n=1), severe mitral regurgitation (n=2), significant myocardial 
bystander disease (cardiac amyloidosis n=6; Fabry Disease n=1)[234]. 
Characteristics of the remaining 168 patients (age 70±10 years, 55% male; 70% 
trileaflet AS) are summarized in Table 14 and Table 15. 
9.1.4.2 Details of surgery 
The treatment received was tissue or mechanical valve in 64% and 29%, 
respectively, with additional bypass grafting in 25% and aortic intervention in 8% 
(interposition graft, reduction aortoplasty, replacement of the ascending aorta). Four 
patients underwent TAVI.  
9.1.4.3 Mortality after AVR 
A total of 8 deaths occurred at 1-year follow-up. This conferred an unadjusted all 
cause mortality rate of 49 deaths per 1000 patient years. There were no deaths in 
the low ECV tertile, 2 deaths in the middle ECV tertile and 6 deaths in the high ECV 
tertile. Mortality in lowest and mid ECV tertile (combined) was 1.8%, whereas in the 
highest ECV tertile it was 10.7%. The unadjusted all cause mortality rates were 34 
and 116 deaths per 1000 patients years for middle and high ECV tertiles, 
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respectively. As described in 6.1.5.4, the six patient excluded with occult amyloid 
had a 50% mortality and all had ECV value that would have put them into the 
highest tertile; this would have resulted in the mortality of 16.1% for highest tertile 
had they been included as in previous studies.   
9.1.4.4 Univariate predictors of mortality 
As described in Table 26, univariate predictors of mortality were ECV (HR 6.2 [1.3-
31.2], p=0.02), age (HR 1.1 [1.0-1.3], p=0.048), LVEF (HR 0.98 [0.93-0.99], 
p=0.023), indexed end-systolic volume (HR 1.02 [1.00-1.42], p=0.03), indexed left 
atrial area (HR 1.3 [1.1-1.4], p<0.001), LGE mass (HR 6.4 [1.3-31.7], p=0.023), hs-
TnT (HR 2.5 [1.02-6.13], p=0.045) and NT-proBNP (HR 2.5 [1.3-4.8], p=0.023), but 
not sex, LV mass, native T1 or parameters of aortic valve stenosis severity. As 
shown in the Kaplan-Meier curves in Figure 59, patients with severe fibrosis (highest 
tertile ECV) had a higher event rates than patients with mild to moderate fibrosis 
(middle and lowest tertile ECV). 
  HR 95%CI Chi2 p-value 
Age 1.1 1.00-1.25 3.8 0.048 
Sex 1.4 0.3-5.8 0.2 0.6 
LVEF 0.98 0.93-0.99 5.6 0.023 
EDVi 1.02 0.99-1.11 3.1 0.09 
ESVi 1.02 1.00-1.05 5.3 0.03 
LAAi 1.3 1.13-1.42 21.0 <0.001 
LV mass index 1.0 0.98-1.03 0.2 0.6 
ECV (Tertiles) 6.2 1.3-31.2 6.7 0.024 
Native T1 (tertile) 1.9 0.5-7.9 0.9 0.4 
LGE 3SD (tertile) 6.4 1.3-31.7 6.8 0.023 
Trop (ln) 2.5 1.02-6.13 4.1 0.045 
NT-proBNP (ln) 2.5 1.3-4.8 9.2 0.009 
 
Table 26: Cox Regression.  
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Figure 59: Kaplan-Meier Curves at 1-year. 
At 1-year, patients with severe fibrosis (highest tertile ECV) have a higher event rates than 
patients with mild to moderate fibrosis (middle and lowest tertile ECV). 
Variable 
Lowest ECV 
Tertile 
Mid ECV 
Tertile 
Highest ECV 
Tertile p-value 
n 56 56 56   
Age (years) 69±9 71±11 69±9  0.4 
Male (%) 61 48 55  0.2 
Valve Type (Tricuspid, %) 64 75 55  0.9 
Hypertension (%) 68 70 86  0.08 
Diabetes (%) 11 18 32  0.3 
Coronary artery disease (%) 32 27 38 0.7 
CABG (%) 29 27 16 0.2 
Bypass time (min) 102±35 92±24 89±27 0.1 
          EDVi (ml/m2) 64±19 62±16 76±27 <0.01 
ESVi (ml/m2) 18±13 18±11 32±28 <0.01 
LVEF (%) 73±12 73±12 63±18  <0.01 
LVMi (g/m2) 86±23 81±22 97±26  <0.01  
LAAi (cm2/m2) 12.7±3.3 13.0±2.6 14.8±4.5 <0.01 
Late enhancement (g) 12.9±9.1 11.4±7.8 17.2±13.3  <0.01  
Native T1 (ms) 961±26 973±24 999±30  <0.001  
ECV (%) 25.5±1.1 28.6±1.0 31.8±1.6  <0.001  
          Troponin T (pmol/L) 16±15 16±14 22±19 0.2  
NT-proBNP (ng/L) 98±150 110±128 302±341  <0.001 
SBP (mmHg) 134±16 133±21 131±18 0.7  
DBP (mmHg) 75±10 76±13 75±11  0.8 
6MWT (m) 497±158 468±192 412±204  0.1 
          AVAi (cm2/m2) 0.39±0.12 0.41±0.14 0.40±14 0.8  
Vmax (m/s) 4.3±0.6 4.4±0.6 4.3±0.6  0.5 
Mean Grad (mmHg) 47±13 49±14 46±15  0.5 
VTI ratio 0.22±0.06 0.23±0.09 0.23±0.08  0.7 
E-wave 0.74±0.24 0.81±0.27 0.98±0.32  <0.001  
E/A ratio 0.86±0.37 0.93±0.43 1.11±0.63 0.04  
E/e' 12±5 12±4 17±7  0.001  
 
Table 27: Patient characteristics by ECV Tertile 
 
Results 5: ECV as a Predictor of Outcome following AVR	 Treibel TA, PhD Thesis 2017 
 
Page 153 of 193 
9.1.4.5 Patient characteristics by ECV Tertile 
As shown in Error! Reference source not found., patients in the highest ECV 
tertile had worse LV remodeling, worse LVEF, more focal and diffuse fibrosis, larger 
left atrial area, high NT-proBNP and worse diastolic dysfunction. There were no 
significant differences in age, sex, valve type, aortic valve stenosis severity, co-
morbidities in particular coronary artery disease (there was a trend towards higher 
prevalence of hypertension, but no difference in absolute blood pressure) or 
duration of surgery (bypass time). 
9.1.4.6 Post-hoc Power calculation 
On post-hoc power calculation, the actual event rates give a power of 75.5% to 
show a difference in mortality between the highest and lower ECV tertiles.  
9.1.5 Discussion 
Diffuse myocardial fibrosis assessed by ECV prior to AVR is a univariate predictor of 
all-cause mortality at 1-year follow-up. Patients with the highest fibrosis also have 
worse myocardial remodelling, systolic and diastolic function. The all-cause mortality 
in this cohort was 4.8%, and due to a low number of deaths, multivariate analysis 
was not performed.  
This 1-year mortality was lower than expected from our sample size calculations (in 
a previous study in our institution, mortality overall and in the highest ECV tertile at 6 
month were 7.9% and 19%). Therefore, although we over-recruited to our study, we 
missed the targeted power of 80%, achieving a power of 75.5%). Intensive 
recruitment for the RELIEF-AS study in our institution yielded the recruitment of 
nearly 50% of all patients undergoing AVR for severe AS into the study; this may 
have resulted in the recruitment of a less severe, though more representative 
phenotypes with lower mortality rates – overall the cohort had less fibrosis then the 
previous cohort in our institution [114]. Furthermore, in comparison to previous 
studies, we were able to detect patients with occult amyloid on myocardial biopsy 
and subsequently exclude these from our cohort. We believe this is correct as the 
high mortality in this group of patient in our study (50%) is suggestive that bystander 
TTR amyloid is an important disease modifier in elderly patients with severe AS. If 
we had included patients with occult cardiac amyloid, we would have had 50% more 
deaths in the high ECV tertile (i.e. an increase in mortality from 11.7% to 16.1%).  
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9.1.5.1 Limitations and Outlook 
Neither cardiovascular mortality, nor major adverse cardiovascular events were 
available for analysis. Longer follow-up would have yielded in more events and a 
higher power – this will be pursued during post-doctoral work. Larger studies are 
required to confirm ECV as an independent predictor of cardiovascular mortality. 
9.1.6 Conclusion 
Diffuse myocardial fibrosis assessed by ECV prior to AVR predicts outcome (death) 
at 1-year follow-up. Patients with the highest fibrosis also have worse myocardial 
remodelling, systolic and diastolic function.   
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Chapter 10 Discussion and Conclusions  
10.1 Background  
In this thesis, I explored whether AS was a disease not just of the valve, but of the 
myocardium. I focused on myocardial remodelling in general and extracellular matrix 
– focal and diffuse fibrosis invasive and non-invasively (CMR with LGE, CMR with 
ECV and CT ECV) I applied ECV quantification to three key patient cohorts: Aortic 
Stenosis and hypertension (afterload-induced cell hypertrophy and matrix 
expansion), as well as cardiac amyloidosis (matrix expansion due to amyloid 
deposition in the myocardium).   
10.2 Technical Development 
As a by-product of the RELIEF-AS study, I developed the synthetic ECV 
methodology for CMR then CCT allowing instantaneous ECV quantification without 
the need of a venous haematocrit, and co-developed a simplified, bolus-only 
approach to quantify ECV by CCT and calibrated ECVCT to diagnosis cardiac 
amyloidosis. 
10.3 Key findings 
10.3.1 Myocardial remodelling and fibrosis prior to AVR 
In severe AS, CMR revealed sex dimorphism in myocardial remodelling way in 
excess of that recognised using conventional echocardiography. Given equal valve 
severity, and the associated biomarker and fibrosis changes, the myocardial 
response to AS appeared more maladaptive in men then previously reported.  
10.3.2 Occult Amyloid in severe AS 
I found that six percent of patients over the age of 65 years had wild-type 
transthyretin amyloid (wtATTR) deposits on cardiac biopsy, which was associated 
with poor outcome. There seemed to be a hierarchy of imaging diagnostic 
performance for identification of wtATTR amyloid, with DPD bone tracer scintigraphy 
superior to CMR, which was superior to echocardiography. 
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10.3.3 Combination of invasive and non-invasive tissue characterisation 
Intra-operative myocardial biopsy revealed three patterns of fibrosis: endocardial 
fibrosis, microscars (mainly in the subendomyocardium), and diffuse interstitial 
fibrosis. CVF best captured the transmural gradient of fibrosis and microscars, 
whereas LGE appeared to capture mainly microscars, ECV likely captured mid-
myocardium related functional changes beyond LGE. Combining LGE and ECV 
allowed better stratification of AS patients according to their myocardial response. 
10.3.4 Diffuse Fibrosis regression after AVR 
Following AVR, we show for the first time non-invasively that myocardial fibrosis 
regresses at 1-year – but less than cellular regression, so there is a small rise in 
ECV post-AVR. These data support the position that human diffuse fibrosis is 
dynamic and that this is measurable by CMR - a key biological result and proof-of-
concept for drug development targeting myocardial fibrosis. 
10.3.5 Outcome after AVR 
Diffuse myocardial fibrosis assessed by ECV prior to AVR is a univariate predictor of 
all-cause mortality at 1-year follow-up (event rate was too low to perform multivariate 
analysis). Patients with the highest fibrosis also have worse myocardial remodelling, 
systolic and diastolic function. Studies with larger samples size are required.  
10.4 Implication of Findings: Clinical Insights and Potentials 
The findings presented in this body of work have important implications that I would 
like to address step by step:  
1. The sex dimorphism in myocardial remodelling (more maladaptive 
myocardial response to AS in men) revealed by our study is way in excess of that 
recognised using conventional echocardiography and poses important questions: 
Firstly, given the stark differences in myocardial remodelling, how do these affect 
the interpretation of the haemodynamic severity of the valve stenosis? Secondly, 
these changes may be adaptive or maladaptive – can LVEF, NT-pro-BNP and hs-
Troponin adequately highlight the transition into maladaptation, or are other 
biomarkers needed? And are blood biomarkers more informative than imaging? 
Finally, what are the mechanisms driving the sex differences in remodelling? Timing 
of aortic valve intervention is one of the greatest challenges in AS, in particular in 
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asymptomatic patients. Recent focus has turned towards the complex interplay 
between AoV stenosis, vascular load and myocardial response (inappropriate 
hypertrophy, myocardial stress [NT-proBNP], fibrosis [troponin, LGE, ECV], 
myocardial perfusion reserve). Our data supports the notion that we may need to 
treat men and women differently as they experience a different cardiac “milieu”, 
different combined (valve and vasculature) afterload and display a different 
myocardial response. Crucially, data showing reverse remodelling after valve 
replacement and its impact on outcome is required and pending. 
 
2. Occult cardiac amyloid is a significant bystander in patients with severe 
aortic stenosis (six percent of patients > 65 years had wtATTR amyloid deposits on 
cardiac biopsy) and this was associated with poor outcome. The prevalence and 
adverse clinical outcomes suggest that wtATTR amyloid is important in elderly 
individuals with AS, but more work is needed. Prevalence in wtATTR increases with 
age. Future studies should focus on elderly patients (aged >75) who more and more 
undergo TAVI. In this setting, biopsy for amyloid is not practicable but bone tracer 
scintigraphy could be used. The data here suggests it could have a routine role in 
selected patients and influencing their management in terms of decisions 
surrounding intervention, procedure performance and specific amyloid therapies. 
Wider use of cardiac scintigraphy with bone tracers, by detecting early amyloid, is 
likely also to improve our understanding of conventional testing, such as 
echocardiography. We have therefore embarked on the ATTRact-AS study (see 
10.5.2.2), a single centre, 250 patients, prospective observational cohort study with 
1-year follow-up in patients aged >75 with severe AS referred to the Barts Heart 
Centre for consideration of intervention (surgical AVR or TAVI) using DPD 
scintigraphy. 
  
3. Intra-operative myocardial biopsy revealed a characteristic pattern and 
distribution of fibrosis in AS (endocardial fibrosis, microscars [mainly in the 
subendomyocardium], and diffuse interstitial fibrosis). When measuring by biopsy or 
CMR, location, sampling and technical aspects of analysis matter. Invasive biopsy is 
limited by size and sampling error, whereas LGE and ECV capture different regions 
of myocardium and provide complementary information. The combination of LGE 
and ECV – a multi-parametric approach – better identified worse adverse LV 
remodelling, altered biochemical and histological parameters, and functional 
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capacity than each parameter alone. Further combined advanced histology and 
multi-modality non-invasive imaging studies will be required to elucidate other 
aspects of the pathophysiology of AS, with focus on the cellular and microcirculatory 
adaptations required.  
 
4. Following AVR, we show for the first time non-invasively that myocardial 
fibrosis regresses at 1-year – but less than cellular regression, so there is a small 
rise in ECV post-AVR. These data support the position that human diffuse fibrosis is 
dynamic and that this is measurable by CMR - a key biological result and proof-of-
concept for drug development targeting myocardial fibrosis. Whilst LVH regression 
occurs early post-AVR, myocardial normalization is not always possible. We show 
that focal replacement fibrosis is not plastic but irreversible, which is not surprising, 
but may represent a point in the clinical progression of AS at which valve 
replacement should be recommended to prevent further irreversible damage. If this 
transition point to maladaptive remodelling could be anticipated then intervention 
could be performed before the emergence irreversible focal replacement scar – a 
combination of blood and imaging biomarkers may be able to identify these 
transition points in the future. Furthermore, drug therapies could be used post-AVR 
to augment or accelerate normalization of both cell hypertrophy and diffuse fibrosis. 
 
5. Diffuse myocardial fibrosis assessed by ECV prior to AVR is a univariate 
predictor of all-cause mortality at 1-year follow-up (event rate was too low to perform 
multivariate analysis). Patients with the highest fibrosis also have worse myocardial 
remodelling, systolic and diastolic function. Larger studies are required to confirm 
ECV as an independent predictor of cardiovascular mortality. 
Current management strategies for AS mainly rely on waiting until the onset of 
symptoms. However, it is recognized that for some this is too late; furthermore, there 
is a discrepancy between symptom development and markers of long-term outcome 
post AVR (e.g. LGE).  While existing models of AS may be simplistic, our current 
understanding is that AS is a disease of both the valve and myocardium. Thus, 
treatment strategies need to assess both haemodynamic insult imposed by the 
valve lesion and the extent of myocardial structural remodeling, particularly when 
seeking to quantify irreversible changes and predict outcome.  
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10.5 On-going / Future work: 
10.5.1 Occult amyloid in AS: A sTudy invesTigating the Role of occult cardiac 
amyloid in the elderly with Aortic Stenosis (ATTRact AS). 
This work is a direct product of my work on occult amyloid in AS detailed in Chapter 
7.3. I supervised the successful funding application (British Heart Foundation CRTF 
FS/16/31/32185; Dr Paul Scully; £233,914) and continue to support Dr Paul Scully in 
his the on-going research.   
Aim: To confirm the prevalence, clinical impact (procedural complications, symptom 
response to aortic valve replacement, 1-year mortality) and potential place of 
imaging (DPD scintigraphy, ECV by CT, CMR and echocardiography) in occult 
amyloid in severe AS. We hypothesize that in the elderly with severe AS being 
considered for intervention (TAVI, sAVR), ATTR is common, conveys a worse 
prognosis and can be reliably detected non-invasively. 
Design: Single centre, 250 patients. Prospective observational cohort with 1-year 
follow-up in patients aged 75 or older with severe AS referred to the Barts Heart 
Centre for consideration of intervention (surgical AVR or TAVI).  
 
Figure 60: ATTRact-AS study scheme 
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10.5.2 ECV quantification by CCT  
10.5.2.1 Amyloid cohort II - 3D volumes, co-registration, segmentation. 
We have successfully recruited and scanned 50 patients with systemic amyloidosis 
at the National Amyloidosis Centre, Royal Free Hospital, in order to develop more 
advanced analysis processes and to thereby obtain a better understanding of the 
regional variation of amyloid deposition in the heart. Co-locating the test with the 
National Amyloidosis Centre has improved the patient experience and has also 
allowed us to take advantage of using the newest 3rd generation CT technology. 
10.5.2.2 ATTRact-AS  
ECV quantification by CCT is an integral part of the ATTRact-AS project; a cardiac 
CT is an integral part of pre-procedural planning prior to TAVI – adding ECV 
quantification is simple and safe.  
10.5.3 Dark blood LGE for subendocardial scar in AS. 
Dark blood PSIR late gadolinium enhancement imaging is an exciting new 
technique, that is particularly promising in revealing under-diagnosed 
subendocardial enhancement in AS [282]. 
 
Figure 61: Dark blood PSIR LGE 
Example of PSIR LGE dark and bright blood showing subtle subendocardial scar in the 
anteroseptum that is poorly visualised with bright blood imaging (Adapted from Kellman 
JCMR 2016 [282]) 
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10.5.4 Basic science collaborations – ongoing work 
10.5.4.1 Collagen Metabolism in Aortic Stenosis 
Collaborator: Prof Javier Díez / Dr Begoña Lopez / Dr Arantxa Gonzalez, Center for 
Applied Medical Research, University of Navarra, Pamplona, Spain. 
Aims: To evaluate the prognostic value of alterations in the extracellular matrix. To 
study the association between ECV and collagen quantity and quality.To analyse 
the potential incremental prognostic value of combining both. 
10.5.4.2 ChipSeq 
Collaborator: Prof Folkert Asselsberg / Dr Magdalena Harakalova, Department of 
Cardiology, Division Heart & Lungs, UMC Utrecht, the Netherlands. 
Aim: To map the chromatin active regions in human myocardium with AS-induced 
myocardial remodelling to help identify key epigenetic pathways in disease aetiology 
using chromatin immuno-precipitation followed by read sequencing (ChIP-seq). 
10.5.4.3 Proteomics 
Collaborator: Dr Kevin Mills and Dr Anna Baud, Institute of Child Research, UCL. 
Aim: To proteomic profiles in myocardial tissue from patients with different pattern of 
myocardial remodelling in AS and other forms of LVH. 
10.5.4.4 Confocal Microscopy 
Collaborator: Dr Patrizia Camelliti, University of Surrey, Guildford, UK. 
Aim: Validation of ECV by CMR using confocal microscopy – insights into the 
constituents of the myocardium and their individual contribution to cellular and 
matrix volume. 
10.5.4.5 Energy metabolism and stress response pathways in Aortic Stenosis  
Collaborator: Prof Alun Hughes / Dr Anish Bhuva, ICS, UCL.  
Aim: To explore the contribution of energy metabolism and stress response 
pathways to differential myocardial remodelling in AS.  
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10.6 Conclusion 
In this thesis focussing on patient with severe aortic stenosis, I demonstrated the 
utility of invasive and non-invasive myocardial tissue characterisation, showing sex 
dimorphism in remodelling with worse remodelling in men, a significant prevalence 
of occult amyloid in AS associated with worse outcome, complex pattern of 
myocardial fibrosis on histology and CMR requiring combination of biopsy and 
imaging to broadening our understanding of AS pathophysiology, and finally a 
regression of diffuse fibrosis after aortic valve replacement. These insights support 
that AS is a disease of the myocardium as well as valve open up the potential for 
important further work to deepen our understanding of myocardial remodelling in 
aortic stenosis. 
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Chapter 12 Appendix  
12.1 Location of research  
Clinical Research was carried out at the Heart Hospital (part of UCLH NHS trust), 
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Research, University of Navarra, Pamplona, Spain. 
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12.7 Publications arising from research activities  
In total, there are 36 papers published so far from this thesis. This includes papers 
in Circulation, European Heart Journal, JACC, Circulation Research, Radiology, 
JACC imaging, Circulation imaging and others. There are 2 more first author 
manuscripts under review and multiple more middle author papers pending. 
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